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Abstract  
 
Hypertension and coronary artery disease are complex diseases with both 
environmental and genetic contributions. Genome-wide association studies (GWASs) 
have revealed a number of common genetic variants with modest effects on the 
disease susceptibility. One of the novel genetic variants (SNP rs13107325, C ! T, 
Ala391Thr) identified in GWASs has been associated with a number of CVD-related 
traits, including SBP, DBP, HDL-C, body mass index, and schizophrenia. This SNP is 
located at exon 8 of the solute carrier family 39 member 8 gene (SLC39A8), and 
results in an amino acid substitution from Alanine to Threonine at amino acid position 
391. SLC39A8 was first found to be highly induced by Mycobacterium bovis BCG cell 
wall and TNF-α. The encoded protein ZIP8 is a divalent cation/bicarbonate co-
transporter with different affinities for a number of metal ions. Recent studies revealed 
the major role of ZIP8 in the uptake of cadmium and manganese. The objective of this 
project is to investigate whether the Ala391Thr polymorphism has an impact on the 
structure or function of ZIP8, and the underlying mechanisms responsible for the 
deleterious cell events associated with cadmium exposure, that over time, may 
contribute to the development of hypertension.   
 
 We showed that ZIP8 containing the Ala391 variant resulted in higher 
intracellular accumulation of Cd2+ at low dose and Zn2+ at physiological concentration. 
Lower cell proliferation and higher cell death were observed in transfected HEKs and 
HuVECs exposed to Cd2+. This was accompanied by stronger ERK1/2 and NF-ĸB 
activation in HEK293 possibly induced by Cd2+ uptake. We also showed some 
evidence of ZIP8 participation in HDL3-mediated cholesterol efflux, however this needs 
to be further validated in an improved experimental model.  
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Bioinformatics analysis suggested a possible structural impact of Ala391Thr on 
ZIP8 function, which was supported by conservation analysis of the alanine amino acid. 
Membrane protein structure analysis predicted a shift of an α-helical domain possibly 
caused by the change of the amino acid hydrophillicity. The secondary structure 
predicted by the Robetta algorithm based on a similar homologue supported that this 
structural change may be caused by the Ala391Thr variation. 
 
Our data indicate that the amino acid substitution (Ala391Thr) caused by SNP 
rs13107325 alters the transport activity of ZIP8 on metal ions, leading to differential 
activation of ERK1/2 and NF-κB pathways, which subsequently results in different 
levels of cell death on human kidney and endothelial cells. This study sought to provide 
the preliminary mechanistic explanations for the association of rs1310725 with blood 
pressure and HDL-C following the GWAS. These observations have demonstrated a 
promising start for further investigation of SLC39A8 in the context of hypertensive mice 
or human populations. This may enable further pharmacological studies for the 
development of a potential therapeutic candidate for hypertension treatment.  
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1. Introduction 
 
Cardiovascular diseases (CVDs) are a combination of diseases including coronary 
heart disease (heart attack), cerebrovascular disease (stroke), raised blood pressure 
(hypertension), peripheral artery disease, rheumatic heart disease, congenital heart 
disease and heart failure.  CVDs are known to be the number one cause of death 
globally. An estimated 17.5 million people died from CVDs in 2012, representing 31% 
of all global deaths. Of these deaths, coronary heart disease is responsible for 7.4 
million, while stroke accounts for 6.7 million.1 CVDs are caused by disorders of the 
heart and blood vessels. The high incidence of CVDs has caused enormous health 
and socioeconomic burden to all countries. Most CVDs are results of complex 
interactions of lifestyle and genetic contributors. A large proportion of CVDs is 
preventable through the understanding of established risk factors, such as unhealthy 
diet, physical inactivity, excessive use of alcohol, obesity, etc. This study mainly 
focuses on essential hypertension and coronary heart disease.  
 
1.1 Aetiology of essential hypertension (HTN) 
 
Hypertension is one the earliest recorded medical conditions (Huangdi Neijing around 
221 BC), and is known to be a complex disorder affecting more than a quarter of the 
world’s adult population,2 accounting for 9.4 million deaths worldwide.3 It is a major 
modifiable risk factor that relates to a range of diseases including coronary heart 
disease, cerebrovascular disease, peripheral vascular disease, chronic kidney disease 
and atrial fibrillation.4; 5 The relationship between HTN and increased cardiovascular 
risk and CVD mortality has been demonstrated in numerous studies including 
prospective cohort studies and meta-analysis,6-8. The association between blood 
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pressure (BP) and stroke mortality is strong and direct across different age groups, 
almost as strongly with ischaemic heart disease (IHD) and with those from other 
vascular causes.6 Lowering blood pressure has been linked with dramatic reduction in 
stroke, and smaller reduction in myocardial infarction.9 An individual’s BP depends on 
the complex interplay of blood vessels, as is controlled by two variables according to 
analogy of Ohm’s law (shown in Fig.1.1).10 The peripheral vascular resistance (R) is 
modified mainly by arterial wall modifications due to ageing or medial hypertrophy; the 
blood flow (Q) is modified by increased fluid volume due to elevated salt intake:  
 
ΔP = Q x R 
 
(ΔP = pressure difference, Q = bulk flow, R= resistance) 
 
This relation can be restated for the whole circulation, suggesting that an 
elevation of mean BP is a result of increase in cardiac output, total peripheral vascular 
resistance, or a combination of both.  
 
MAP = CO x PVR 
 
MAP = mean arterial pressure, CO = cardiac output ( = stroke volume x heart rate), 
PVR = total peripheral vascular resistance 
 
Tremendous efforts have been placed to investigate the relationship of heart 
and blood vessels, which are key to the understanding of the pathophysiology of HTN. 
Any small changes in arterial diameter will result in a profound effect on the blood flow 
(or resistance). In short term, the diameter of small arteries and arterioles are 
controlled by the contractile state of their smooth muscle, which in turn are regulated 
by a network of local and systemic factors (Fig. 1.1). 10  
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Figure 1.1. Mechanisms regulating mean arterial blood pressure. ADR= 
adrenaline, Aldo= aldosterone, Ang II= angiotensin II; ADH= antidiuretic hormone 
(arginine vasopressin); CNS= central nervous system; HR= heart rate; NO= nitric oxide; 
ParaNS= parasympathetic nervous system; SV= stroke volume; SNS= sympathetic 
nervous system. 10 
 
Several established constitutional and environmental factors that modify BP 
levels include: dietary salt intake, alcohol consumption, inactivity and body mass index. 
Despite its severe consequences (myocardial infarction, stroke and heart failure), the 
aetiology of HTN remains obscure; only approximately 5% of cases have an 
identifiable secondary cause.11 Human essential or primary hypertension is defined as 
‘high blood pressure in which secondary causes such as renovascular disease, renal 
failure or other causes of secondary hypertension or Mendelian forms are not 
present.’12 Essential or primary HTN accounts for approximately 95% of the HTN 
incidence.13 Besides the high incidence, the rates of HTN control are generally poor, 
with an estimation of only 38% of the patients being treated to the target level across 
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Europe.14   
 
1.2 Genetics of essential hypertension 
 
Human essential hypertension is a complex (polygenic) trait, which arises from a 
combination of genetic and environmental factors. Data from the Framingham Heart 
Study suggest that heritability is 30-50% for long-term systolic or diastolic BP,15 and is 
broadly related to a combination of pathophysiological conditions. The best example of 
genetic influence on BP is the presence of a HTN family history increases the risk of 
developing the disease by about four times compared to the general population.16 
Efforts to identify blood pressure related genes have been mainly relying on three 
approaches: linkage analysis, candidate genes, and genome-wide association studies.  
 
1.2.1 Mendelian disorders of hypertension 
 
Many successes have been achieved in the field of linkage study of Mendelian forms 
of hypertension and hypotension in which variations within single genes impart large 
effects on blood pressure. The methodology began with the identification of a 
chromosomal region that is transmitted within families, along with the disease 
phenotype of interest.17 Between 1996 and 2004, 26 candidate genes had been 
identified by this method,18 including genes encoding baroreceptors, natriuretic 
peptides and components of the renin-angiotensin-aldosterone system.19-21 These 
systems have been extensively studied for their contributions to short-term blood 
pressure regulation through homeostatic response.19 Most of the mutations in genes 
influencing renal salt handling pathways exhibit large effects on BP. All the mutations 
identified by this approach are rare variants, with minor allele frequency (MAF) <0.1%, 
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and additively explain only a small proportion of cases in the population. The vast 
majority of phenotype variance in the population is due to common genetic variations. 
The complex pathophysiology of HTN, as well as the pathways affecting long-term high 
blood pressure, remains largely elusive. The drawbacks of linkage studies are the lack 
of statistical power and low mapping resolution for variants of modest effects. As a 
consequence, the application of linkage analysis for complex disorders without an 
obvious Mendelian inheritance pattern has achieved limited success. The genes 
known to contribute to monogenic HTN is shown in Fig. 1.2.  
 
Given the high heritability of high BP, more genetics approaches have been 
developed for the identification of BP related genes. They aims are to not only to reveal 
more primary physiological mechanisms of HTN but also provide insights into the 
architecture of this complex trait comprehensively.22  
 
 
1.2.2 Identification of blood pressure related genes  
Candidate gene study  
 
Candidate gene studies are hypothesis driven, direct tests of common potentially 
functional variants in large samples combined with high-throughput strategies for 
genotyping and rigorous control of multiple tests. This approach has yielded a few 
consistently replicated candidates: two common variations at the NPPA-NPPB locus 
harbouring genes encoding atrial and B-type natriuretic peptides were associated with 
increased circulating natriuretic peptide concentrations and lower SBP (0.9-1.5 mmHg) 
and DBP (0.3-0.8 mmHg) (effect of two minor alleles rs5068 and rs198358), as well as 
reduced risk of hypertension.23 The limitations for this method are the tested variants 
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are based on imperfect understanding of the biological pathway, therefore the 
associations observed are often inconsistent thus difficult to replicate.24 
 
 
 
 
Figure 1.2. Pathways affected in monogenic hypertension in the kidney. The 
location of the mutated genes in monogenic hypertension are shown. Proteins mutated 
in monogenic HTN syndromes are marked by a red star. TAL, thick ascending limb of 
the loop of Henle; DCT, distal convoluted tubule; CD, collecting duct. (Adapted from 
Newton-Cheh et al., 2009, Nat. Genet.) 22 
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Genome-wide association study (GWAS) 
 
The HapMap and 1000 Genomes projects have identified millions of single nucleotide 
polymorphisms (SNPs) across the human genome.25 GWAS represents a powerful tool 
to investigate the global genetic architecture of complex diseases. It has led to 
important achievements in identifying a considerable number of genetic variants 
associated with CVD phenotypes. HTN is one of the first diseases studied by GWAS. 
The first hypertension GWAS performed by the Wellcome Trust Case Control 
Consortium in 2007 revealed no SNP associated with BP at the genome-wide 
significance threshold of p<10-7.26 In the following eight GWAS papers published, some 
SNPs have begun to be associated with BP related traits with considerable statistical 
power, for instance SNPs within the serine threonine kinase 39 (STK39) at 
chromosome 2q24.3, which encodes a protein involved in cation transports within the 
nephron. A breakthrough from GWAS in BP was made in 2009 when two large meta-
analysis from the Global BP Genetics (Global BPgen) and Cohorts for Heart and Aging 
Research in Genome Epidemiology 27 consortia identified a total of 13 loci associated 
with BP, in which two loci overlapped genes related to hypertension identified 
previously.  
 
GWAS offers advantages in studying complex diseases because of its 
unbiasedness in interrogation of common genetic variants against the disease of 
interest. DNA samples from large size of cases and controls populations are 
genotyped using micro-array chips covering up to a million of SNPs. Specific GWAS 
algorithms can identify variants with statistically different frequencies in cases and 
controls. Testing a large number of SNP markers leads to a large number of multiple 
comparisons and thus increases false positive rates. Bonferroni corrections or the false 
discovery rate is generally applied to avoid false positive rates. Typically, the 
Bonferroni-corrected p value is set to 0.05 divided by the total number of SNPs 
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analyzed (e.g., p=1 x 10-7 for 500K SNPs, p=1 x 10-8 for 1 million SNPs).28 A stringent 
genome-wide thresholds (nominal p values < 5x10-8 ) is usually used for a conventional 
GWAS, although a possible relaxation of variants at boarderline association (p < 1x10-7) 
may also be considered in the replication process. Top ‘hits’ are taken forward for 
replication in independent case-control sets using genotyping approach. These 
disease loci are then subjected to further functional studies to identify causal variants 
and the disease-causing mechanisms.29 Any associations reported in GWAS study will 
ne need to be verified in several well established studies across populations. This is 
particularly suited for discovering common variants with small to moderate effects. To 
date, 15 GWAS have reported associations of 159 common genetic variants (SNPs) 
with BP. 22; 27; 30; 31 The recent GWAS study led by the International Consortium of 
Blood Pressure has identified 10 new loci in or near genes that were not previously 
known to be associated with BP or HTN.30 Each of these reported variants may 
individually have small effect sizes, but they open up new horizons for potentially 
unknown mechanisms that alter the phenotype.32 One of the major limitations of 
GWAS is the lack of direct information provided on the causal SNP. Therefore in order 
to translate GWAS findings into discovery of novel biological functions and future drug 
targets, it is of great importance to prioritize these reported variants for functional 
follow-up studies, and to investigate the molecular effects in the context of CVD 
pathogenesis.  
 
Missing heritability 
 
The collective effect of BP loci identified through GWAS explains only a small 
proportion of BP heritability (<1%). Taken all types of genetic studies together, a large 
proportion of heritability is still unexplained by the current knowledge. The potential 
sources contributing to this missing heritability may be: rarer variants (less than 5% in 
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the population); structural variants that are not covered by the existing genotyping 
arrays; copy number variants (CNVs) or smaller (<1kb) insertion-deletion mutations; 
gene-gene interactions; and inadequate accounting for shared environmental factors in 
families.33 Therefore, besides continuous efforts in uncovering additional common 
variants of small effect, other strategies to identify more types of genetic variants need 
to be sought to fill in our knowledge gap.34  
 
 
  1.3 Coronary heart disease (CHD) 
 
Every year, 3.8 million men and 3.4 million women worldwide die from coronary heart 
disease,35 which represents the leading cause of mortality worldwide. The main 
underlying pathology of CHD is atherosclerosis, which is the process of cumulative 
plaques formation inside the arteries supplying oxygen-rich blood to the heart and 
brain that eventually leads to impaired or absent blood supply and myocardial 
infarction or stroke.36 Over the past decades, atherosclerosis has been considered to 
be a cholesterol storage disease, but now it is been acceped that inflammation also 
plays an important role.37 Vascular injury and thrombus formation are the key events in 
the initiation and progression of atherosclerosis and in the pathogenesis of the acute 
coronary syndromes.38 The mechanism of coronary thrombosis has been addressed 
mainly on plaque rupture, which is the most common cause of fatal acute myocardial 
infarction. The fibrous cap of the plaque typically overlies the necrotic core (lipid-rich 
center) and stands between the blood compartments. Ruptured plaques tend to have 
large lipid cores, and abundant inflammatory cells, as well as punctate or spotty 
calcification,39 which indicate the critical role of lipid composition in the pathogenesis of 
atherosclerosis.  
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1.3.1 Lipoprotein concentrations and CHD  
 
There are four major clinically used blood lipid indexes: total cholesterol, low-density 
lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and 
triglycerides. Consistent and ample evidence from large clinical trials have 
demonstrated the association between lipoprotein-related lipid levels and CVD 
incidence.40; 41 High concentrations of LDL-C are associated with increased risk of CHD, 
whereas high concentrations of HDL-C are inversely associated with the risk. 
Epidemiological studies have estimated that a 10% decrease in LDL-C can reduce the 
cardiovascular death by 10% and cardiovascular events by 25%,37 whereas each 1% 
increase in HDL-C concentrations reduces the CHD risk by 2%.42 While therapies 
including statins have proven the efficacy of lowering LDL in reducing CVD risk across 
the populations,43 other therapies targeting alternative aspects of the lipid profiles have 
so far been disappointing in clinical trials. Despite the association between low plasma 
HDL-C level and increased CVD risk, this has not been translated into proven evidence 
that raising HDL-C prevents CVD, as clinical trials of HDL-C raising interventions have 
shown no benefit.44; 45 More attention has now shifted to specific HDL sub-fractions as 
potential therapeutic targets or biomarkers for cardiovascular protection. 46 
 
1.3.2 Cholesterol efflux and HDL functions 
 
Cholesterol plays an indispensable role for cell structure and function, but excess 
cholesterol may lead to abnormal proliferation, migration, inflammatory responses 
and/or death of cells.47 Intracellular cholesterol may be eliminated through two different 
mechanisms: one is the esterification of cholesterol into cholesteryl esters, an option 
with limited capacity as overloading cells with cholesteryl esters is also toxic; the other 
is cholesterol efflux, an option with potentially unlimited capacity. After being proposed 
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by Glomset in 1968,48 reverse cholesterol transport (RCT) now represents the most 
widely accepted mechanism underlying the HDL-C metabolic pathways.46 RCT is the 
process by which cells transport excessive cholesterol back to the liver for bile acid 
synthesis and excretion, thus lowering the peripheral lipid burden.49 However, more 
recent studies have also shown that the cholesterol efflux from liver cells is also an 
important mechanism that determines HDL-C levels. Cholesterol efflux is regulated by 
a number of intracellular transporters, such as ATP-binding cassette subfamily A, 
member 1 (ABCA1) and subfamily G, member 1 (ABCG1) and scavenger receptor 
class B1 (SR-B1).50 ABCA1 and ABCG1 are responsible for the majority (~70%) of the 
total cholesterol efflux to serum or HDL in macrophage foam cells.51 ABCA1-mediated 
RCT can lead to the simultaneous efflux of phospholipids and free cholesterol to lipid-
free apoA-I (plasma pre-β1-HDL), which contributed to the assembly of nascent HDL 
particles.52 The concept of using HDL cholesterol (HDL-C) as a biomarker for 
cholesterol efflux transport, which further associates with CVD risk, has shown certain 
limitations in clinical studies.53 Recent studies have indicated cholesterol efflux 
capacity from macrophages, a metric of HDL function as an independent predictor of 
CVD risk.54 
 
1.3.3 Identification of CHD related genes  
 
Similar to HTN, CHD is also a polygenic disorder in most cases. Although the clinical 
heterogeneous nature of CHD hinders the phenotypic characterization of cases and 
controls for genetic studies,55 GWASs have so far identified a total of ~46 loci 
associated with CHD. Most of these loci are in regions previous unknown to be 
associated with CHD, which altogether explain approximately a total of 10% of the 
CHD phenotypic variance.56 The functions of many of these loci relating to CHD 
pathogenesis remain unknown. Therefore study of the underlying biology mechanisms 
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will broaden our understanding of the disease hence facilitates the translation and 
development of new therapeutic targets.  
 
1.4 Association of SNP rs13107325 in SLC39A8 with hypertension and 
other cardiovascular traits 
 
  1.4.1 GWAS report of SNP rs13107325 (Ala391Thr) 
 
In a GWAS paper published by the International Consortium of Blood Pressure (ICBP), 
an index SNP (rs13107325, C>T) located in the solute family 39 member 8 gene 
(SLC39A8) on chromosome 4q22 was reported to be associated with systolic blood 
pressure (SBP) and diastolic blood pressure (DBP).30 The rare allele T was associated 
with reduction of SBP (β = -0.981, p=3.3 x 10-14, 0.98 mmHg), DBP (β = -0.684, p = 2.3 
x 10-17, 0.69 mmHg) and high expression of this gene in liver tissues.22; 57 This SNP is 
also independently associated with circulating high-density lipoprotein cholesterol 
(HDL-C) concentrations [allele T, β = -0.023 (0.004), p=1.6 x 10-8], but not with CHD 
[allele T, OR=0.89 (0.79-0.99), p = 0.04].57 In a seperate meta-analysis of GWAS 
in >200,000 individuals the same SNP was significantly associated with SBP and DBP, 
and this was the only significant SNP in the SLC39A8 region (P. Munroe, personal 
communication). This SNP is a nonsynonymous polymorphism located in exon 8 of 
SLC39A8, causing an amino acid change from alanine to threonine (Ala391Thr). Its 
minor allele frequency (MAF) is ~9.7% in individuals of European ancestry (CEU), but 
is much lower in other populations. According to HapMap statistics, this SNP is 
approximately 1% in Southwest USA African (ASW), 1.2% in Han Chinese Beijing 
(CHB), 10.5% in Toscans in Italy (TSI), and absent in Japanese (JPT) and Yoruba 
African (YRI).  
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Apart from the association with BP and HDL-C, this SNP has also been 
associated with two additional phenotypes, which are body mass index [allele T, β = 
0.19 (± 0.04) kg/m2, p = 1.93 x 10-7] and schizophrenia [allele T, OR=3.30 (1.76-6.17, 
95% CI), p=0.027x10-8, homozygous genotype].57-59 The associations with different 
phenotypes indicate pleiotropy of this allele, which may be caused by different 
underlying molecular mechanisms.  The variant allele T seems protective for BP, but 
risk-increasing for all other phenotypes reported (debatable on HDL-C). Therefore 
caution is required when interpretating functional result, as the mechanism affecting 
one phenotype may not be applicable to others. Given all these associations are true, 
when characterizing the underlying biological mechanism of pleiotropic effects, several 
alternative models can be proposed to fit the observed data. If the variant decreases 
the risk of HTN but increases the risk of obesity, schizophrenia, questions need to be 
addressed on whether the opposite effects correspond to functional changes in 
different cell lines. It is important to test the following hypothesis: the effects of the 
same allele in different cell populations underlying associations with different diseases, 
a single molecular effect on multiple morphological or physiological consequences, or 
tagging of other potential causal variants within the same gene that result in different 
functions and phenotypes.60  
 
Bioinformatics prediction 
 
Bioinformatics tools are commonly used in prioritizing genes and variants based on 
their potential functionality. First of all, the linkage disequilibrium (LD) structure in the 
genomic region is examined. LD indicates the non-random association of alleles at 
different loci. The principle behind this method is that the index SNP can presumably 
display the association signal through its LD with causal variants.61 Once the variants 
within the target region in LD with the index SNP are identified, a series of 
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bioinformatics tools can be used to evaluate the possible properties of these variants. 
Evaluation criteria include prioritization of functional SNPs and mutations, annotation of 
known functional sites, predicted impact on splicing, transcription factor binding and 
gene expression, the effect of amino acid substitution on protein function.  
 
This SNP is located in a highly conserved genomic region with only one SNP in 
high LD across 100 kb of genomic sequence spanning the SLC39A8 gene in the CEU 
population according to HapMap release 21 (r2>0.8) by SNAP proxy research, and is 
not in high LD with any other SNP based on results from the 1000 Genome database, 
which implies a high possibility of this index SNP being functional (Fig. 1.3 A). The 
predicted topology of the ZIP8 protein consists of 7 putative transmembrane (TM) 
domains. The alanine-to-threonine substitution resulting from SNP rs13107325 is 
predicted to be located on the TM domain 6. Based on the fact that alanine at this 
position is found to be well conserved among mammals and birds,62; 63 the change of 
hydrophilicity from alanine to threonine can possibly have an effect on the protein 
function (Fig. 1.3 B). 
 
SNP rs13107325 is in LD (r2 = 0.841) with SNP rs1813006 located at the 
intergenic region near the gene BANK1, which encodes a B-cell-specific scaffold 
protein that functions in B-cell receptor-induced calcium mobilization from intracellular 
stores. Polymorphisms in this gene are associated with susceptibility to systemic lupus 
erythematosus.64 Being predominantly a complex disorder of perturbations in 
vasculature, kidney and central nervous system, some links have been established 
between inflammatory cells and end-organ damage which may contribute to HTN.65 
The role of B-lymphocyte in the pathophysiology of HTN has been reported to be 
through activation and agonistic autoantibodies to the angiotensin II type I receptors.66 
However, the MAF of ~2% for rs1813006 makes it difficult to perform genetic study on 
this SNP with our existing sample pool.  
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Conservation analysis revealed that the common allele C at rs13107325 site is 
well conserved in 22 out of the 23 amniote vertebrates in the alignment (Fig. 1.3 C), 
which suggests that the C allele may be important in preservation of protein function. 
The output of ConSurf analysis also indicates the alanine residue is highly conserved 
and buried (normalized conservation score 9, structural residual) when compared with 
142 reference sequences (Fig. 1.3 D). The degree to which an amino acid position is 
evolutionarily conserved is strongly dependent on its structural and functional 
importance. The substitution from a hydrophobic amino acid (Ala) to a hydrophilic polar 
amino acid (Thr) may change the position of the amino acid across the lipid bilayer of 
the cell membrane.  
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Figure 1.3. Bioinformatics prediction of rs13107325. (A) LD block of rs13107325 
by SNAP proxy search (https://www.broadinstitute.org/mpg/snap/ldsearch.php), under 
HapMap release 21 database (B) Amino acid change arising from the SNP 
rs13107325 (C) Comparative genomics from 23 mammals from Ensembl version 78 (D) 
The output of ConSurf Server analysis based on 142 reference sequences, the arrow 
points the major amino acid alanine at position 391 on the protein sequence of ZIP8. 
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1.4.2 Transmembrane protein and Solute Carrier (SLC) gene family  
 
Transmembrane protein 
     
Membrane proteins can selectively transport molecules to allow the cell to control and 
maintain its intracellular composition. There are three main ways for molecules to pass 
through cell membranes.67 Passive transport allows small uncharged solute particles 
diffuse across the membrane by the concentration gradient, until both sides of the 
membrane reaches an equilibrium. Facilitated diffusion, mediated by transporter 
proteins, also passes molecules from high to low concentrations in an attempt to 
achieve equilibrium, for instance glucose transport. However, charged molecules are 
unable to diffuse through a phospholipid bilayer, hence active transport is required by 
transmembrane proteins. These transport proteins determine the selective permeability 
of cell membranes and play a critical role in membrane function. Two classes of 
membrane transport proteins are reported, which are channel proteins and carrier 
proteins.   
 
Solute carrier family 39  
 
The solute carrier gene (SLC) superfamily comprises at least 374 putative protein-
coding genes spanning across 58 families. SLC39 family proteins are members of the 
zinc- and iron-related protein (ZIP) family of metal ion transporters, which transport a 
wide range of substrates including essential metals, amino acids and various ions.68 
The human SLC39 family contains 14 members of the ZIP members, which transport 
divalent metal ions from cell exterior or lumen of intracellular organelles into the 
cytoplasm.69 These proteins are highly conserved in human and mouse.70 ZIP proteins 
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appear to play crucial roles in metal homeostasis and perhaps unrevealed signalling 
pathways.71 
 
SLC39A8 encodes a zinc (Zn2+) transporter protein ZIP8, which also exhibits 
high affinity for other divalent metals such as cadmium (Cd2+), manganese (Mn2+) and 
iron (Fe2+).33 Residing primarily on the plasma membrane of cells,72 ZIP8 functions as a 
divalent cation/HCO3- symporter, bringing metal ions from blood into tissues and 
organs such as lung, pancreas, placenta, kidney tubules and testis.73; 74 It has been 
shown in Madin-Darby canine kidney cells that ZIP8 is largely internalized during Zn2+ 
homeostasis, but moves predominantly to the cell surface membrane during Zn2+ 
depleted conditions.75 Down-regulation of ZIP8 reduces cellular Zn2+ content in lung 
epithelia and correlates with reduced rates of Cd2+ uptake in small cell lung cancer 
derived cell lines transfected with glutamate-cysteine ligase catalytic subunit (GCLC). 
76; 77 
 
ZIP8 was first identified in 2002 in a screen of monocyte cDNAs induced by 
Mycobacterium bovis bacteria cell wall components.78 ZIP8 closely relates to ZIP14 in 
structure and function, both encompassing nine exons and three alternatively spliced 
noncoding exons 1.70 They are distinguished by a signature sequence (HEXPHEXGD) 
in TM-V that is not found in other ZIP transporters. HEXXH is a Zn binding motif found 
in most Zn metalloproteases.79 In ZIP8, the first histidine in this motif is replaced by a 
glutamic acid (E), which is suggested to confer the ability to bind/transport other metal 
ions such as Cd2+, Mn2+ and Hg2+.80 ZIP8 has been reported to transport Cd2+, Zn2+, 
Mn2+, Fe2+ and Co2+ in cRNA-injected oocytes, with a νmax value of Cd2+ >Zn2+ > Fe2+,81; 
82 There is not enough evidence yet in whether other divalent metals can also be 
transported by ZIP8.82  
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1.4.3 Distribution and functional characterization of ZIP8 
 
ZIP8 functions as a divalent cation/bicarbonate symporter,83 moving both metal ions 
(Zn2+, Mn2+, Fe2+, Hg2+) and HCO3- into the cell in an electroneutral manner.84; 85 ZIP8 
has been found to be ubiquitously expressed in various tissues and is localized 
predominantly on the apical side of the plasma membrane, which is a key feature for 
metal uptake and disposition.86 The presence of ZIP8 on the intracellular membranes 
of endoplasmic reticulum, Golgi apparatus, lysosomes and mitochondria were also 
reported.76; 87; 88 The distribution of ZIP8 in other cellular domains suggests the 
possibility of trafficking between the intracellular compartments and membrane during 
physiological and pathophysiological conditions.84 
 
ZIP8 is expressed at medium to high levels in 32 organ systems, most 
abundant in kidney, testis, breast, placenta, lung, duodenum, etc.89; 90 Gene expression 
can be induced in primary human lung epithelia, monocytes and macrophages in 
response to tumour necrosis factor alpha (TNFα) or lipopolysaccharide (LPS).91; 92 This 
up-regulation can be significantly inhibited by NF-κB suppression using an inhibitor 
(Bay11-7082) or RELA-specific siRNA. This transporter has been reported to be a NF-
κB negative feedback regulator and is known to participate in the immune balance 
regulation through zinc-mediated suppression of IKK activity in monocytes, 
macrophages, and lung epithelia.93 In fact, SLC39A8 transcription is directly regulated 
by NF-κB; binding of NF-κB to the SLC39A8 promoter region has been demonstrated 
by chromatin immunoprecipitation 59 and electrophoretic mobility shift assay (EMSA).93 
 
Glycosylation is a common post-translational modification in ZIP proteins. In 
fact the predicted N-linked glycosylation sites have been proposed to modulate metal 
ion transport activity.94 Glycosylation of ZIP8 has been reported by many research 
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groups.86 There are three predicted N-linked glycosylation sites in the N-terminal 
region of ZIP8. The fact of heavy glycosylation following stimulation indicates the 
occurrence of additional post-translational regulatory events in controlling protein 
function.93 
 
A considerable body of evidence identified ZIP8 as a regulator of intracellular 
Cd2+: down-regulation of ZIP8 and ZIP14 were found in the metallothionein-null Cd-
resistant cells,95 whereas ZIP8 shRNA resulted in a decrease in Cd2+ accumulation; 
ZIP8-expressing mouse fetal fibroblasts have demonstrated a 10-fold increase in the 
rate of intracellular Cd2+ uptake and accumulation;96 ZIP8 was responsible for the 
genetic difference in damage to the testicular vasculature endothelium in mouse;97 He 
et al. reported that ZIP8-mediated Cd2+ transport acts in an active transporter manner 
in MFF cells by moving metal ions against concentration gradient in an energy-
dependent manner.84 As a cotransporter, ZIP8 has its maximal activity at an extra-
cellular pH of 7.5, which is the physiological pH of a lot of tissue fluids. Electrogenicity 
studies showed an influx of two HCO3- anions per one Cd2+ (or one Zn2+) cations, 
suggesting the transport occurred in electroneutral complexes. In organ with different 
HCO3- gradient such as kidney, HCO3- might act as the driving force for Cd2+ uptake, 
which is ~24mM at the proximal tubule then decreases as the glomerular filtrate 
passes through S2 and S3 through to the ascending loop of Henle. Abundant 
expression of ZIP8 on the apical side of the renal epithelial tubule cells may be 
responsible for the reported accumulation of Cd2+ in kidney proximal tubule.98 This 
altogether might explains the accumulation of Cd2+ in kidney proximal tubule and the 
ultimate nephrotoxicity. Studies have revealed that ZIP8 is responsible for causing Cd-
induced testicular necrosis and acute renal failure -- the symptoms seen in BTZIP8-3 
mice (harbouring 3 additional times copies of SLC39A8), implying its function as an 
important metal transporter involved in renal metabolic acidosis and kidney damage in 
human.99 
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              The global SLC39A8(-/-) knockout was prone to be early embryo-lethal, 
resulting in hypomorphic SLC39A8(neo/neo) mice with a marked reduction in ZIP8 
expression in the embryo, yolk sac, fetus and placenta. Additionally, there was the 
presence of severe congenital defects, including hypoplasia of multiple organs, 
followed by death between gestational day 18.5 and 48 hours postnatally.100 
Histologically, SLC39A8 (neo/neo) mice had diminished levels of plasma iron, zinc, 
total iron-binding capacity (TIBC), serum alanine aminotransferase (ALT), aspartate 
aminotransferase (AST) and triglycerides (TGs) comparing to SLC39A8 (+/+) and 
SLC39A8 (+/neo) at postnatal day 1. This suggests ZIP8-mediated metal ion transport 
plays a critical role in utero, promoting neonatal growth, organ morphogenesis, and 
haematopoiesis. Other improved models such as SLC39A8 (neo/neo) BTZIP8-3 line 
and hypomorphic SLC39A8 (neo) allele mouse with downregulation of ZIP8 have 
circumvented the mentioned congenital defects.100; 101 BTZIP8-3 line has 3 additional 
copies of the SLC39A8 gene comparing to its diploid pair found in WT mice, therefore 
expresses ~ 2.5 times greater amounts of ZIP8 comparing to WT mice on the cDNA 
level. A single dose subcutaneous administration of Cd2+ (30µmol/kg) caused acute 
renal failure and histological evidence of proximal tubular damage in the BTZIP8-3 
mice but not their non-transgenic littermates.70 Supplementation of CdCl2 in drinking 
water (100mg/L-8,800 mg/L for 20 weeks) of the BTZIP8-3 mice resulted in increase in 
tissue-specific increase in Cd2+ (kidney, liver and lung but not testis), Zn2+ (liver > 
kidney, lung or testis) and Mn2+ content (liver and lung > lung or testis) and decrease in 
Ca2+ content when compared with the WT. No difference was seen in both WT and 
BTZIP8-3 mice in terms of levels of AST, ALT, iron and copper in liver, kidney, lung 
and testis.102  
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1.4.4 Structural analysis  
 
Transmembrane protein is a type of membrane protein that spans across the 
entire biological membrane. It is been classified into the integral and peripheral 
membrane proteins. Integral membrane proteins are polypeptide chains embedded 
into biological membranes, whereas peripheral membrane proteins adhere only 
temporarily to the biological membrane by attaching to integral membrane proteins or 
penetrating the peripheral regions of the lipid bilayer. Membrane proteins are typically 
associated with lipid bilayers by extending through the lipid bilayer in an α-helical 
conformation. Most of these transmembrane proteins are amphipathic by consisting of 
both hydrophobic and hydrophilic regions. The hydrophobic regions pass through the 
membrane and interact with the hydrophobic tails of the lipid molecules in the interior 
of the bilayer and are composed largely of amino acid residues with nonpolar side 
chains, whereas the hydrophilic regions are exposed to water on either side of the 
membrane and composed mainly of amino acids with polar side chains. A 
representative interpretation of membrane-spanning segments of polypeptide chains is 
illustrated in Fig. 1.4.  
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Figure 1.4. Segment of transmembrane polypeptide chain crossing the lipid 
bilayer as an α-helix. Hydrophobic amino acids are labelled in green and yellow. 
Usually an α-helical region consists of 20-25 hydrophobic amino acids. (from Molecular 
biology of the Cell, 4th edition) 103 
 
 
1.5 Biological effects of trace metals and their relationship with CVD  
 
  1.5.1 Zinc   
 
Zinc (Zn) is an essential metal element serving as catalytic or structural components of 
enzymes and proteins that are indispensable in our body. It is estimated that ten 
percent of genes encode zinc-binding proteins.104 Zn2+ maintains the normal structure 
and physiology of cells by participating in a variety of biological events including 
intracellular signal transduction,105 cell cycle and proliferation,86 and maintenance of 
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numerous transcription factor functions.106 Zn2+ homeostasis is particularly important 
during anti-inflammatory response, for example Zn2+ deficiency increases systemic 
inflammation, tissue injury in response to sepsis.107 Zn2+ plays a critical role in the 
redox signalling pathway, whereby deficiency of Zn2+ under oxidative stress leads to 
the degradation of critical proteins, i.e. protein kinase C (PKC).108 Zn2+ deficiency may 
also result in an increased risk of infections including pneumonia and diarrhoea.109 
Lower serum Zn2+ level has been assoiciated with coronary heart events in patients 
with Type II diabetes.  
 
1.5.2 Cadmium  
 
Cadmium (Cd) is a highly toxic metal and one of the concerned pollutants that is 
distributed widely in air, soil, sediment and water.110 It is commonly considered as a 
‘guest’ metal generated in the lead : zinc mining, smelting and use of fertilizers.111 It is 
one of the hazardous pollutants widely distributed in soil, sediment, and water, 
particularly in areas with high levels of particulate matter under diameter of 2.5 µΜ 
(PM2.5).110 Non-occupational exposure mainly comes from diet and smoking,and it 
accumulates in the human body with a long biological half-life of 15-30 years.86 It has 
been classified as a group I carcinogen by International Agency for Research in 
Cancer (IARC) and group B1 human carcinogen by Environmental Protection Agency 
(EPA).112 It is also been classified as the Class D element, together with mercury, lead, 
for which is highly toxic even at low levels, with no clear biological function established 
to date.113 The critical cadmium concentration in the kidney cortex defined by the World 
Health Organization is 200mg/kg, which corresponds to approximately 1mM.114 The 
direct exposure to Cd2+ may cause harm to a variety of organs including lung, liver, 
kidney and bone.115; 116 Long-term exposure to low doses of Cd2+ can result in severe 
diseases such as nephropathy and osteomalacia.84 The main mechanism of Cd2+ 
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toxicity is through oxidative stress, and damage of enzymes and proteins by forming 
disulphide bonds.99 The main target organs in humans are kidney and liver.117 
 
The damage that Cd2+ causes to a target cell becomes effective only after influx 
(Cd2+ uptake) by that cell. Following its primary absorption from the intestinal or lung 
(portals of entry), the main means of transportation is through binding with various 
polypeptides such as metallothionein (MT), reduced glutathione and other thiol-
proteins in the blood. The complex accumulates in liver and especially kidney cells, 
and ultimately deposited predominantly in these two organs. Because Cd2+ is not 
essential to living organisms, its transport mechanisms can be related to channels 
developed for other essential metals. Several ion channels and transporters have been 
described to transport Cd2+ across the plasma membrane, such as DMT1 (encoded by 
SLC11A2),118 and voltage-gated calcium channels.119 By sharing the same transporters, 
other divalent cations (i.e. Zn2+, Cu2+, Mg2+, Mn2+) can compete with Cd2+ for cell 
entry.75 Among all the transporters, it is reported that ZIP8 has higher Cd2+ transport 
affinity (Km=0.48µM) than that of DMT1 and Ca2+ channels. It is therefore speculated 
that under low Cd2+ exposure, ZIP8 may be favoured over other transporting systems 
in transporting Cd2+.99 The cellular Cd2+ detoxification/efflux pathway is mostly 
dependent on the up-regulation of MT proteins. MT consists of multiple cysteine 
residues by which heavy metal ions can be immobilized and becomes less toxic.120 
Cd2+ efflux system is also mediated by the multidrug resistance protein (MRP) family. 
Human MRP1 is induced by Cd2+ exposure and its expression levels are associated 
with Cd2+ resistance.121 
 
The renal cortex is one of the major target sites for acute or chronic Cd2+ 
exposure. Absorbed Cd2+ in the blood circulation in the MT-binding complex is filtered 
by the glomeruli, followed by reabsorption at the proximal tubule.113; 122 Several studies 
have suggested that endothelial cells of the kidney can be damaged by low level of 
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Cd2+. The endothelial nitric oxide synthase (eNOS) has been shown to be up-regulated 
by 10 to 20 fold in rats after 9-week sub-chronic exposure to Cd2+.123 Cd can also 
stimulate the release of a number of pro-inflammatory components from endothelial 
cells that would facilitate the progression of atherosclerosis.124; 125 
 
1.6 Relationship between metal exposure and CVD  
1.6.1 Effects of Cd2+ exposure and hypertension 
 
Chronic Cd2+ exposure is associated with hypertension in animal models.126 A large 
number of epidemiological studies have suggested a possible link between exposure 
of Cd2+ and the development of hypertension.127; 128 However, the exact influence of 
Cd2+ on human BP has been inconsistent in the literature.129 Tellez-Plaza et al. 
analysed data from the 1999-2004 US National Nutrition Examination Survey 
(NHANES) consisting of 10,991 participants (hypertensive and non-hypertensive) and 
they reported a modest association of blood Cd2+ (BCd) levels with elevated BP (SBP: 
1.36 mmHg, CI=-0.28-3; DBP: 1.68 mmHg, CI=0.57-2.78),130 followed by a similar 
association reported in a high Cd2+ exposure Korean population.131 A recent meta-
analysis in 2010 based on 12 studies demonstrated a positive association between 
BCd level and BP among women (including premenopausal and antihypertensive 
women), the BCd showed a larger estimated effect in the smoking-adjusted anaysis 
(SBP: =1.85 mmHg; 95% CI, 0.52-3.19; DBP: = 2.01 mmHg; 95% CI, 0.86-
3.15).129 This finding was supported by three recent studies on the positive association 
between BCd and BP in women.132-134 On the contrary, a prospective study led by 
Staessen et al. including 692 subjects failed to establish any significant link between 
BCd or urinary Cd2+ (UCd) with increased HTN risk, albeit the positive association 
between BCd and BP in premenopausal women (n=179).135 Based on available 
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literature, the positive relationship seems to be more evident  in females. The 
discrepancies across studies might be due to outcome misclassification bias 
(inconsistently defined across studies), limited small sample size, lack of adjustment 
for potential confounders (presence of other metals), or lack of standardization on BP 
measurements.130 This line of research would benefit from both physiological studies of 
cadmium mode of action, and longitudinal epidemiological studies of never-smoking, 
general populations to evaluate the relationships among BCd and UCd, and SBP, DBP, 
and sustained HTN. Most review papers highlighted the possible effect on 
cardiovascular systems at low Cd2+ exposure levels.125 136-138 
 
1.6.2 Effects of Cd2+ exposure and other CVD  
 
The types of Cd2+ exposure are through intake of contaminated food, drinking water, or 
by inhalation of polluted air or industrial occupation. Increased cardiovasculcar 
mortality was documented in areas with increased potential for cadmium exposure 
[geometric mean levels: 0.28 and 0.40 g/g (urinary cadmium per gram of urinary 
creatinine) for men and women] based on 13,958 adults from The Third National 
Health and Nutrition Examination Survey.139 Cadmium exposure has been associated 
with numerous CVDs including atherosclerosis, peripheral arterial disease, myocardial 
infarction. In the Atherosclerosis Risk Factor in Female Youngsters (ARFY) study from 
195 healthy individuals, Cd2+ level was independently associated with early 
atherosclerotic vessel wall thickening.140 Houtman et al. also observed a higher 
incidence of atherosclerosis in a Cd-contaminated area in the Netherlands.141 
Numerous studies reported the adverse cardiovascular effects Cd2+ exerts by 
promoting atherosclerosis and causing abnormal cardiac function.125; 138 Urinary Cd2+ 
level was independently associated with myocardial infarction 142 and serum Cd2+ level 
was associated with high intima media thickness as a sign of early atherosclerotic 
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vessel wall thickening.140 The National Health and Nutrition Examination Survey 
(NHANES) in 1999-2000 reported the blood Cd2+ (BCd) and Pb2+ levels were 
associated with peripheral arterial diseasewhich is defined as a blood pressure ankle 
brachial index <0.9 in at least one leg. 31;143 UCd levels were reported to be 36% higher 
in subjects with PAD than in those without, BCd was 16% higher in PAD cases than in 
noncases.143 Circulating Cd2+ level has also been reported to be increased in patients 
with coronary artery disease. However, epidemiological data has not yet firmly 
established a link between Cd2+ levels and CVD, with possible confounding effects 
such as smoking status and other confounding metals.144 Evidence of endothelial cell 
death induction is thought to be fundamental in the atherosclerosis-promoting 
properties of cadmium. 136 
 
1.6.3 Mechanism of actions of Cd2+ poisoning  
 
The established hypothesis is that Cd2+ exerts its toxicity to the vascular endothelium 
through several mechanisms, typically through direct vasoconstriction and inhibition of 
the vasodilator substance nitric oxide.145 A separate mechanism is the increase of 
oxidative stress caused by lipid peroxidation leading to injury of cellular components 
due to the interaction of metal ions with the cell organelles.146 Cd2+ can display its 
detrimental effect to the vascular cells by increasing monocyte/macrophage 
transdifferentiation into foam cells, by causing endothelial dysfunction and subsequent 
cell death, and by stimulating smooth muscle cell proliferation at low Cd2+ 
concentrations.136 These actions can lead to the initiation and promotion of 
atherosclerosis. It is noteworthy that different effects have been observed with high 
and low doses of Cd2+ exposure.147 Cadmium is toxic to the vascular system as well as 
the kidney, but it remains to be determined how these various effects of Cd summate 
to influence the net regulation of BP. 148  
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1.6.4 Effect of Zn2+ exposure and CVD  
 
Low serum Zn2+ levels are correlated with hypertension, CHD, type II diabetes and 
hyperlipidemia.149; 150 Zinc deficiency may lead to increased oxidative stress, 
mitochondrial dysfunction, cardiomyocyte dysfunction, which can lead to abnormal 
cardiac remodelling, heart failure, or hypertension.151 An inverse correlation of BP and 
serum Zn2+ was observed in 35 hypertensives compared to 50 normotensives (75.34 ± 
13.33 µg/dL in hypertensives, and 89.62 ± 23.79 µg/dL in normotensives, p<0.001).152; 
153 Increased gastrointestinal absorption and urinary excretion of Zn2+ was confirmed in 
primary arterial HTN from experimental models and clinical studies.154 Loss of Zn2+ 
homeostasis may either considered to be the primary (cause) or the secondary (effect) 
of increased arterial blood pressure.155 Zinc can inhibit gene expression including NF-
κB and is an important cofactor for superoxide dismutase (SOD), therefore is served as 
an antioxidant.149 Low serum Zn2+ levels were found in elderly hypertensives with low 
plasma renin activity.156 These effects altogether may account for the antihypertensive 
effects of Zn2+.149; 157 
  
Zinc has shown to have protective effects in coronary artery disease and 
cardiomypathy.104 On the molecular level, its mediation of adhesion molecule 
expression through inhibiting NF-κB transcription in endothelial cells may act as a 
critical step in development of atherosclerosis.158 According to the “response to injury” 
hypothesis proposed by Ross and Glomset that atherosclerosis commences with 
endothelial cell injury,159 Zn2+ may have a protective role in maintaining the integrity of 
endothelial cells and thus decrease vessel susceptibility to atherosclerosis.160 
Myocardium dysfunction is intimately involved in the aetiology of many forms of CVDs 
and the possible relationship of Zn2+ homeostasis and heart failure has been 
investigated by a number of studies. In humans, it has been demonstrated that plasma 
41"
"
Zn2+ levels decreased after acute myocardial infarction.161-163 The involvement of Zn in 
insulin signalling and pathogenesis of diabetes has further indicated its potential role in 
diabetic cardiomyopathy.164; 165 A graphic summary of the effects of Zn2+ deficiency on 
CVD pathogenesis is shown in Fig. 1.5.   
 
 
Figure 1.5. Role of Zn2+ deficiency in cardiovascular pathologies 
(cited from P.J.Little et al, Nutrition, 2010) 104 
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1.7 Proposed mechanisms of metal ions contributing to the pathogenesis 
of vascular disease  
 
1.7.1 NF- ĸB pathway  
 
NF-ĸB is a transcription factor that regulates a broad spectrum of physiological 
processes including innate- and adaptive-immune response, cell adhesion and 
proliferation, embryonic development and tissue remodelling.166 Most mammalian cells 
comprise of five NF-ĸB family members, RelA (p65), RelB, c-Rel, p50/p105 (NF-ĸB1) 
and p52/p100 (NF-ĸB2), which form different NF-ĸB complexes in homo- and 
heterodimers.167 The predominant complex in many cell types is the p65:p50 
heterodimer. NF-ĸB complexes are normally retained in the cytoplasm by a family of 
inhibitory proteins IĸBα, which is phosphorylated by IĸB kinase (IKK) and degraded by 
the 20S proteasome. This process results in IĸBα degradation and release of NF-ĸB, 
allowing it to translocate into the nucleus to transactivate target genes.168 These 
pathways are classified as canonical (classical) and non-canonical (alternative). In the 
canonical pathway, the IKK dimer is activated by signalling through TNFR1 and IL-1R, 
TLRs (Toll-like receptors) in response to cognate ligands, leading to the modification of 
TRAF6 with Lys63-linked polyubiquitin chains (Ub). A schematic representation of TNF-
R1-induced NF-ĸB activation is shown in Fig. 1.6.  
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Figure 1.6. Schematic representation of the TNF-R1-induced pathway of NF-κB 
activation.169 
 
 
Various techniques can be used to assess the activation triggered by 
extracellular stimuli based on essential steps in this pathway. These include activation 
of IKK complex (western blotting, ubiquitination and kinase assay), the phosphorylation 
and proteolysis of IκBs (western blotting), phosphorylation of RelA/p65 (western 
blotting), induction of NF-ĸB transcriptional activity (luciferase reporter assay), etc.  
 
44"
"
Effect of Zn2+ influx on NF-κB activation and cholesterol efflux  
 
Studies in humans and animals suggest that Zn2+ can potentially affect lipoprotein 
metabolism and hence impact on CVD risk.170 Zn2+ metabolism is primarily coordinated 
by ZnT (exporters) and ZIP (importers) transporters which maintain its normal cellular 
homeostasis. ZIP8 is a major Zn2+ importer, supported by the fact that SLC39A8 
hypomorphic mice exhibited reduced Zn2+ uptake and increased NF-kB activation.93 
Overexpression of ZIP8 results in enhanced Zn2+ uptake in Chinese hamster ovary 
cells, which highlights its important role in Zn2+ transport in the cells devoid of efficient 
Zn2+ transporters.171 Zn2+ can inhibit NF-kB activation through binding of IKKβ kinase, it 
is therefore proposed that ZIP8 acts as a negative feedback regulator of NF-kB and 
innate immune activator through coordination of Zn metabolism (Fig. 1.7).93 The 
association between HDL-C and rs13107325 in SLC39A8 brings forward the possible 
involvement of ZIP8 in cholesterol efflux which participates in the pathogenesis of 
coronary artery disease. HDL is a complex molecule containing apolipoproteins such 
as ApoA-I which is an acceptor for cholesterol. As discussed earlier, the transporter 
ABCA1 plays an important role in cholesterol efflux from cells. The ABCA1 expression 
is positively regulated by NF-kB in macrophages.172 It is possible that ZIP8 could 
partially influence cholesterol efflux through its effect on Zn2+ metabolism and 
consequently on NF-kB activity. Zn2+ influx can negatively regulate NF- kB activation, 
leading to downregulation of ABCA1, which will result in reduced cholesterol efflux 
activity and lower levles of extracellular HDL-C. However formation of HDL-C is a 
complex process whereas some steps are ABCA1 independent.   
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Figure 1.7. Schematic representation of regulation of Zn2+, NF- kB signalling and 
cholesterol transport pathway (diagram adapted from M.Liu et al. Cell Reports, 
2013)93  
 
NF- kB signalling in CVD 
 
NF-kB  has been linked to both cardiovascular health and disease. In the adult, NF- kB 
can have both beneficial and detrimental effects in the cardiovascular system, with the 
pathway being either over- or under-stimulated in certain disease settings.173 It is 
shown that NF-kB is cardioprotective during acute hypoxia and reperfusion injury, 
whereas prolonged activation appears to be detrimental and promotes heart failure by 
inducing chronic inflammation and through enhanced elaboration of cytokines including 
TNF-, interleukin-1 and 6.174 The NF-kB signalling controls many processes including 
inflammation, cell survival, differentiation and proliferation, in particular its effect on cell 
survival/apoptosis may have larger impact on CVDs. The canonical pathway is 
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implicated in atheroslerosis, myocardial infarction, ischaemic preconditioning, 
hypertrophy and heart failure. NF- kB is considered to play a pathophysiological role in 
the development of pulmonary arterial hypertension, however its role in arterial 
hypertension is not well documented.175  
 
1.7.2 Extracellular-signal-regulated kinases (ERK1/2) pathway 
 
Extracellular-signal-regulated kinases (ERKs) are members of the larger family of 
mitogen-activated protein kinases (MAPKs). ERK1/ERK2 (also known as p44/p42 
MAPK, respectively) are two isoforms of ERKs which are 84% identical and similar in 
functions.176 Activation of ERK involves diverse sequential phosphorylation cascades. 
One route is through stimulation of G protein-coupled receptors (GPCRs) and release 
of Gβγ subunits, the other is through activation of growth factor-stimulated tyrosine 
kinase receptors such as the epidermal growth factor (EGF) (Fig. 1.8). The ligation of 
EGF and cell adhesion receptors lead to GTP loading and activation of Ras, a small 
GTPase which recruits the MEK kinase Raf to the membrane where it is activated, 
which in turn activates MEK. ERK1/2 are activated through the Ras/Raf/MEK cascade, 
where activated MEK will then phosphorylate threonine 202 and tyrosine 204 residues 
on the dual-specificity motif (T-E-Y) to activate ERK1/2.177  
 
The proposed ERK response to Cd2+ poisoning can be via multiple pathways, 
as shown in Fig. 1.8. In the calcium-mitochondria-caspase apoptosis pathway, Cd2+ 
enters cells through the ZIP8 transporter, the accumulation of the ions may act on the 
endoplasmic reticulum to increase the cytosolic Ca2+ concentration and subsequently 
the production of ROS.178 ROS participates in both the activation of ERK and in the 
inhibition of dual-specificity phosphatases including MKP3, which may further 
participate in the constitutive and long-term activation of ERK.179 This activation will 
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ultimately result in the activation of caspase-3 and -8 and cell apoptosis.180 In the ROS-
GSK3 pathway, Cd2+ might act on the mitochondria to generate ROS, which in turn 
activates GSK-3 and leads to autophagic cell death. Other parallel pathways may be 
present such as protein kinase C (PKC) signalling, which is shown to play a prodeath 
role.181 Cd2+-induced cell death can cause nephrotoxicity which will have a further 
impact on the regulation of blood pressure. The ability of ZIP8 to transport Cd2+ is 
essential to the accumulative toxicity of Cd2+. Therefore, genetic variation of SLC39A8 
which leads to less accumulation of Cd2+ will protect cells from the Cd2+-induced 
cytotoxicity.  
 
 
 
Figure 1.8. Schematic diagram of the potential mechanisms of Cd2+ induced 
ERK1/2 activation and cell death in kidney. EGF, epidermal growth factor; GPCR, G 
protein-coupled receptor; MEK, mitogen-activated protein kinase kinase; (Diagrams 
modified from P. Martin et al., FEBS,  2009 and L. Yang et al., Autophagy, 2009) 182; 183 
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Phosphorylated ERK1/2 can enter the nucleus, and thereafter phosphorylate 
transcription factors involved in cell-cycle regulation. ERK is a promiscuous kinase 
which can phosphorylate more than 100 different substrates. It has been widely 
associated with every major aspect of cell physiology, including cell proliferation, 
survival, apoptosis, motility, transcription, metabolism and differentiation.177 Activated 
ERK can control many cell responses depending on the kinetics of activation,184 the 
subcellular localization and scaffolding proteins.185 The biphasic kinetics of ERK 
activation is characterized by a rapid and transient burst of activation (phosphorylation 
of Tyr and Thr residues) upon first few minutes of stimulation, followed by a second 
stable activation that lasts for a few hours.186 
 
The Ras/Raf/ERK pathway is found to be frequently deregulated in tumours. 
Many studies have associated its oncogenic properties to increased cell survival, by 
upregulating the pro-apoptotic proteins such as Bax,187 or by promoting the activity of 
anti-apoptotic proteins such as Bcl-2 and Bcl-X1.177; 187 ERK is also reported to 
promote the activity of the tumour suppressor gene p53, which is supported by its 
ability to bind to p53 and phosphorylating Ser15 in vitro.188; 189   
 
Evidence for ERK activity in hypertension  
 
Basal intracellular ERK activities are elevated in a number of animal models of 
hypertension, including aorta of the spontaneously hypertensive rats (SHRs).190-192 In 
addition, inhibition of ERK activation attenuates the VSMC response to 
vasoconstrictors. ERK also plays a role in mediating vascular smooth muscle cell 
growth.  
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Role of ERK1/2 in cell death 
 
A growing body of evidence suggests that aberrant ERK activation can promote cell 
death. Sustained cytoplasmic ERK activity might promote senescence or autophagy, 
whereas sustained nuclear sequestration of ERK activity triggers apoptosis.193 The 
intrinsic apoptotic pathway is characterized by release of cytochrome c from 
mitochondria and activation of initiator caspase-9,194; 195 whereas the extrinsic apoptotic 
pathway is linked to the activation of caspase-8/3, poly (ADP-ribose) polymerase 
(PARP) cleavage and DNA condensation.184; 186; 196  
 
Role of ERK in vascular smooth muscle cell (VSMCs) growth regulation  
 
Abnormal growth and proliferation of VSMC lead to thickening of the SMC layer and 
narrowing of the lumen which are key features of hypertension.197 The association 
between ERK activation and cell proliferation suggests a potential role for ERK 
activation in the regulation of vascular smooth muscle cells proliferation: prolonged 
ERK activation is associated with the modulation of VSMCs from a contractile to a 
proliferating phenotype; transactivation of the EGF receptor leading to activation of 
ERK has been shown to be involved in the induction of VSMC growth after treatment of 
α1-adrenoceptors;198 therapeutic inhibition of ERK activation in vitro has been shown to 
improve smooth muscle hyperplasia and contributed to the restoration of the contractile 
response of SMC at tissue level.199  
 
Cd2+ uptake and ERK activation  
 
An unconventional activation pattern has been observed in cells exposed to 
micromolar concentrations of cadmium. A sustained ERK activation, which lasts up to 
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6 days post cadmium stimulation (1.25µM) was reported in HEK293 cells.196 Similar 
observations have been made in other cell types (primary mouse and rat fibroblasts, 
kidney-derived epithelium cell lines, bone marrow derived macrophages, primary 
calvaria cells, HeLa cells, mouse myoblast cells, human T cells, mouse macrophages, 
rat lung cells).181; 200-203 However, the classical anti-apoptotic function of ERK following 
cadmium exposure has been reported in other cell types, for example ERK1/2 activities 
were decreased in human non-small cell lung carcinoma CL3 cell line (<80 µM Cd2+) 
and moderately activated at higher doses.179 Others have reported a MAPKs-
independent cell apoptosis induced by Cd2+ in human lymphoblastoid Boleth cells. 
These apparent discrepancies indicate that the relationship between ERK activation 
and cell death may be cell type specific, in which different regulation mechanisms may 
be in place contributing to Cd-induced cell death. In conclusion, the sustained 
activation of ERK in a number of cells can associates with, or at least partially 
contribute to cell death signalling.  
 
The entry of cadmium into cells is necessary for the sustained ERK activation, 
which is tightly associated with cell death,183 however the cadmium-induced sustained 
activation of ERK may be a result of survival mechanism following cadmium poisoning. 
Cadmium has been reported to induce two types of cell death in mesangial cells, 
including both autophagy and apoptosis,194 which suggests that activation of ERK also 
occurs through a caspase-independent pathway. Cd2+ induces an increase of cytosolic 
Ca2+, followed by ERK activation and mitochondrial depolarization, which then triggers 
autophagy and apoptosis.194 Similar observations were also seen in NIH3T3 cells, rat 
astrocytes and tumour-derived Saos-2 cells.204;178; 188 The increase of Ca2+ in turn leads 
to an increase in reactive oxygen species (ROS) and mitochondrial impairment. Taken 
together, these correlations suggest that Ca2+ might play a role in the cadmium 
response upstream of ROS production.  
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In addition, the entry of Cd2+ in cells can also result in a time- and dose-
dependent oxidative response by production of ROS.205 Several studies demonstrated 
the role of ROS in ERK activation, supported by a strong activation of ERK leading to 
apoptosis which can be alleviated by antioxidants in vitro.205 However, the mechanisms 
by which ROS activate MAPK are still inconclusive. Some groups reported ROS could 
stimulate the Ras/Raf/ERK pathway by promoting the activation of tyrosine kinase 
receptors or increasing activation of Raf signalling;184; 186 whereas others demonstrated 
a correlation between MKP3 degradation and a strong activation of ERK.206 It is likely 
that ROS production in response to Cd2+ results in the activation of the MAPK cascade 
and inactivation of MKP3 that contribute to the initiation and stabilization of ERK 
activation, respectively.183  
 
The occurrence of cell death following cadmium poisoning including apoptosis, 
necrosis and autophagy. The type of cell death induced depends on factors such as 
the cadmium concentration, and the inducing pathway (i.e. lipid peroxidation, ROS 
production, intracellular calcium concentration).194; 207 Although ERK alone is sufficient 
to induce cellular response leading to cell death in certain systems, cadmium can 
trigger a panel of pathways other than caspase activation that also culminate in cell 
death.208  
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1.8 Summary  
 
These molecular pathways identified a potential link between ZIP8 and CVD events 
possibly via transportation of Cd2+. The entry of Cd2+ into the cells causes sustained 
activation of the extracellular signal-regulated kinases signal transduction pathway.123 
Cd2+ exposure results in a complex response including increased oxidative stress,209 
kinase activation, protein degradation, and sustained activation of ERK,183 which has 
been directly linked to cell death signaling.196 ZIP8 might be involved in the activation 
of some of these pathway by transporting Cd2+ into the cells, which leads to the 
development of various cardiovascular events.  
 
Further studies are required in order to understand the roles of ZIP8 and the 
molecular functional effects of the SLC39A8 variant that has been found to be 
associated with BP and HDL-C levels. Knowledge gained from such studies may 
facilitate development of novel therapeutic interventions.  
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 1.9  Aims and objectives  
 
1. To investigate whether the Ala391Thr substitution resulting from SNP rs13107325 
affects SLC39A8 gene expression in human umbilical vein endothelial cells and 
human umbilical artery smooth muscle cells at mRNA and protein levels 
 
2. To perform a functional study of the Ala391Thr substitution resulting from SNP 
rs13107325 in relation to ZIP8 function in transporting metal ions in vitro, i.e. Cd2+ 
and Zn2+ 
 
3. To perform pathway analysis on whether SLC39A8 overexpression or the 
Ala391Thr substitution triggers different signalling pathway activations (i.e. ERK1/2 
and NF-ĸB) under Cd2+ treatment  
 
4. To investigate a possible effect of SLC39A8 overexpression and Ala391Thr 
substitution on cholesterol efflux in vitro, a potential underlying mechanism for the 
reported association of rs13107325 with circulating HDL-C level 
 
5. To investigate whether the Ala391Thr substitution has an effect on Cd2+ toxicity 
shown by phenotypic change (i.e. proliferation and apoptosis) in transfected 
HEK293 and HUVECs in vitro 
 
6.  To conduct bioinformatics study on the impact of Ala391Thr substitution on ZIP8 
function and secondary structure of the protein 
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2. Materials and Methods 
2.1 Subjects and samples  
2.1.1 Collection of human umbilical cords for isolation and primary 
culture of vascular cells 
 
Fresh human umbilical cords of about 10cm in length were collected from healthy 
newborn babies from the Royal London Hospital. Cords from miscarriages, stillbirths, 
HIV positive, group B Streptococcus positive or hepatitis B infected mothers were 
excluded, however pre-eclamptic or diabetic individuals were not included in the 
exclusion criteria. The sections were stored for less than 48h at 4°C in sterile 
physiological saline solution (PSS, components of PSS are listed in A2) (Ethical 
approval number: 08/H0704/140, AM05 Minor Amendment, 01 Jan 2013).  
 
Human umbilical artery smooth muscle cells (HUASMCs) 
 
The dissection of the umbilical arteries was performed under sterile conditions 
containing PSS at 37 C°. The Wharthon’s jelly adventitia surrounding the arteries was 
removed. The thick wall of the arteries was stripped off. Once the arteries were 
separated from all the connective tissues, they were then transferred to a clean Petri 
dish and cut into small fragments of about 2mm long using a scalpel. They were 
washed twice with PSS, and once with serum-free DMEM. After washing, the pieces of 
artery were evenly distributed onto a gelatin coated (0.2%, Sigma, G1393) T-25 flask 
(Nunc). The medium was removed and the flask was placed inside the incubator in a 
vertical position for 1-2 hours to allow the attachment of the pieces to the culturing 
surface. After the incubation, 5ml of Dulbecco’s modified Eagle’s medium (DMEM, 
Sigma, D5796) (additional supplements listed in A2.5) was added to the flask, which 
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was then placed flat inside the incubator for one week without disturbance to allow for 
explant of smooth muscle cells from the tissue to the dish surface. Subsequently, the 
medium was changed and the detached tissues were removed from culture until cells 
reached 90% confluence. For passaging, the cells were rinsed with 0.5ml of pre-
warmed trypsin (Sigma, T4049) and then incubated with the same solution for no 
longer than 10 min, until all the cells were detached. The trypsin was neutralised by 
addition of FBS containing medium, and the cells were then transferred into a newly 
coated T-25 flask and cultured as required.  
 
Human umbilical vein endothelial cells (HUVECs) 
 
The isolation of HUVECs was carried out following a protocol established by Jaffe et 
al.210 In summary, the veins of the umbilical cords were identified, then cannulated and 
clamped in position. Hank’s Balanced Salt solution (HBSS, 50ml) was poured through 
the cannula to rinse off the intraluminal clots. Following the wash, type I collagenase 
(Sigma, C9891, 0.2% w/v) diluted in HBSS was infused into the vein via the cannula. 
Cords were clamped on both sides when the collagenase started to drip out from the 
distal end. Further collagenase was added until the vein was significantly distended.  
An average of 15 to 20 ml of collagenase solution was used for a section of 15 cm 
umbilical vein. The preparation was then incubated for 10 min at 37°C with gentle 
massaging of the cord at the start.  
 
After incubation, the collagenase solution containing the endothelial cells was 
collected in a sterile falcon tube, and the vein was further flushed by perfusion with 
PBS to achieve a final volume of 50 ml. The solution was centrifuged at 1,000 x g for 
10 min at room temperature. The supernatant was discarded and cell pellet was re-
suspended in supplemented M199 (Sigma, M4530) medium. (Supplements listed in 
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Appendix 2.5) The cells were plated in T-75 flasks pre-coated with 0.2% w/v gelatin. 
The medium was changed the next day to remove non-adherent cells. Subsequently, 
the medium was changed every two or three days until appropriate confluency was 
reached for further subculture.  
 
2.1.2 Cell culture 
Cell culture and maintenance  
 
HUASMCs and HUVECs were both isolated from human umbilical cords. HUASMCs 
were cultured in DMEM supplemented with 15% fetal bovine serum (FBS), 1% 
penicillin/streptomycin and supplements (listed in A2.5). HUVECs were cultured in 
supplemented M199 (supplements listed in A2.5). All the cells were incubated at 37°C 
with 5% CO2. When passaging, cells were trypsinized and split in 1:3 ratio. 
 
   HepG2 is a human liver hepatocellular carcinoma cell line. HepG2 cells are 
adherent, epithelial-like cells growing as monolayers and in small aggregates. They 
were cultured in DMEM supplemented with 10% FBS and 1% antibiotics. The rest of 
the culture protocol was consistent with other cell types. Cells were passaged in 1:4 
ratio or had culture medium changed every 3 days. MCF-7 is a breast cancer cell line 
given by Barts Cancer Institute. MCF-7 cells were cultured in DMEM supplemented 
with 15% FBS and 1% antibiotics. The cells were processed every three days by 
changing medium, passaging or freezing.  
 
    Human embryonic kidney 293 cells (also referred to as HEK293), are a specific 
cell line derived from human embryonic kidney cells, initiated by the transformation and 
culturing of normal HEK cells with sheared human adenovirus type 5 (Ad5) DNA. The 
transformation resulted in the incorporation of approximately 4.5kb from the viral 
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genome into human chromosome 19 of the HEK cells. HEK cell line has been 
extensively used as an expression tool for recombinant proteins over the last 35 years. 
The HEK293 cells used in this project were derived from commercial source, and 
maintained in DMEM supplemented with 10% FBS and 1% antibiotics. A summary of 
all the experimental cells lines are listed in Table 2.1.  
Cell type Rationale Experiment type 
HUASMC Primary human embryonic smooth 
muscle cells;  representative of 
human vasculature with endogenous 
genetic variation 
SLC39A8 expression study 
(AEI, immunoblotting) 
HUVEC Primary human embryonic 
endothelial cells;  
SLC39A8 expression study (AEI, 
immunoblotting) 
Cd2+ uptake, ERK1/2 and NF-B 
signalling activation studies 
HEK293 Embryonic kidney cells, good 
transfection model, representative of 
the human nephron 
Cd2+ uptake, ERK1/2 and NF-B 
dual luciferase reporter, cell 
death  
HepG2 Encompass cholesterol efflux 
machinary (transporter) and efficient 
transfection model 
Zn2+ uptake, cholesterol efflux 
and qRT-PCR 
MCF-7 Breast cancer cell line, positive 
control for SLC39A8 expression 
SLC39A8 expression positive 
control, ZIP8 transfection 
 
Table 2.1. Summary of experimental cell lines 
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Cryopreservation  
 
For long-term storage, cells were trypsinized, re-suspended in an appropriate freezing 
medium (components listed in A2.5) and transferred into cryovials. They were placed 
in a cryopreservation box and gradually frozen in a -80°C freezer and then transferred 
to liquid nitrogen tank for long term storage. 
 
2.2 Genomic DNA and Polymerase chain reaction 
2.2.1 Assessment of linkage disequilibrium  
 
Before genotyping the index SNP of interest, the linkage disequilibrium (LD) block of 
the region containing the SNP of interest was determined using SNAP program 
(www.broadinstitute.org/mpg/snap/), under the category of HapMap release 21 dataset 
(contains all processed data from the HapMap project, including phase I+II, completed 
in year 2006).211 The population panel was set at Northern Europeans from Utah 
(CEU), and the square of the correlation coefficient between two indicator variables (r2 
value) was set at threshold of greater than 0.8. The aim of this search was detect 
whether any other SNPs in the genomic region were in high LD with the index SNP in 
the available ancestries.  
 
2.2.2 Preparation of samples for genotyping  
 
 
DNA was extracted from cell pellets. Lysis buffer (components listed in A2.2) was 
added directly to the pellets, followed by addition of 275µl of 5M NaCl and 5 min 
incubation with gradient agitation. After centrifugation, the supernatant was mixed with 
500 μl isopropanol. The precipitated protein in the supernatant was discarded and the 
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DNA pellet was washed with 70% ethanol. Supernatant was again removed and the 
DNA pellet was left to air dry. Finally, 40µl of nuclease free (NF) - H2O was added, 
followed by mixing and incubation at 50°C for 10 min. The DNA concentration was 
determined by using NanoDrop Spectrophotometer ND-1000. A260/A280 ratio and 
A260/A230 ratio provide additional information on the purity of the DNA sample. An 
A260/A280 ratio value of between 1.8 and 2 indicates that the DNA is of high purity. A 
lower value of this ratio indicates contamination of the sample with proteins which have 
the highest absorbance at 280nm. An A260/A230 value of 2.0-2.2 indicates the sample is 
free from, or has minimal salt contamination, whereas a lower value will suggest that 
the sample is contaminated with salts or other impurities such as carbohydrates, or 
other precipitating agents such as phenol, guanidine or glycogen.   
 
2.2.3 Polymerase chain reaction (PCR) 
 
Polymerase chain reaction (PCR) is a technique used to amplify a piece of DNA 
fragments, generating thousands to millions of copies. Where not specified, PCR 
conditions and primers were designed according to the following protocol. All primers 
used (listed in A1) were designed using Primer3 program (http://bioinfo.ut.ee/primer3-
0.4.0/). For SNP specific primers, the primers were designed to flank the region of 
interest with 100-200 bp on either side of the target DNA region. Default settings were 
used for all the other parameters. The PCR reaction components for genomic DNA and 
cDNA are listed in A2.2. The amplification program is listed in Table 2.2. A duration of 
35 sec was chosen for the extension step, because Taq polymerase synthesizes about 
1,000 bp per minute, and 35 sec would be sufficient for the extension step in a PCR to 
amplify a fragment of 200-300bp in size.  
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Temp (°C) gDNA/cDNA Time (sec) Cycles Description 
95 300 n/a Initial denature 
94 35 
30-40 
Denature 
48/ 52 
(dependent on primers) 
35 Anneal 
72 35 Extension 
72 600 n/a Elongation 
 
Table 2.2. Thermal cycling conditions for PCR reaction of genomic DNA and 
cDNA 
 
2.3 Genotyping  
 
Genotyping is a method for determination of the genetic make-up (genotype) of 
individual human-derived sample. As described below, 3 genotyping methods were 
performed in this project. KASPar genotyping was primarily used on HUASMC DNAs. 
Due to the presence of false positive results generated by KASPar, TaqMan assay was 
applied to both HUASMCs and HUVEC DNAs, whereas aditional restriction enzyme 
digestion method was used to verify the genotyping results of the two methods above.  
 
2.3.1 KASPar genotyping  
 
KASPar is a genotyping system developed by KBioscience Ltd. It is a PCR-based 
technology that consists of two major components: the KASP primer mix and master 
mix. The primer mix contains two allele-specific forward primers (listed in A1, primer 1 
and 2) each having a proprietary tail containing sequence complementary to the FAM 
or VIC dye in the master mix, and one common reverse primer (listed in A1, primer 3). 
Each oligo was resuspended in ddH2O to a concentration of 100µM (Table 2.3 A). The 
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master mix was the same for every KASP assay, containing the FAM™ and VIC™ 
specific FRET (fluorescence resonance energy transfer) cassette reporter system, Taq 
polymerase, dNTPs, ROX passive reference dye and MgCl2 (2.5mM) in an optimized 
buffer solution. The 2 x master mix was defrosted and diluted to 1 x by NF-H2O and 
mixed well before use. The components for PCR reaction on one 384-well plate are 
listed in Table 2.3. The schematic workflow of the assay is shown in Fig. 2.1.  
 
A 
Components Volume (µl) 
Allele specific primer 1 
(100µM) 
12 
Allele specific primer 2 
(100µM) 
12 
Common primer 
(100µM) 
30 
NF-H2O 46 
  
B 
 
 
 
 
 
 
 
 
 
Table 2.3. KASPar SNP genotyping. (A) Components of primer mix (B) Constituent 
reagent volumes for the 384-well plate genotyping  
 
 
Components 
Volume required for a 
384-well plate (µl) 
DNA (5ng/ml, dried) n/a 
1 x Reaction mix 1060 
Primer mix (100µl) 14.1 
MgCl2 (50mM) 6.7 
Total volume for 1 well 2.5 
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The 384-well plate was subjected to the cycling program detailed in Table 2.4. 
Some reactions may proceed faster hence the number of cycles can be reduced from 
21 to 18 in the latter part of the program. Some reactions may proceed slower and 
additional cycles may be necessary to achieve a better separation of the clusters.  
 
Temp (°C) Time (sec) Cycles Description 
94 900 n/a Hot-start activation 
94 10  
20 
Denature  
57 5 Anneal 
72 10 Extend 
94 10  
21 
Denature 
57 20 Anneal 
72 40 Extend 
Additional cycling conditions 
94 20  
5 
Denature 
57 60 Anneal 
72 40 extension 
 
Table 2.4. Thermal cycling conditions for KASPar genotyping 
 
 
After the PCR was completed, the end plate read was performed immediately 
using an ABI 7900HT sequence detection system using FAM or VIC detectors. The 
fluorescence data were analysed using SDS2.4 software (Applied Biosystems). Four 
separate sample clusters could be identified on the output plot, three corresponding to 
the different genotypes and one to the non-template controls. Fluorescence signals 
uniquely corresponding to either VIC or FAM represented major and minor 
homozygotes, whereas the presence of dual fluorescence signals indicated 
heterozygous populations (Fig. 2.1 B).  
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Figure 2.1. Workflow of KASPar genotyping. (A) Schematic workflow of KASPar 
genotyping (Diagram referenced from KASP genotyping chemistry user guide and 
manual) HEXTM dye was shown in the workflow diagram whereas VIC dye was used in 
our assay)212  (B) Representative image of genotyping outcome 
 
2.3.2 TaqMan® SNP genotyping assay 
 
KASPar assays generated some inaccurate genotype clusters in a smaller sample pool 
i.e. HUVECs. Therefore a second assay was used to confirm genotyping results. 
TaqMan® SNP genotyping assay (5’-nuclease allelic discrimination assay) was also 
used to distinguish genotypes for DNA samples (Fig. 2.2). Relying on the FRET 
technology, the pre-designed TaqMan SNP genotyping assay consists of two allele-
specific TaqMan® minor groove binder (MGB) probes labelled with a FAM or VIC 
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reporter fluorescent dye, and a sequence-specific forward and reverse PCR primers to 
amplify the DNA sequence containing the polymorphism of interest. FAM™ or VIC™ 
reporter dye is located at the 5’ end of the probe and a non-fluorescent quencher lies in 
the 3’ end of the probe. The reporter dye is quenched when the MGB probe is intact. 
During the PCR reaction, the 5’-nuclease activity of Taq DNA polymerase cleaves the 
reporter dye from the probe that is completely hybridized to the DNA strand, which 
then fluoresces upon separation from the quencher. When a single point mismatch is 
present in the DNA sequence due to a SNP, the binding of the probe to DNA is 
destabilized during strand displacement in PCR, which will in turn reduce the efficiency 
of the one of the probe cleavage and the fluorescence intensity from the corresponding 
reporter dye. Therefore an increase in either FAM or VIC fluorescence will indicate 
homozygosity for FAM- or VIC- specific alleles (X:X or Y:Y), an increase in the 
fluorescence for both dyes indicates heterozygosity (X:Y).213 
 
 
Figure 2.2. Mechanism of the allelic discrimination of the Taqman 5’ nuclease 
assay (from Life Technologies TaqMan SNP genotyping assays product bulletin) 214 
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The extraction of genomic DNA is described in Section 2.2.2. The procedure for 
performing the TaqMan SNP genotyping is described as follows: 10 ng genomic DNA 
was added to each well of the 384-well optical PCR plate (Thermo Scientific, AB-1384), 
and then been dried down in a 37°C oven overnight. A representation of TaqMan 
master mix setup is shown in Table 2.5. The loaded plate was then centrifuged at 2000 
x g for 1 min to ensure the equal amount of the solution in each well. The PCR plate 
was then sealed with an optical adhesive cover and placed in an MJ-Tetrad PTC-225 
PCR thermal cycler.  
 
 
Reagent volume per 
384-well plate (µl) 
Master mix volume with 
10% excess (384x1.1) (µl) 
20x SNP genotyping assay 
(Applied Biosystems, 
c_1827682_10) 
0.125  52.8 
2x TaqMan universal PCR 
master mix 
1.25  528 
NF H2O 1.125  475.2 
Genomic DNA (dried) 10 ng n/a 
Total volume 2.5  n/a 
 
Table 2.5. TaqMan genotyping master mix setup 
 
 
PCR was performed using the thermal cycling conditions described in Table 2.6. 
After the PCR was completed, the end plate read was performed immediately using an 
ABI 7900HT sequence detection system (Applied Biosystems, Foster City, CA, USA). 
This system can distinguish and quantify the two signals from FAM or VIC, which then 
form three clusters representing genotypes of the DNA samples, similar to the 
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description above in Section 2.3.1. 
 
Temp (°C) Time (sec) Cycles Description 
95 600  AmpliTaq Gold, UP Enzyme activation 
92 15 
40 
Denature 
60 60 Anneal/extend 
 
Table 2.6. Thermal cycling conditions for TaqMan SNP genotyping 
 
 
2.3.3 Restriction enzyme digestion genotyping  
 
The underlying principle of this technique is that the nucleotide substitution of a SNP 
may create or abolish a restriction endonuclease cutting site and therefore can be 
utilized for genotype determinations of DNA samples. If a SNP results in a C to T 
substitution and the DNA sequence including the SNP is a specific target of the 
restriction enzyme, a PCR reaction can be used to amplify the DNA sequence of 
interest, which, in turn, can be used as a template for restriction enzymatic restriction. 
In the case of SNP rs13107325, the site is targeted by BcgI enzyme. As such, DNA 
amplicons homozygous for the C allele are cleaved into two fragments, whereas DNA 
amplicons homozygous for the T allele will not be cleaved by BcgI. In the case of a 
DNA samples from a heterozygote, 50% of the PCR amplicons will be cleaved and the 
other 50% will not. The genotyping outcome can be visualized using a 2% agarose gel, 
where a single band represents uncleaved homozygotes (T/T), double bands represent 
cleaved homozygotes (C/C), and triplicate bands indicate heterozygotes (C/T). 
Therefore, analyzing the BcgI digests of the PCR products by gel electrophoresis will 
allow one to determine the genotypes of the DNA samples (Fig. 2.3). 
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The relevant sequence flanking the SNP was obtained from dbSNP 
(http://www.ncbi.nlm.nih.gov/snp/). The NEBcutter V2.0 software was used to search 
for a restriction site that is affected by the polymorphism by selecting a particular 
enzyme which cuts only one allele. In this project, BcgI (NEB, R0545S) enzyme was 
used. The full length uncut PCR product was 274 bp in length. After cutting, the PCR 
amplicon will generate one fragment of 123 bp and the other of 151 bp (shown in Fig. 
2.3, C/C genotype). All samples showing 3 clear bands (274 bp, 151 bp, and 123 bp in 
Fig. 2.3 C/T genotype) were subjected to DNA sequencing and confirmed to be 
heterozygotes. The reagent mix for post PCR restriction enzyme digestion reaction is 
listed in A2.2. The mixture was incubated at 37°C overnight on a heating block before 
subjecting to gel electrophoresis.  
 
                              
 
Figure 2.3. Gel electrophoresis of the genotyping executed by restriction 
enzyme digestion 
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2.4 cDNA synthesis and quantitative gene expression analysis  
2.4.1 mRNA extraction  
HUVECs and HUASMCs 
 
Total messenger RNA (mRNA) was extracted from cell lysates and purified using the 
GenElute™ Mammalian Total RNA Miniprep Kit (Sigma, RTN350-1KT). In summary, 
isolated RNA preserved from degradation by addition of β-mercaptoethanol was first 
bound to the extraction column, followed by multiple washing steps and then eluted as 
described by the manufacturer’s protocol.215 Once the extraction was finished, the RNA 
concentration was determined by NanoDrop Spectrophotometer ND-1000 instrument, 
as described previously in Section 2.2.2, with an A260/280 of ~ 2 is considered to be pure 
for RNA.  
 
HepG2 
 
HepG2 cells were cultured on 12-well plates, and transfected with pCDNA3.1(+/-)-
SLC39A8-Ala/Thr391 and pCDNA3.1 vector control plasmids followed by cholesterol 
efflux assay. By the end of the assay, cells in each well were washed with PBS and 
pelleted, whereas half of the cell pellets were used for the assay and half were 
subjected to mRNA extraction. Additional mRNA was extracted from HepG2 cells 12h 
post transfection without performing cholesterol efflux. Total mRNA was extracted from 
cell lysates and purified using the GenElute™ mammalian total RNA miniprep kit.  
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2.4.2 Reverse transcription and cDNA synthesis  
 
After determining the concentrations of the RNA samples, 0.5µg or 1µg of the RNA 
was mixed with random primers (RP, Promega, C118A) at a ratio of 1µg RNA/1µg (RP) 
and the required amount of NF-H2O to make up to the final reaction volume of 25µl. 
The mixture was incubated at 70°C for 5 min to disrupt the secondary structures of the 
template. The reverse transcription (RT) reaction was performed using the cocktail 
described in A2.3. The PCR program for RT was 25°C for 5 min, 42°C for 1.5 h, and 
70°C for 15 sec. After synthesis, cDNA was diluted to a stock concentration of 10ng/µl 
with NF-H2O.  
 
2.5 Allelic expression imbalance (AEI)  
 
Allelic imbalance is a powerful method to identify cis-acting regulatory variation for 
gene expression. The rationale behind it is that trans-acting regulatory elements and 
environmental factors influence gene expression at both chromosomes while cis-acting 
regulatory elements affect gene expression in an allele-specific manner.216 Expression 
levels from each of the two alleles can be directly compared within the same 
heterozygous individual and within the same experiment, therefore variations in trans-
acting regulatory elements and environmental effects are not expected to affect the 
ratio between the two alleles. Departure of cDNA expression ratios from those 
observed in genomic DNA provide unequivocal evidence of cis-acting polymorphisms. 
The cDNA samples used in this assay were derived from the mRNA extraction and 
cDNA synthesis described in the Methods Sections 2.4.1-2.4.2. The gDNA used was 
derived from the same cell lines as described in methods Section 2.2.2. The cDNA and 
gDNA from the cell samples identified as heterozygous for SNP rs13107325 were used 
and amplified using primers specific for rs13107325 (primers 5 and 6 for gDNA, 
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primers 8 and 10 for cDNA, as listed in A1). After gel electrophoresis, the 
corresponding PCR products were excised and purified using the Wizard® SV gel and 
PCR clean-up system (Promega, A9282). The purified PCR products were then 
subjected to Sanger sequencing. AEI quantifies the cDNA levels of the two alleles 
within the same cell, the higher the expression of an allele, the higher its relative peak 
height is on the sequencing chromatogram. If the ratio of the peak heights ratio of the 
two alleles from PCR products of the cDNA sample is significantly different than that in 
the gDNA sample, this indicates that the SNP, or other SNPs in LD, regulates the 
mRNA expression of this gene. However low transcript levels can affect measurement 
of gene expression and reproducibility. Intra-sample variation can also be increased 
with reduced copy number of the target and (or) increased length of the amplicon.217 
These limitations need to be taken into consideration of the experimental design.  
 
2.5.1 Quantification of peak heights and statistical analysis  
 
The sequencing results were aligned and analysed by BioEdit software (version 7.1.3). 
The relative fluorescent intensities for the two alleles at the SNP site were quantified 
and compared between cDNA and gDNA. PeakPicker software 
(http://genomequebec.mcgill.ca/EST-HapMap) was used to analyse the sequencing 
data to quantify the relative fluorescent intensities for the two alleles at the SNP site. 
The ratio of normalized peak heights, allele 1 versus allele 2, was calculated. By 
pooling the results from all heterozygote samples, the allelic expression would be 
considered imbalanced if mean ratio difference was deemed to be different as 
indicated by p<0.05 by Mann-Whitney t test.  
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2.6 Real-time quantitative reverse transcription PCR using SYBR Green I 
method (qRT-PCR) 
 
2.6.1 SYBR Green I principle and reaction set up  
 
Two of the most commonly used real-time qRT-PCR assays are TaqMan and SYBR 
Green I assays. First reported by Santhosh et al.,218 SYBR Green I-based qRT-PCR is 
a sensitive method for rapid detection and quantification of target gene mRNA 
expression using primers specific to the gene of interest.219 SYBR Green I chemistry is 
a sequence-independent cost effective method that relies on the intercalation of the 
SYBR Green I dye into double stranded DNA (PCR products). However if reaction 
conditions are not optimized, this technique is susceptible to low specificity of 
hybridization of the SYBR Green I dye to the PCR product of interest. The specificity of 
SYBR Green I may be compromised by the formation of primer dimers, lack of primer 
specificity, sub-optimal primer concentrations. All of these factors could lead to the 
creation of unexpected double stranded DNA products that result in false fluorescent 
signal from incorporation of SYBR Green I dye. Primer pairs were designed to amplify 
the gene of interest targeting a specific region of 100 to 150bp, which were shown to 
produce the most effective amplification. Primer concentration was used based on 
empirical data, which proved to be optimal when specific amplification relative to primer 
dimer was maximal in a positive versus negative control experiment. The components 
of PCR reaction are listed in Table 2.7.  
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Components Volume (µl) 
2 x Buffer 5 
Forward and reverse primer mix (2µM) 1 
DNA 4 (10ng) 
Total volume 10 
 
Table 2.7. Components of real-time qRT-PCR reaction 
 
 
2.6.2 qRT-PCR primer design   
 
The primers used were selected from an online primer database GETPrime 
(http://updepla1srv1.epfl.ch/getprime/). The primers in this database have been 
experimentally validated extensively demonstrating high transcript specificity in 
complex samples.220 This enables users to design their primers with tailored criteria 
specific to their needs, for example, targeting all gene splice variants or specific gene 
product isoforms. In our study, we chose primer pairs that allowed detection of all gene 
splice variants predicted for genes of interest. The primer sequences for the genes 
under investigation are listed in A1. These were tested using end-point PCR and 
agarose gel to ensure single product detection before qRT-PCR application (Fig. 2.4). 
The target PCR amplicon size for all primers tested is expected to be around 100bp. 
Bands below 100bp would normally be considered primer dimers. If any primer pair 
generated more than one band (e.g. ABCG1 in Fig. 2.4 A), alternative primer set would 
be tested and used for the subsequent qRT-PCR assay (Fig. 2.4 B).  From our primer 
test, ABCG1 seems to minimumly/not expressed in HUASMC samples.  
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A                                                                               B     
 
 
Figure 2.4. End-point PCR assessment of qRT-PCR primers. (A) Electrophoretic 
gel image of qRT-PCR primers testing. Bands at ~100bp are the specific PCR products 
corresponding to the target gene. DNA samples are labelled at the top (B) 
Electrophoretic gel image of PCR products from alternative primer pairs for ABCA1 
and ABCG1  
 
2.6.3 Analysis and calculation of SYBR Green I results 
 
The real-time qRT-PCR read-out is given as the fractional PCR cycle number at which 
the reporter fluorescence is greater than the threshold (‘cycle threshold’, CT). The 
threshold is an arbitrary level of fluorescence chosen on the basis of the baseline 
variability. Threshold can be adjusted for each experiment to ensure it is in the region 
of exponential amplification across all plots. The PCR cycle can be divided into three 
stages. During the exponential phase of the PCR the fluorescent signal doubled at 
each cycle. After certain number of cycles, the intensity of fluorescent signal usually 
began to plateau, indicating that the PCR had reached a saturation status (Fig. 2.5). As 
CT is proportional to the logarithm of initial amount of target in a sample, the relative 
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concentration of target gene to the reference gene is calculated by the difference in 
cycle number (ΔCT) (ΔCT = CT of the target gene - CT of the reference gene). In our 
experiment, the reference housekeeping gene 18S was used to normalize mRNA 
levels between different samples. The PCR program is listed in the Fig. 2.6 A&B. CT 
values were generated automatically by the SDS 2.4 program (ABI) after the PCR 
cycles finished. The ΔΔCT method was used to calculate the fold expression 
differences of the target gene in different samples compared to the control sample. The 
fold difference was calculated as 2- ΔΔC, where ΔΔCT=ΔCT (sample of interest) - ΔCT(control sample). 
In our experiment, two groups of samples (transfected with the pCDNA3.1-SLC39A8-
Ala and pCDNA3.1-SLC39A8-Thr plasmids) were evaluated against the control sample 
(transfected with the pCDNA3.1 vector control). The fold difference was described as 
2- ΔΔC, whereas ΔΔC = ΔCT (pCDNA3.1-SLC39A8-Ala391/Thr) - ΔCT (pCDNA3.1) 
 
A dissociation/melting curve analysis is routinely performed for SYBR Green 
qRT-PCR following the PCR thermal cycling to verify the correct PCR product 
according to its specific melting temperature (Tm). It is important to perform this 
analysis to detect the presence of primer-dimers or nonspecific products, which also 
generate fluorescent signals that reflect in the final CT values. A single peak in the 
amplification plot suggests the presence of a single size product, because the target 
sequence should have a specific Tm (indicated as peak B in Fig. 2.6 C). Melting curve 
analysis can identify the presence of primer-dimers because they exhibit a lower Tm 
than the amplicon (pointed as peak A in Fig. 2.6 C).  
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Figure 2.5. The annotation of a qRT-PCR amplification curve. The ΔRn values are 
plotted versus the cycle number. ΔRn is an increment of fluorescent signal for each 
time point. Baseline is defined as PCR cycles in which reporter fluorescent signal is 
accumulated beneath the detection limit of the instrument   
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Figure 2.6. SYBR Green based real-time qRT-PCR. (A) and (B) Steps and thermal 
conditions of qRT-PCR (C) Representative of a melting curve graph generated by SDS 
software.  
Step Temp (°C) Time 
(min) 
cycles 
Uracil DNA 
glycosylase 
activation 
50 2 1 
DNA polymerase 
activation 
95 10 1 
Melt 95 0.25 40 
anneal and extend 50 1 
Dissociation/melting 
curve 
95 0.25 1 
60 0.25 
95 0.25 
Uracil DNA  
glycosylase  
activation 
DNA 
polymerase 
activation 
PCR cycle 
Melt, 
anneal/extend 
Dissociation 
curve 
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2.7 Protein study  
2.7.1 Protein isolation 
Total protein extraction 
 
Total cell lysates were harvested from cultured cells from either 6 well plates or T-25 
flasks. Each well or flask was first washed with ice cold PBS and drained completely 
before addition of radio-immunoprecipitation assay (RIPA) lysis buffer containing 
protease inhibitor (PI) (components listed in A2.4). Cells were detached using single-
use cell lifters. The mixture was transferred to an ultracentrifuge tube, sonicated in a 
cold water bath for 1 min, and then incubated on ice for 30 min with further disruption 
by a vortex mixer at 10 min intervals. Subsequently, the tube was centrifuged for 10 
min at 13000 rpm at 4°C to pellet the cell debris. The supernatant solution, containing 
the total cellular protein, was then transferred to a new tube and stored at -80°C.  
 
Subcellular protein fractionation  
 
Different subcellular protein fractions were extracted and separated according to 
weight differences. Confluent cells of HUASMC or HUVEC were lysed with 500µL 
homogenization buffer (components listed in A2.4), then scraped immediately and 
transferred to 1.5mL ultracentrifuge tubes. The lysates were then passed through 25G 
needle 10 times using a 1mL syringe. The lysates were centrifuged at 900 x g for 10 
min at 4°C. The supernatants were transferred to a clean EP tube and the pellet 
(containing the nucleic fractionation and cell debris) was resuspended in 35µL RIPA 
lysis buffer (+P.I.), followed by sonication to further shear nuclear DNA. The 
supernatant from above procedure was centrifuged again at 10,000 x g at 4°C to 
generate pellet containing mitochondria fraction, which was resuspended in 35µL RIPA 
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lysis buffer (+ proteinase inhibitor). The supernatants from above procedure was then 
subjected to ultra-centrifugation at 100,000 x g for 1h at 4°C, generating a small pellet 
containing the membrane fractionation, which was also resuspended in 35µL RIPA 
lysis buffer (+P.I.). The supernatant from above procedure was treated as the cytosolic 
fraction. All the protein fractions were stored at -80°C. 
  
2.7.2 Protein quantification 
 
Protein concentrations were quantified using the bicinchoninic acid assay (BCA) 
protein assay reagent (Pierce, 23227). The BCA protein assay utilizes the reduction of 
cuprous cation Cu2+ to Cu1+ by protein in an alkaline medium and the selective 
colorimetric detection of Cu1+ by bicinchoninic acid. For each quantification, a standard 
curve was performed by using serial dilutions of bovine serum albumin (BSA) solutions. 
First a total of 10µl of either BSA or protein solution was added to each well on a 96 
well plate, then 200µl of the reagent A and B (50:1) mixture was added into each well, 
followed by incubation at 37°C for 30 min. The plate was read by a spectrophotometer 
with the Revelation program (Dynex Tech. V. 4.22) at a wavelength of 570nm. A 
standard curve was first generated from known amounts of bovine serum albumin 
(BSA), then the concentration of each of the protein samples was determined using the 
standard curve.   
 
2.7.3 Immunoblotting assay for detection of ZIP8 expression  
 
Proteins were mixed with lysis buffer (+P.I) and 5 x loading buffer (components listed in 
A 2.4) containing 5% β-mercaptomethanol. Membrane proteins were denatured by 
heating at 70°C for 5 min and denaturation for other protein fractions was carried out at 
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95°C for 8 min. Proteins were then electrophoretically separated on a 10% 
polyacrylamide gel (or lower percentage, if bigger size proteins were to be detected), 
and transferred to a PVDF membrane (Amersham Hybond-P, GE Healthcare). The 
membrane was incubated with Tris-buffered saline containing 0.1% Tween-20 (TBST) 
and 5% (w/v) non-fat milk (Marvel) in for 1h. The blot was then incubated overnight at 
4°C in the blocking buffer containing polyclonal rabbit anti-SLC39A8 antibody (Abcam, 
ab103182). On the next day, the membrane was washed 3 times at 10 min intervals 
with TBST and subsequently incubated with anti-rabbit IgG HRP-conjugated secondary 
antibody (Cell Signalling, 7074S). Immunoreactivity was developed by using enhanced 
chemiluminescence (ECL, components listed in A2.4) and visualized on the 
autoradiography film. Mouse anti-β-actin was used as the loading control antibody 
(Abcam, ab8226).  
 The initial immunoblotting experiments were presented with dark background 
on the X-ray films. Therefore we focused on optimization of the primary and secondary 
antibody concentration, as well as their inbucation time. In the end, the best 
performance was found using a primary antibody concentration of 25ng/ml and a 
1:3000 dilution of the secondary antibody with an incubation time of 2h.  
 
Blocking peptide  
 
Non-specific binding is common with polyclonal antibodies. Blocking peptides are 
peptides of approximately 50 amino acids long which resembles the epitope 
recognized by the target antibody and block antibody-antigen binding. The peptide 
resembles the epitope recognized by the antibody. Antibodies bound to the blocking 
peptide will no longer bind to the epitope on the protein. The remaining signals which 
are not diminished by blocking peptide will be due to non-specific binding.  
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To investigate the specificity of ZIP8 proteins upon transfection, immunoblotting 
analysis was performed with the ZIP8 antibody as described above. Two bands were 
detected by SDS-PAGE. To test the specificity of the antibody, the rabbit anti-
SLC39A8 antibody (0.25mg/ml, 50µl) was pre-incubated with the corresponding 
excess blocking peptide (ab171521, 1mg/ml, 25 µl), mixed with 5% milk (in TBST) and 
0.02% NaN3 in a total volume of 5ml. One membrane was cut into half with two strips 
of identical samples, which were placed into two separate tubes containing only ZIP8 
antibody and ZIP8 antibody mixed with blocking peptide, respectively. Both strips were 
blocked overnight at 4°C with rotation, followed by the same immunoblotting procedure 
as described previously.  
 
2.8 Cloning 
2.8.1 Construction of pCDNA3.1(+)-SLC39A8-alanine plasmid  
 
The full-length reference cDNA sequence for human ZIP8 (GenBank Accession No. 
NM_022154.5) was purchased from Origene (Cat. No. SC112817). It was used as the 
template to amplify the open reading frame (ORF) of SLC39A8 by using primers based 
on the sequences at the 5’ and 3’ of the ORF, attached with additional EcoRI and 
HindIII restriction sites sequences (shown in primer sequence table A1, primer 11 and 
12). The PCR reaction was carried out using Phusion High-fidelity DNA polymerase 
(NEB, M0530S). The PCR product was first verified by gel electrophoresis, then 
excised and purified using a PCR clean-up kit (Promega A9281). The DNA was first 
bound to the column followed by washing and final elution. Subsequently the PCR 
products and pCDNA3.1 vector were digested using EcoRI and HindIII enzymes, 
followed by agarose gel electrophoresis. The bands corresponding to the size of the 
vector and insert were excised and purified by using the PCR clean-up kit. The full-
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length SLC39A8 ORF sequence was ligated to the pCDNA3.1 vector at EcoRI and 
HindIII restriction sites by using T4 DNA ligase (NEB, M0202S) with incubation at room 
temperature incubation overnight.  
 
2.8.2 Transformation of E.coli bacteria with plasmid vector DNA 
 
JM109 competent E. coli cells (Promega, L2001) were thawed from -80°C on ice. 
Plasmid DNA (200ng/µl) was mixed with bacteria in 1:20 or 1:10 ratio (weight : volume) 
in a total volume of 10µl containing 100ng or 200ng plasmid DNA. The 
plasmid/bacteria mix was then incubated on ice for 30 min. Heat shock was performed 
at 42 °C for 60s on a PCR block, followed by incubation on ice for 1m. The 
plasmid/bacteria mix was then added to 500µl of pre-warmed LB broth medium without 
ampicillin and incubated in a thermal shaker at 37 °C for 1h. The LB solution was then 
centrifuged at 5000 rpm for 5 min, and approximately 460µl of the supernatant was 
discarded. An aliquot (40-50µl) of the solution was then dispersed on a pre-warmed 
agar plate (containing 50µg/ml ampicillin) and incubated at 37°C for 16h (can be longer 
depending on speed of colony formation but no longer than 22h). On the next day, any 
grown colonies were picked out and propagated in 5ml LB medium containing 
100µg/ml ampicillin and incubated in a 37°C rotation incubator (225 rpm) for further 18-
22h. On the next day, the plasmid DNA was extracted from the bacterial LB solution by 
using GenElute™ plasmid miniprep kit according to manufacturer’s instruction (Sigma, 
PLN70-1KT).  
 
2.8.3 Plasmid DNA extraction by mini and midi-preps 
 
The plasmid DNA was extracted by GenElute™ plasmid miniprep kit, and the eluted 
DNA were quantified with NanoDrop Spectrophotometer before been subjected for 
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sequencing. The plasmids with confirmed sequence were then subjected to midi-prep 
(Invitrogen, K210004) extraction to generate higher yields of plasmid DNA.  
 
 The mini- and midi- preps were performed according to the manufacturer’s 
protocols. The miniprep kit utilizes a silica-binding technology whereas the midiprep 
adopts an anion-exchange resin to purify plasmid DNA. First, adequate amount of 
E.coli cells were harvested and re-suspended in the Re-suspension Buffer containing 
RNaseA. Then the cells were lysed with Lysis Buffer, followed by addition of 
Precipitation Buffer to neutralize the lysates. At this stage, cell debris, proteins, lipids, 
and chromosomal DNA should fall out of solution as a cloudy, viscous precipitate. The 
supernatant of the lysates were then passed through a pre-packed column. Depending 
on the types of columns used, the DNA was bound to the column resin by different 
mechanisms. For midiprep extraction, plasmid DNA remains bound to the resin under 
moderate salt conditions, while RNA, proteins, carbohydrates and other impurities 
were washed away with the Wash Buffer. After multiple washing, the plasmid DNA was 
eluted under high salt conditions. Last, desalting and DNA precipitation would be 
performed with alcohol precipitation. For miniprep extraction, lysates were first 
adjusted to high salt condition and purification was achieved by adsorption of plasmid 
DNA on the silica gel column. After washing away the impurities, the plasmid DNA was 
eluted with nuclease-free H2O. 
 
2.8.4 Sequencing  
 
The sequence of the insert of the plasmid was verified by Sanger sequencing. Several 
primers complementary to the sequence located across the cDNA of SLC39A8 were 
used in the sequencing reactions to verify in-frame ligation and full sequence of the 
insert (Primer No.15-19 listed in A1). Sequencing result is displayed in A3.  
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2.8.5 Site-directed mutagenesis and generation of pCDNA3.1(+)-SLC39A8-
threonine plasmid 
 
Site-directed mutagenesis    
 
The QuickChange® Lightning site-directed mutagenesis kit (Agilent, 210518) was used 
to mutate the C allele to T allele, which resulted in the change of amino acid alanine to 
threonine at position 391 on the SLC39A8 ORF sequence to generate the pCDNA3.1-
SLC39A8-threonine plasmid. The primers used are listed in the A1 (Primer 13 and 14), 
with the mutation sites underlined. The first step was to perform a PCR reaction to 
synthesize the mutant strand. The components for the site-directed mutagenesis PCR 
reaction are listed in A2.6. The PCR reaction parameters were denaturation at 95°C for 
2 min, 18 cycles of 95°C for 20s, 60°C for 10s, and 68°C for 5 min, followed by a final 
extension step at 68°C for 10 min. During PCR, the mutation resulting in the desired 
base changes was incorporated into the amplicon. A schematic representation of the 
reaction is illustrated in Fig. 2.7.  
 
DpnI digestion 
 
In this step non-mutated parental PCR products were digested by endonuclease DpnI. 
The DpnI (target sequence: 5’-Gm6ATC-3’) is specific for methylated and hemi-
methylated (non-mutated) DNA and selectively digests the parental supercoiled dsDNA, 
while leaving the newly synthesized mutant strands intact. DNA isolated from almost all 
E.coli strains is methylated therefore susceptible to DpnI digestion.221 Dpn I (20 units) 
was added to the amplified PCR reaction mixture, followed by incubation at 37°C for 5 
min.  
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Figure 2.7. Overview of the QuickChange II XL site-directed mutagenesis. Cited 
from Agilent mutagenesis kit manual  
 
Transformation and generation of the mutant plasmid  
 
The products of the mutagenesis PCR reaction incorporating the desired mutations 
was then transformed into XL10-Gold® Ultracompetent cells (components of the 
mutagenesis kit). The plasmid DNA was then extracted by mini-prep, and sequenced 
to verify the full sequence and the mutated site of the plasmid pCDNA3.1(+)-SLC39A8-
threonine. The sequences of the inserts of both plasmids, determined by the DNA 
sequencing, are listed in A3.  
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2.8.6 Transfection 
Transfection of SLC39A8 expression plasmids on HEK293 cells by calcium phosphate 
transfection 
 
Calcium phosphate transfection was used primarily to transfect HEK293 and MCF-7 
cells using the pCDNA3.1-SLC39A8-alanine/threonine plasmids. HEK293 cells were 
plated in 6-well plates/T-25 flask 12-24h before transfection when the culture reaches 
25-30% confluence. For each transfection, two tubes of solutions were required. Tube 
1 contained 2 x HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) buffer 
(pH=7). Tube 2 consisted of a series of solutions: 2M CaCl2, plasmid DNA /vector DNA, 
filtered ddH2O (the amount of each component is listed in Table 2.8, with two scales of 
cell culture vessels listed). The mixture in tube 2 was added to tube 1 in a drop-wise 
manner, and incubated at room temperature for 5 min. An aliquot of 109µl or 283µl of 
mixture was then added to each well/flask in small drops. These volumes were 
sufficient for transfecting cells in one well of a 6-well plate (surface area 9.5cm2) or one 
T-25 flask (25cm2). The cells were cultured for further 48-72h before harvesting for 
protein extraction or functional assays, respectively.  
 
X-tremeGENE HP DNA transfection optimization 
 
Transfection of ZIP8 expression plasmid on HepG2 cells was carried out by X-
tremeGENE HP DNA transfection system (Roche, 06366236001). This method utilizes 
a multi-component formula that complexes with plasmid DNA, and then transports the 
complex into animal cells to overexpress the target gene.  
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 Components 1 well (6-well plate) T-25  
Tube 1 2 X HEPES (µl) 72.3 187 
Tube 2 
H2O (µl) 62.1 161 
CaCl2 (µl) 8.82 22.9 
DNA (µg) 1 2 
Volume of Tube 1&2 mixture per transfection (µl) 109 283 
 
Table 2.8. Components of calcium phosphate transfection reaction. All the 
amounts are listed for one transfection. 
 
 
HepG2 cells were passaged into a 6-well / 12-well plate 24-48h prior to 
transfection, until they reached 70%-90% confluence on the day of transfection. For 
optimization purpose, 1µg and 2µg of plasmid DNA (100µl) were mixed with 3µl and 
6µl of transfection reagent. The transfection reagent was pipetted directly into the DNA 
diluent without any contact with the interior walls of the plastic tubes. The ratio of 3:1 of 
transfection reagent (µl) to microgram (µg) DNA was used because it was shown to be 
optimal for many cell types. The transfection reagent: plasmid DNA complex was 
incubated at room temperature for 15 min, then either 100µl or 200µl of the complex 
was added to the cells in a drop-wise manner. The cells were then kept in the 
incubator for 48h without any disturbance, before being harvested for protein 
expression analysis. The total protein of each cell sample was extracted and quantified 
by BCA protein assay, followed by western blot to quantify the expression of ZIP8.  
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Transfection of ZIP8 expression plasmid on HepG2 cells by X-tremeGENE HP DNA 
transfection 
 
HepG2 cells were passaged to 12-well culture plates until a high confluence of 70-90% 
was achieved on the day of transfection. Plasmid DNA was diluted with serum-free 
DMEM to a final concentration of 0.01µg/µl. Then the X-tremeGENE HP DNA 
transfection reagent was added to the diluted DNA (2µl) in the 3:1 ratio (3µl reagent: 
1µg DNA). The transfection reagent: DNA complex was incubated for 15 min at room 
temperature, then been added to the culture medium in a drop-wise manner, followed 
by gentle swirling to ensure an even coverage of the transfection reagent over the cell 
surface. Cells were then cultured for 24-48h before harvesting for protein expression 
measurements or follow-up assays, respectively.  
 
2.9 Cadmium uptake by Measure-iTTM cadmium assay  
 
The Measure-iTTM Cadmium assay kit (Invitrogen, M36353) was used to measure 
intracellular Cd2+ concentration. This assay utilises a fluorescent dye that can fluoresce 
when bound to Cd2+ hence used to  quantify Cd2+ content, which has a linear detection 
range of 5-200nM of cadmium in the solution.   
 
2.9.1 Preparation of cadmium standard dilutions  
 
A number of cadmium standard solutions were prepared according to Table 2.9. The 
stock cadmium chloride standard solution provided by the kit was 8.4µM in deionized 
H2O. The stock solution was subjected to serial dilution with lysis buffer.   
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Concentration of cadmium 
 standard (nM) 
Volume of cadmium stock 
solution (8.4µM) (µL) 
Volume of Iysis buffer 
(µL) 
0 0 1000 
210 25 975 
420 50 950 
840 100 900 
1680 200 800 
2520 300 700 
3360 400 600 
4200 500 500 
 
Table 2.9. Preparation of cadmium standards solutions 
 
A range of 1-10µM of Cd2+ has generally been used in the literature for in vitro 
experiments. In order to determine our treatment dose, we used kinetics study as a 
reference which suggests a Km value of 0.62 µM for ZIP8-mediated Cd2+ transport in 
mouse fetal fibroblasts that is in line with the Michaelis-Menten model. The Km value is 
the concentration of Cd2+ at which uptake rate is half of Vmax (maximum uptake rate). 
Therefore a concentration close to the Km value was used (1µM) was used in our 
assay. 
 
2.9.2 Optimization of lysis buffer  
 
Some lysis buffer produce high background fluorescence, which interfere with the final 
readout. In order to select the lysis buffer with the lowest fluorescent background, a 
few lysis buffer was tested, of which the components are listed in Table 2.10. 
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Table 2.10. Components of lysis buffer for cadmium uptake assay 
 
 
2.9.3 Intracellular cadmium concentration measurements 
Cadmium solution preparation 
 
Cadmium chloride (CdCl2, Sigma) was dissolved in ddH2O to a concentration of 500µM 
for use as the stock solution. The stock solution was dissolved in serum-free culture 
medium to the required concentrations prior to each experiment.  
 
   HEK293 cells were seeded at the number of 0.3x106 cells on six-well plates 
followed by transfection according to methods in Section 2.7.5. 48h  later, the culture 
 Components Final concentration 
1. Tris-HCl     
    8.0 
NaCl  
1.0% NP-40 (or 0.1% triton X-100) 
Tris-HCl pH 8.0 
Protease inhibitor  
150 mM 
1% or 0.1% 
50 mM 
1x 
2. RIPA buffer Tris-HCl, pH 7.4 
NP-40 
Na-deoxycholate  
SDS 
NaCl 
EDTA 
Protease inhibitor mix 
50 mM  
1% 
0.5% 
0.1% 
150 mM 
2 mM 
1x 
3. IP buffer NaCl  
Tris pH 7.5 
Nonidet P40 
Sodium deoxycholate  
Protease inhibitor mix  
150 mM 
50 mM 
1% 
0.5% 
1x 
91"
"
medium was aspirated and replaced with serum-free DMEM containing 1uM Cd2+, 
followed by incubation of 2h at 37°C in a humidified, 5% CO2 incubator. After 2h of 
incubation, the culture medium was aspirated and then cells were washed once with 
PBS. IP lysis buffer (50µl) was added to each well and transferred to EP tubes, 
followed by sonication for 1 min and intermittent vortex over 30 min. The tubes were 
spun down at 13,000 rpm for 10 min, and 10µl of the supernatant was transferred to a 
well on a 96-well plate, followed by addition of 200µl of the Measure-iT kit reagent 
containing 1µL of Measure-iTTM cadmium reagent and 200µl of 1x buffer. The 
fluorescence intensity was recorded for each well at 520nm (λex: 490nm). Each sample 
was analysed in duplicate. A cadmium standard curve was generated for each 
experiment by using CdCl2 standards ranging between 0 and 4200nM. Each 
concentration of cadmium standard solution was performed in duplicates of 10µl in 
volume. The standard curve was used to determine the Cd2+ concentration in each 
sample. The adjusted cadmium uptake was calculated by standardizing the Cd2+ 
content against ZIP8 transfection efficiency as measured in the lysates of each sample 
in one experiment.  
 
2.10 Zinc uptake assay by flow cytometry 
2.10.1  Principle of flow cytometry  
 
Flow cytometry provides rapid analysis of multiple characteristics of single cells by 
measuring their optical and fluorescence characteristics. The fluidic system (sheath 
fluid) transports stained cells through the cytometer for interrogation by an illumination 
system. The fluid surrounds a thin core thread of sample, which space the cells out so 
that only one passes the laser beam at a time. Detection of cells are achieved by the 
momentary pulse of fluorescence emitted by the cell measured by photomultipliers at 
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90° angle from the beam. Typically 2-3 detectors are used with different wavelength 
bandpass filters to collect fluorescent signals. The resulting light scattering and 
fluorescence are collected and converted into digital signals, which can be visualized 
and manipulated on the computer system (shown in Fig. 2.8). Gating allows the 
operator to extract data only from single, viable cells measured at the desired 
fluorescence settings, by eliminating data from cell debris, dead cells and clumps of 2 
or more cells. The characteristics from a cell population measured by flow cytometry 
include physical properties, such as size (represented by forward light scatter) and 
internal complexity (represented by right-angle or side scatter), as well as DNA and 
RNA content, and proteins. Fluorescent dyes may bind to different cellular components, 
thus generate quantitative measurements of those components (i.e. intracellular levels 
of Zn2+).222 
 
 
 
 
Figure 2.8. Schematic of a flow cytometer 
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2.10.2 Determination of Zn2+ uptake in HepG2 transfected with ZIP8 
plasmids  
Quantification of intracellular zinc by fluorescent probe - Zinquin ethyl ester   
   
Flow cytometry was used to measure the intracellular level of Zn2+ with the 
incorporation of Zinquin ethyl ester (Santa Cruz, sc-222427). It is a lipophilic, cell-
permeable fluorescent probe which is retained within the cell membrane with a 
negative charge after it has been cleaved by cytosolic esterase. When labelled cells 
pass through a light source, the fluorescent molecules are excited to a higher energy 
state (λex= 405nm), followed by data collection at emission wavelength at the range of 
425-475nm. In order to subtract the auto-fluorescence present in the cell components 
(such as riboflavin and flavoproteins), a non-stained sample was included for each 
experiment. The levels of Zinquin fluorescence are correlated with the total cytosolic 
Zn2+ (free or loosely-bound intracellular Zn2+).  
 
Preparation of ZnCl2 treatments and Zinquin working solution  
 
Zinc chloride anhydrous powder (ZnCl2, 208086, Sigma) was dissolved in filtered 
ddH2O to generate a stock solution of 1M. The stock solution was further diluted to the 
desired concentration for each treatment with Opti-MEM (31985062, Life Technologies) 
on the same day of the Zn2+ uptake assay.  
 
One milligram of Zinquin ethyl ester was dissolved in 1ml DMSO to generate 
stock solution of 2.4mM. The working concentration (25µM) was made up by diluting 
the stock solution in opti-MEM medium 1h prior to administration. The solution 
containing the dye was protected from light exposure to prevent bleaching of the 
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fluorescent dye. 
 
2.10.3 Zinc uptake assay  
Cell preparation  
 
HepG2 cells were seeded at 100,000 cells/well on 12-well plates 24h prior to 
transfection. Cells were then transfected with pCDNA3.1-SLC39A8-Ala391/Thr 
expression plasmids and vector by X-tremeGENE HP DNA transfection in triplicate, 
with one set for the Zn2+ uptake assay, one set for verification of transfection efficiency, 
and another set served as a non-stain control. 47h after transfection, cells were treated 
with 18µM ZnCl2 (a near physiological concentration of 18µM were added to cells in 
duplicates), while the other half of cells were treated with medium only, followed by 2h 
incubation at 37°C in the incubator. After incubation, ZnCl2 was removed and cells 
were washed with PBS twice before incubating with Zinquin dye solution (25µM). A 
vehicle control was included for the detection of auto-fluorescence present in the cells 
(no dye control). After 1h incubation, the culture medium was removed and cells were 
washed with PBS twice. After complete removal of PBS, 500µl of pre-warmed 
Accutase® (Sigma, A6964) was added to each well and followed by 5-10 min 
incubation in a 37°C incubator. Upon Accutase® digestion, cells would detach from the 
cell culture surface into suspension. The suspension from each well was transferred to 
an ultracentrifugation tube, and then centrifuged at 4500 rpm for 5 min at RT. The 
supernatant in each tube was removed and cells were re-suspended in 300µl PBS 
(containing 1% BSA) and transferred to corresponding flow cytometry tubes. The tubes 
were protected from light exposure prior to flow cytometry analysis.  
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2.11 Cholesterol efflux  
 
This assay utilizes the fluorescent cholesterol-bound dye BODIPY-cholesterol (Avanti, 
810255), which features boron dipyrromethene difluoride linked to sterol carbon-24 
(Fig. 2.9). This molecule can bind to the plasma membrane of cells and behaves 
similarly to cholesterol in normal cells and cells with abnormal cholesterol-storage. In 
this study, HUVEC/HepG2 cells were cultured to 70-80% confluence, BODIPY-
cholesterol was added to the culture medium to the final concentration of 25µM, 
followed by an incubation at 37°C for 1h. Thereafter, the medium was removed and the 
cells were washed with serum-free medium. The cells were then incubated with culture 
medium containing 0.2% BSA for 18h. HDL3 (Amsbio, A95332H) was diluted in phenol-
free DMEM to achieve the final concentration of 25mg/ml (N.B. in vehicle controls, 
phenol-free medium instead of HDL3 added). Cells were incubated with HDL3 at 37°C 
for 4h, and the culture medium was collected for measurement of fluorescence 
intensity. After medium removal, cells were lysed by the addition of a solution 
containing 99.7% (v/v) acetic acid (Sigma, A6283) and 1% (w/v) cholic acid (Sigma, 
C1129) and followed by incubation at room temperature for 4h with shaking. 
Fluorescence intensities in the culture medium and cell lysate were determined by a 
fluorometer (Victor2 1420 multi-label counter) with excitation and emission wavelengths 
of 485nm and 535nm, respectively.  
 
Cholesterol efflux ratio =  X 100% 
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Figure. 2.9. Structures of cholesterol and BODIPY-cholesterol 
 
(http://www.avantilipids.com/index.php?option=com_content&view=article&id=1905&It
emid=306&catnumber=810255) 
 
 
2.12 Low dose cadmium exposure and ERK1/2 activation 
2.12.1 ERK1/2 signalling in HEK293 cells  
Cell culture and transfection  
 
HEK293 cells were seeded on 12-well plates at 5 x104 cells/well density, and 
maintained in DMEM supplemented with 10% FBS and 1% antibiotics. Cells were 
transfected with pCDNA3.1-SLC39A8-Ala/Thr391 plasmids and pCDNA3.1 vector 
control by calcium phosphate transfection in duplicates. The transfection procedure 
was carried out with the listed components in Table 2.11  
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 Components Volume (µl) 
Tube 1 2 x HEPES 144.6 
Tube 2 
H2O 121.2 
CaCl2 17.64 
DNA (500ng/µl) 4 
Volume of Tube 1&2 mixture per transfection 43.6 
 
 
Table 2.11 Calcium phosphate transfection for assessing ERK1/2 signalling 
 
Optimization of cadmium treatment 
 
Cadmium chloride salt was dissolved in filtered ddH2O to 500µM, and then been 
diluted to 1µM with culture medium on the day of experiment. Cells were then 
subjected to CdCl2 treatment 24h post transfection. 1ml of DMEM containing 1µM Cd2+ 
was added to the transfected HEK293 cells, followed by 1h, 2h, 4h and 24h incubation 
in a 37°C, 5% CO2 incubator. 
 
 Detection of phosphorylated ERK1/2 in HEK293 
 
Cells were harvested at the end of incubation with CdCl2. They were washed once with 
PBS, then lysed with 50µl cold lysis buffer (RIPA) containing protease inhibitor (P.I) 
and phosphatase inhibitor mixture (2mM Na4VO3). Total cellular protein concentrations 
were determined by BCA assay. Equivalent amounts of proteins were analysed by 
SDS-PAGE and then transferred onto PVDF membranes. Membranes were blocked in 
5% non-fat dried milk in TBST buffer for 1h, followed by several washes with TBST 
buffer. Membranes were then incubated in antibodies at the following concentrations 
(developed with no stripping in between the antibodies): first with phospho-p44/42 
98"
"
MAPK (Erk1/2) rabbit polyclonal antibody (Cell Signalling, #9101): 1:1000; then with 
total ERK (Cell Signalling, #9102) 1:1000. The p44/42(ERK1/2) antibody was diluted in 
5% BSA in TBST, and the anti-rabbit secondary antibody was also diluted in 5% BSA 
at 1:3000 final dilution. Signals were detected by enhanced chemi-luminescence.  
 
2.12.2 ERK1/2 signalling in HuVECs 
Cell culture and cadmium treatment  
 
HuVECs were seeded on 12-well plates at density of 0.1x106 cells/well. 24h after 
seeding, cells were either treated with culture medium containing designated amount 
of CdCl2 or no CdCl2. For each cell from different human umbilical cords, duplicates 
were performed on both the treatment and non-treatment group.  
 
Optimization of Cd2+ treatment  
 
Two concentrations of Cd2+ treatment (1µM and 10µM) and four time points (1h, 2h, 4h, 
24h) were assessed on HuVEC to investigate the optimal condition resulting in 
maximum ERK1/2 activation. HuVEC from one umbilical cord was passaged in a 12-
well plate at the densities mentioned above. After incubating with cadmium for the 
designated length of time, cells were then lysed with 50µl chilled lysis buffer (RIPA) 
containing protease (P.I) and phosphatase inhibitor mixture (2mM Na4VO3). The rest of 
the procedures were consistent with described above.  
 
Quantification of pERK1/2 in HUVECs of Ala/Ala and Ala/Thr genotypes for rs13107325   
 
ERK1/2 activation was assessed in HUVEC cell lines of either Ala/Ala or Ala/Thr 
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genotype under Cd2+ treatment. Each HuVEC cell line was passaged to 4 wells on 12-
well plates, two for cadmium treatment and two for non-cadmium controls. 24h after 
passage, 1ml of M199 supplemented with 15% FBS and 1µM cadmium and vehicle 
control were added to the corresponding wells, respectively, followed by incubation of 
2h at 37°C, 5% CO2. After incubation, cells were then been lysed with 50µl chilled lysis 
buffer (RIPA) containing 1x protease (P.I) and phosphatase inhibitor (2mM Na4VO3). 
The rest of the procedures were consistent with described in Section 2.7.2.  
 
2.13 NF-ĸB dual luciferase reporter assay  
 
κB-luciferase reporter assays employ the co-transfection of two reporter plasmids. One 
reporter plasmid expresses the firefly (Photinus pyralis)  luciferase gene under control 
of a minimal promoter (essentially a TATA box) and one or more copies of a ĸB cis-
element, whereas the other ‘control’ plasmid expresses the Renilla (Renilla reniformis) 
luciferase gene that is served as an internal control for transfection efficiency. The 
activities of firefly and renilla are measured sequentially from a single sample. The 
luciferase protein encoded by the κB-luciferase plasmid and renilla-luciferase plasmids 
display luminescence that is detected by spectrophotometry.  
 
   This assay allows detection of two individual reporter enzymes within a single 
sample. The dual-reporter assay produces more reliable interpretation of the 
experimental data by eliminating variability. Normalizing the activity of the experimental 
reporter to that of the internal control minimizes experimental variability caused by 
differences in cell viability or transfection efficiency.  
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2.13.1 Co-transfection of reporter plasmids and pCDNA3.1-SLC39A8 
plasmids 
 
At Day 1, HEK293 cells were seeded onto wells of 24-well tissue culture plates (5 x 104 
cells/well) in 0.5mL pre-warmed DMEM, and incubated at 37°C in 5% CO2. The assay 
was performed in triplicate. After 24h (Day 2), cells were subjected to transient co-
transfection of the according to the formulation listed in Table 2.12 by using the 
calcium phosphate transfection method.  
 
Preparation of cadmium treatment   
 
24h after transfection (day 2), CdCl2 (1µM) solution was prepared using pre-warmed 
DMEM containing 10% FBS, after aspirating old medium, 0.5mL CdCl2 solution was 
added to the cells in 18 of the 24 wells. The remaining 6 wells were added with only 
DMEM containing 10% FBS.  
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 Tube 1 Tube 2 
2 x HEPES 47.1  
pCDNA3.1-SLC39A8-Ala/Thr or 
pcDNA3.1 plasmid (500 ng/µl) (µl) 
 1 
NF-κB-luci plasmid(150ng/µl) (ul)  1 
Renilla-luci 
plasmid (1.5 ng/µl) (µl) 
 1 
H2O (µl)  38.5 
CaCl2 (µl)  5.75 
 
Table 2.12 Calcium phosphate transfection reagents components used for 
one 24-well plate. A volume of 71.01µl of the final mixture was added to each well 
on the 24-well plate 
 
 
Luciferase activity detection  
 
Cells were incubated at 37°C in 5% CO2 for 2h. During treatment, 1x luciferase lysis 
buffer were prepared by adding four volumes of ddH2O to one volume 5 x passive lysis 
buffer, and pre-equilibrated to room temperature. After 2h CdCl2 treatment, the culture 
medium was aspirated from the wells, followed by PBS wash once (without disturbing 
the cells).  
 
   The luciferase activity was measured by Dual-Luciferase reporter assay kit 
(Promega, E1910). The volume of 100µl 1 x luciferase lysis buffer was added to each 
well, the plate was wrapped in a sealed plastic bag (to avoid excess evaporation) and 
shaken for 30 min at room temperature. Cells were then detached from the bottom of 
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the wells by using a single-use cell lifter and transferred to sterile 0.8mL ultracentrifuge 
tubes, followed by centrifugation at 13,000 rpm for 30s at 4°C. An aliquot of 20µL of 
the supernatants was harvested and transferred to new 1.5mL tubes. Lyophilized 
luciferase assay substrate was re-suspended in luciferase assay buffer II (LAR II, 
Cat.1910), Stop & Glo® substrate was diluted with Stop & Glo reagent in 1:50 ratio. 
Both reagents were protected from light before and during the luciferase assay. 
 
   The firefly luciferase intensity was first measured by adding 100µL of the LAR II 
to the cell lysates and the luciferase was measured immediately with time delays of 
less than 10s. The first reading showed NF-κB-dependent transcriptional activities 
within each sample lysate. The reaction was quenched and the Renilla luciferase 
reaction was simultaneously initiated by adding 100µL of the Stop&Glo reagent to the 
same cell lysates in the same manner, which indicated the Renilla luciferase intensity. 
For each sample, the luminescence intensity was normalized by dividing the Firefly 
luciferase reading of NF-κB by Renilla luciferase levels.  
 
2.14 Immunoblotting for detecting NF-ĸB activation  
 
HUVECs of Ala/Ala and Ala/Thr genotypes were cultured on 12-well plates and were 
exposed to various durations of cadmium treatments (1µM Cd2+ for 2h, 4h and 24h). 
Cells were lysed in RIPA lysis buffer containing proteinase inhibitor and phosphatase 
inhibitor on ice for 45 min. Total protein concentrations were quantified by BCA assay. 
Proteins were separated by SDS-polyacrylamide gel electrophoresis, blotted onto 
PVDF membrane and probed with IkBα (Santa Cruz, sc-371, 1:1000), pIkkα/β (Cell 
Signalling, 2697, 1:1000), and phosphor-p65 (Cell Signalling, 30335, 1:200) antibodies. 
The rest of the protocol was in accordance with the immunoblotting assay described in 
2.7.3. 
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2.15 Cell toxicity assay  
2.15.1 LDH cytotoxicity assay 
 
Lactate dehydrogenase (LDH) cytotoxicity assay is a colorimetric method for 
quantification of cellular cytotoxicity mediated by chemical compounds. LDH is a 
cytosolic enzyme which is released from cells into the culture medium when plasma 
membrane damage occurs. LDH acts as the catalyst for the conversion of lactate to 
pyruvate via NAD+ reduction to NADH. Diaphorase then uses NADH to reduce a 
Tetrazolium salt (INT) to a red formazan product with a colorimetric absorbance at 
490nm which can be measured by a spectrophotometry. The level of formazan 
formation is directly proportional to the amount of LDH released into the medium, 
which indicates the cytotoxicity. (Fig. 2.10) 
 
 
 
Figure 2.10. Principle reaction of LDH cytotoxicity assay 
 
 
 
HuVECs were seeded on 96-well plates at a density of 5,000 cells/well with 
100µl medium in 6 wells for each cell line. On the following day, CdCl2 stock solution 
(500µM) was diluted in M199 medium containing 0.1% FBS and loaded to cells to 
induce cytotoxicity which led to the release of LDH.  Culture medium containing 
equivalent amounts of H20 were added to another set of duplicate to be served as 
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Spontaneous LDH activity controls. For maximum LDH activity controls, 10 µl of lysis 
buffer (10x) were added to another set of duplicate wells and mixed by gentle tapping, 
followed by incubation at 37°C, 5% CO2 for 45 min. After incubation, 12.5µl of the cell 
culture medium was transferred to a new 384-well plate and mixed with 12.5µl reaction 
mixture (assay buffer: substrate=1:19). After a 30 min incubation at room temperature 
protected from light, reactions were stopped by adding 12.5µl Stop Solution. 
Absorbance at 490nm and 630nm was measured by a plate reader spectrophotometer. 
To determine LDH activity, 630nm absorbance value (background) was subtracted 
from the 490nm absorbance before calculation of % cytotoxicity. Net LDH= [(LDH at 
490nm)-(LDH at 630nm)]. Additional wells containing M199 (supplemented with 0.1% 
FBS) and serum free medium without cells were also included for detection of the 
amount of basal LDH activity in sera.   
 
Calculation of cytotoxicity 
 
% Cytotoxicity =  x100% 
 
2.15.2 CellTiter 96® Aqueous One solution cell proliferation assay  
 
In order to test the toxicity of Cd2+ on HUVEC and HEK293 cells, the CellTiter 96® 
AQueous One Solution reagent (Promega, G3582) was used to determine the number 
of viable cells, as an indicator for cytotoxicity of Cd2+. The reagent contains a novel 
tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium, inner salt; MTS] and an electron coupling reagent 
(phenazine ethosulfate; PES). The MTS tetrazolium compound (Owen’s reagent) is 
bio-reduced by cells into a brown formazan product that is soluble in tissue culture 
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medium. The conversion is presumably accomplished by NADPH or NADH produced 
by dehydrogenase enzymes in metabolically active cells.223 The chemical reaction is 
listed in Fig. 2.11. The quantity of formazan products as measured by the colorimetric 
absorbance at 490nm is directly proportional to the number of viable cells in culture.  
 
 
 
Figure 2.11. Structure of MTS tetrazolium and its formazan product223 
 
HEK293 cells were passaged on a 96-well plate and a 6-well plate 24h prior to 
transfection at confluency of 20-30%. On day 1, cells were transfected by calcium 
phosphate method with pCDNA3.1–SLC39A8-Ala391/Thr plasmids and pCDNA3.1 
vector control. The volume of transfection reagent/DNA mixture was adjusted 
according to the surface area of each well, therefore 1/30 of the transfection 
reagent/DNA mixture volume for a well on the 6-well plate was used for one well on the 
96-well plate. CdCl2 aqueous solution was diluted in phenol-free DMEM (to avoid 
binding of Cd2+ with components of the serum) to the final concentration of 1µM. 48h 
later, the culture medium was aspirated and replaced with phenol-free DMEM 
containing 1 µM CdCl2, followed by incubation of 2h at 37°C in a humidified, 5% CO2 
incubator. By the end of the incubation, 20µl/well of CellTitre 96® AQueous One 
Solution reagent was added to each well, followed by approximately 1.5h incubation at 
37°C in a humidified, 5% CO2 incubator, to allow a sufficient development of the colour. 
The colorimetric absorbance at 490nm was recorded using a plate reader. The cells 
cultured on the 6-well plate were harvested for testing of transfection efficiency, which 
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is representative of the 96-well plate by sharing the same transfection reagent. 
 
Viable cells percentage=  
x100% 
 
 
2.16 Bioinformatics analysis  
2.16.1 Prediction of Ala391Thr variation on ZIP8 function  
 
At the beginning of this project, we conducted intensive bioinformatics search to predict 
the potential functional impact of Ala391Thr variation on ZIP8 function. A number of 
bioinformatics tools included Phenotype Polymorphism (PolyPhen 2.0), Sorting 
Intolerant from Tolerent (SIFT), SNPs&Go, Screening for Non-Acceptable 
Polymorphisms (SNAP), Panther, dbSNP, Pmut, PROVEAN, iMutant, Mutpred. (The 
links for each of these tools have been listed in Results section Table 4.3) They usually 
use features based on sequence, structure, or known function. Some of these tools 
used learning algorithms to predict protein structure (use a training set of positive and 
negative examples to ‘learn’ sites). Others use substitutions based on disease-
associated human alleles.  
 
 It is now been recognized that transcription factor (TF) binding can occur at 
exonic regions within the genome, in which codons that are highly conserved may also 
specify TF recognition sites.224 Protein-coding DNA also often contains enhancers 
functioning at the transcriptional level.225 Two algorithms have been used with an 
attempt to detect any overlapping of potential TF binding site within the polymorphic 
region, which are listed as follows:  
Patch (http://www.gene-regulation.com/cgi-bin/pub/programs/patch/bin/patch.cgi), and     
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P-match      (http://www.gene-regulation.com/cgi-bin/pub/programs/pmatch/bin/p-
match.cgi).  
 
2.16.2 Prediction of Ala391Thr variation on ZIP8 structure 
 
At the later stage of the project, more bioinformatics tools have been employed to 
predict the impact of Ala391Thr variation on the transmembrane structure of ZIP8. 
Conservation analysis was performed at both the nucleotide and amino acid position, 
followed by protein secondary structure prediction based on a structurally similar 
homologue.  
 
In the conservation analysis, protein sequences for human ZIP8 were retrieved 
from Ensembl version 78 (http://www.ensembl.org/index.html).226 The longest isoform 
(ENST00000356736), deemed as canonical, was chosen for further analysis. 
Conservation analysis was performed on Ensembl using 23 way alignment of high-
coverage amniote vertebrate genomes. The ConSurf server (http://consurf.tau.ac.il/) 
was used to predict functional domains based on the evolutionary conservation of 
amino acid positions.227 This technique relies on UniRef protein clusters to infer the 
phylogenetic relations between homologous sequences.  
 
   The Robetta approach was employed to predict the secondary structure of the 
ZIP8 protein containing either the Ala391 or the Thr amino acid.228 
(http://robetta.bakerlab.org/queue.jsp) This method segments the protein into domains 
that are homologous to proteins with known structure, before an optional structure 
refinement stage. Both the full protein sequences containing the Ala391 and Thr391 
residues were submitted for structure prediction. The domain containing amino acid 
391 for both variants were fully processed and analyzed using PyMol to assess the 
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predicted structural effects of the amino acid substitution in the respective functional 
domain.93 Further to the full structural reconstruction, Prediction of Transmembrane 
Helices In Proteins (TMHMM) v2 was used to predict transmembrane helical domains 
within the input sequences.229  (http://www.cbs.dtu.dk/services/TMHMM/)  
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3. Results 
3.1 Investigation of effect of rs13107325 on SLC39A8/ZIP8 expression  
3.1.1 Identification of human umbilical artery smooth muscle cells and 
umbilical vein endothelial cells of relevant genotypes for functional study 
 
In order to identify cells of the appropriate genotypes for subsequent gene expression 
studies, the DNA from human umbilical artery smooth muscle cells (HUASMCs) and 
umbilical vein endothelial cells (HUVECs) from different individuals were genotyped for 
SNP rs13107325 by KASPar, TaqMan and restriction enzyme digestion. The KASPar 
SNP genotyping assay was mainly used for HUASMCs, whereas TaqMan was used for 
HUVECs. The results of KASPar and TaqMan SNP genotyping were analysed by the 
SDS 2.4 software (Applied Biosystems), which produced an output display shown in 
Fig. 3.1 A. Genotype distributions of SNP rs13107325 in the HUASMC and HUVEC 
collections are summarized in Fig. 3.1 C. KASPar genotyping achieved a call rate of 
97.2% in HUASMC samples, but was lower in HUVEC, hence TaqMan and restriction 
enzyme digestion methods were employed, which resulted in a 98.3 and 100% call rate, 
respectively. In the HUASMC samples, the frequencies of the C/C, C/T and T/T 
genotypes determined by KASPar were 93.8%, 5.8% and 0.4%, respectively. In the 
HUVEC DNA samples, the frequencies of the C/C, C/T and T/T genotypes determined 
by TaqMan were 93.1%, 7.5% and 0, respectively. However after sequencing of 
predicted heterozygous samples in HUVEC (n=13), only 3.4% (n=6) were proven to be 
true heterozygotes, with the rest being common homozygotes. The observed genotype 
distribution of the HUASMC collection was in agreement with Hardy-Weinberg 
equilibrium (HWE) (P = 0.7955, Chi-squared test).230 The observed genotype distributi 
on in the HUVEC collection was in agreement with the expected distribution in HWE 
calculation (P = 0.9597, Chi-squared test). The restriction enzyme digestion of the PCR 
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Figure 3.1. Genotyping of rs13107325 in HUASMC and HUVEC DNA. (A) A 
representative SDS2.4 output of KASPar genotyping assay on HUASMC DNA samples. 
Each red dot is part of a selected cluster which has a predominantly VIC fluorescence 
signal, representing C/C genotype; each blue dot indicates a cluster of largely FAM 
fluorescence signal and thus the T/T genotype, whereas each green dot indicates both 
the detection of both VIC and FAM signals and thus the C/T genotype (B) A 
representative image of agarose gel electrophoresis of restriction enzyme digests of 
PCR products. The presence of the 121bp, 153bp and 274bp bands of similar intensity 
indicates the sample to be C/T genotype, whereas the presence of only the 121bp and 
153bp bands indicates the C/C genotype (C) Genotype distribution of rs13107325 in 
HUASMCs and HUVEC DNA samples. 
 KASPar TaqMan 
Genotype HUASMC 
(n=282) 
HUVEC 
(n=178) 
C/C 257 162 
C/T 16 13 
T/T 1 0 
Unclassified 8 3 
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products method was used to facilitate genotyping, as shown in Fig. 3.1 B, which 
resulted in high success rate but ambiguity for distinguishing genotypes. The 
genotypes of all heterozygous samples were confirmed by Sanger sequencing. The 
rare homozygote sample in HUASMC was not pursued for further experimentation due 
to lack of cDNA or cell stock.  
 
Overall, both KASPar and TaqMan genotyping methods have yielded some 
false positive results in genotype determination. This could be due to poor hybridization 
of the probes with gDNA, or the relatively small sample size (100-200) used in our 
projects. Definitive clustering was not achieved when small number of samples were 
used. Restriction enzyme digestion served as a more efficient method which allow 
individual sample detection. However, the ambiguity of results interpretation in some 
samples have affected its reliability in application.   
 
3.1.2 Comparison of the relative SLC39A8 mRNA expression levels of the 
T and C alleles  
 
In order to investigate whether SNP rs13107325 has an allelic effect on SLC39A8 
expression, allelic expression imbalance (AEI) assays were performed to determine 
whether there was a difference in mRNA expression levels between the T and C 
alleles in the HUASMCs. PCR was performed to amplify the sequence (~200bp) 
flanking SNP rs13107325 in genomic DNA and cDNA in five HUASMC samples of C/T 
genotype. The PCR products from genomic DNA and cDNA were subsequently 
sequenced for AEI analysis (representative sequencing result is shown in Fig. 3.2 A). 
The relative heights of the peaks for T and C alleles at the rs13107325 SNP site were 
quantified with the use of PeakPicker software. In 5 pairs of samples which were 
heterozygous for rs13107325, the mean ratio of the peak height of allele T and allele C 
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at the polymorphic site was not significantly greater in cDNA than in genomic DNA 
(p=0.06 by Wilcoxon test), as shown in Fig. 3.2 B.   
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Figure 3.2 Effect of rs13107325 on SLC39A8 mRNA transcription in HUASMC. (A) 
Representative of sequencing chromatograms from genomic DNA and cDNA of the 
same individual. The arrow points the polymorphic site of rs13107325 (B) Median ratio 
(± range) of allele T over allele C in cDNA and genomic DNA, respectively, in 
HUASMC of individuals heterozygous for rs13107325 (n=5 for each column)  
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          The allelic imbalance analysis in HUVEC samples was hindered by an 
insufficient number of samples that were heterozygous for rs13107325. Two samples 
subjected to sequencing resulted in no major difference of the C/T ratio between cDNA 
and genomic DNA, as shown in Fig. 3.3. Therefore there is not enough evidence to 
demonstrate an allelic difference in mRNA expression in HUVECs. 
                                  
A 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
Figure 3.3 Effect of rs13107325 on SLC39A8 mRNA transcription in HUVEC. (A) 
Representative of sequencing chromatograms from genomic DNA and cDNA of the 
same HUVEC sample. The arrow points the polymorphic site of rs13107325 (B) Ratio 
of allele T over allele C in cDNA and genomic DNA (n=2 for each column). Each bar 
represents median ( ± range) of each sample. 
gDNA (C/T) 
cDNA (C/T) 
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AEI appears to be a reliable method for assessing cis-acting regulatory 
elements when compared to eQTL for the reasons below: 1. AEI minimizes the intra-
sample variation by correction with genomic DNA. When comparing mRNA levels 
between different individuals, other trans-acting regulators or different genetic 
background may contribuate to the differences in gene expression; 2. AEI also offers 
the advantage of assessing such interaction in more relavant tissue samples, as to 
generate a tissue-specific expression pattern. Standard eQTL mapping is done to test 
the linkage between variation in expression and genetic polymorphism. The available 
eQTL (expression quantitative trait loci) association of rs13107325-SLC39A8 is shown 
in Fig. 3.4. These data were obtained from the Genevar program at the Wellcome 
Trust Sanger Institute which can be downloaded from www. 
Sanger.ac.uk/resources/software/genevar/. These results were performed mainly on 
adipose, lateral collateral ligament (LCL) and skin tissues, and have not shown a 
significant difference in mRNA transcription levels among the three genotypes.  
 
 
 
Figure 3.4. eQTL results of the association between rs13107325 and mRNA 
expression of SLC39A8. Data obtained from Genevar.  
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3.1.3 Comparison of ZIP8 protein levels among cells of the C/C and C/T 
genotypes  
 
Total ZIP8 protein expression levels in HUASMC and HUVEC  
 
The total ZIP8 protein expression levels were examined in HUASMCs and 
HUVECs of C/T and C/C genotypes. Immunoblotting with the polyclonal anti-ZIP8 
antibody showed multiple bands of around 150kDa and 60kDa for all the cell lines 
tested (HUASMC, HUVEC and MCF-7) (Fig. 3.5 A, C, F). ZIP8 was reported to be 
expressed in MCF-7 cells, which was used as a positive control.  (Fig. 3.5 F). 
Quantification of the two bands (~60kDa and 150kDa) in HUASMC showed 
approximately 1.6 fold higher expression in C/T samples than C/C samples, as shown 
in Fig. 3.5 B. However the difference was not significant, which might be due to 
insufficient sample numbers. The experiment was repeated twice, and similar results 
were seen. The trend was consistent with the previous finding in AEI, however needs 
to be validated in larger number of samples.  
 
Although AEI failed to reveal any trend of expression difference on mRNA level in 
HUVECs. Given the small number of samples tested, the possible effect of this SNP on 
protein expression still can not be ruled out. HUVEC proteins were probed with the 
anti-ZIP8 antibody pre-incubated with a specific blocking peptide to verify the 
specificity of the antibody and nature of the multiple bands. The blocking peptide 
reduced the intensity of most of the bands, this could be due to incomplete blocking of 
the primary antibody at a high concentration. The band above the 100 kDa was greatly 
abolished by the blocking peptide, as indicated by the double arrow in Fig. 3.5 D. This 
suggested that the band of >100kDa was most specific to ZIP8, hence was used for 
further quantification of ZIP8 expression in HUVEC (Fig. 3.5 E). The expression level 
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of ZIP8 in HUVECs of C/T and C/C genotype was not significantly different. 
  A                                                                       B 
 
C                                                                         D 
 
E                                                                          F 
 
Figure 3.5. Immunoblotting image of total proteins in HUASMC and HUVEC cells 
of C/T and C/C genotypes. (A) Immunobloting analysis for the detection of ZIP8 
expression in HUASMC (B) Quantification of relative ZIP8 expression in HUASMCs of 
C/C and C/T genotypes, n=4 for each genotype (C) Immunoblotting analysis for the 
detection of ZIP8 expression in HUVEC (D) Specificity of the ~100kDa bands was 
determined by preincubating the respective antibody with a ZIP8 specific peptide 
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solution (E) Quantification of relative ZIP8 expression in HUVEC cells of C/C and C/T 
genotype, n=4 for each genotype, p>0.5 by paired Student’s t test (F) ZIP8 expression 
in other positive control cell line (MCF-7). Each bar represents the median value (± 
range) of each sample. 
 
ZIP8 protein in subcellular fractions of HUVECs of C/T and C/C genotypes 
 
In order to determine the ZIP8 expression was further determined in protein fractions 
extracted from different cellular compartments, including membrane, nucleus, 
mitochondrial and organelles. As shown in Fig. 3.6, protein of different sizes were 
observed in these fractions, which may suggest different post-translational modification 
in these cell compartments. The majority of the ZIP8 signals detected were larger than 
130kDa, suggesting that ZIP8 exists as a dimer or multimer in HUVECs. On top of that, 
some of these proteins may be glycosylated, which may explain the presence of 
multiple signals. In the cytosolic fraction, the presence of bands above 250 kDa 
indicates that ZIP8 proteins may exist in heterodimers. The expression levels were 
lower in the 10,000 x g (organelles) and 900 x g (nuclear + cell debris) fractions, which 
was to be expected for membrane proteins.  
 
3.2 Investigation of effect of Ala391Thr on ZIP8 function  
3.2.1 Generation of pCDNA3.1-SLC39A8-Ala/Thr391 plasmids 
 
In order to investigate the effect of Ala391Thr substitution caused by SNP rs13107325 
on ZIP8 protein function, two plasmids for expressing either ZIP8-Ala391 or ZIP8-
Thr391 were generated by a series of molecular cloning experiments. First of all, the 
full open-reading-frame (ORF) sequence of ZIP8 was amplified using a plasmid 
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containing the full-length human ZIP8 cDNA (C allele-containing) as the template  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6.  Immunoblotting image of ZIP8 expression in HUVEC cellular 
fractions. nC/T=4, nC/C=5.  
 
followed by digestion with EcoRI and HindIII restriction enzymes (Fig. 3.7 A, B and C). 
The digested products were then ligated overnight using T4 ligase and subsequently 
transformed into JM109 competent cells.  
 
Positive colonies were further propagated followed by plasmid extraction and 
verification by sequencing. The insert of the pCDNA3.1-SLC39A8-alanine (Ala) 
119"
"
plasmid was sequenced to be in line with the SLC39A8 ORF (corresponding to the C 
allele) without any nucleotide change compared to the reference sequence. This 
plasmid was then subjected to site-directed mutagenesis to generate a corresponding 
pCDNA3.1-SLC39A8-Thr plasmid. Following mutagenesis, the insert of the second 
plasmid was sequenced to verify that nucleotide C had been changed to T at the SNP 
rs13107325 site (Fig. 3.7 D; full sequence shown in Appendix 3). 
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Figure 3.7. Gel electrophoresis results of PCR products for cloning. (A) PCR 
amplicon of the SLC39A8 ORF insert, each lane represents one selected colony (B) 
PCR amplicons of ZIP8 ORF digested by EcoR I and Hind III enzymes: Lane 1 and 2 
represent C allele (Ala391) containing insert, lane 3 and 4 represent T allele (Thr391) 
vector 
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containing insert (C) pCDNA 3.1 plasmid vector digested by Hind III enzyme (lane 1) or 
by both EcoR I and Hind III enzymes (lane 2) (D) Sequencing chromatograms of the 
pcDNA3.1-SLC39A8-Ala and –Thr plasmid containing the C!T mutation. 
 
 
3.2.2 Transfection of cultured cells with pCDNA3.1-SLC39A8-Ala/Thr391 
plasmids  
 
Different transfection methods were used for different cell lines. The calcium 
phosphate method was used to transfect HEK293 with the SLC39A8 expression 
plasmids or the plasmid vector. Subsequent immunoblotting analyses using a 
polyclonal hZIP8 antibody generated two bands (~100 and 150kDa) in transfected 
HEK293 cells (Fig. 3.8, left half), which showed higher intensities in the cells 
transfected with the pCDNA3.1-SLC39A8-Ala/Thr plasmids than cells transfected with 
the vector. Co-incubation of ZIP8 antibody with the ZIP8 antigen peptide resulted in a 
significant reduction of the 100kDa and 150kDa bands (Fig. 3.8, right half), indicating 
that those two bands derived from ZIP8 proteins. Preliminary data showed that 1µg of 
the plasmid DNA produced a good transfection efficiency. Therefore 1µg of plasmid 
was used for subsequent transfections conducted in 6-well plates. The amount of 
plasmid was adjusted proportionally according to the surface area of the culture plate 
when other types of plates were used.  
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Figure 3.8  Immunoblotting of calcium phosphate transfection on HEK293 
cells. HEK293 cells transfected with the ZIP8 expression plasmids, incubated with a 
ZIP8 antibody in the presence or absence of a ZIP8 blocking peptide  
 
 
X-tremeGENE HP DNA method was used to transfect HepG2 cells, as the 
calcium phosphate method yielded very low transfection efficiency and electroporation 
resulted in severe cell death in this cell line. X-tremeGENE HP DNA method did not 
change the morphology or the number of cells (Fig.3.9 A) and caused minimum cell 
death. This method has yielded high transfection efficiency for both plasmids (Fig. 3.9 
B). Without detecting any monomer form of ZIP8, this protein seems to be present in 
dimer or multimer form which is consistent with the previous finding in HUASMC and 
HUVECs (bands ~ 150kDa). The smeary bands shown in Fig. 3.9 B indicate the 
possible presence of more than one band upon transfection.  
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Figure 3.9. X-tremeGENE HD transfection in HepG2 cells. (A) Morphology of 
transfected and untransfected cells 24h after transfection (B) Immunoblot result of 
HepG2 cells transfected with 1µg of ZIP8 plasmid DNA or vector 
 
 
 3.2.3 The effect of SLC39A8 genotype on metal ion uptake  
SLC39A8-Ala391 variant is associated with higher levels of Cd2+ uptake in HUVEC and 
HEK293 cells 
 
The kidney is the one of the primary targets for deposition of Cd2+. Using a human 
embryonic kidney model, only a very low level of endogenous ZIP8 was found in 
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HEK293 cell (Fig. 3.10 A: lanes pCDNA3.1, upper panel). This makes HEK293 cell a 
good cellular model for the study of the genotypic impact of SLC39A8 on cellular 
function. Transfection yielded ZIP8-specific bands of around 100kDa, which are similar 
in size as the ZIP8 signal in HUVEC. As proven by the blocking peptide experiment, 
overexpressed ZIP8 is likely to be packed into different complexes in different tissues. 
Immunoblotting and quantification of ZIP8 expression in HUVECs of Ala/Ala and 
Ala/Thr genotypes is shown in Fig. 3.10 B. Higher levels of Cd2+ uptake were observed 
in transfected HEK293 cells overexpressing the Ala391 variant (Mean=9.29) compared 
to the Thr391 (Mean=1.9) (Fig. 3.10 C). In HUVECs, cells of the Ala/Ala genotype 
(Mean=215) also exhibited higher Cd2+ uptake compared with cells of Ala/Thr genotype  
(Mean=5.1) , as illustrated in Fig. 3.10 D. 
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Figure 3.10. Effect of SLC39A8 genotype on Cd2+ uptake. (A) A representative 
image of immunoblot analysis and the quantification of overexpressed ZIP8 proteins in 
cultured HEK293 cells transfected with pCDNA3.1-SLC39A8 plasmids containing 
either alanine or threonine at residue 391 on the protein sequence (B) A representative 
image of immunoblot analysis and the quantification of ZIP8 proteins in HUVECs of 
Ala/Ala and Ala/Thr genotypes (C) Intracellular Cd2+ levels in transfected HEK293 cells. 
Each column represents the difference of Cd2+ content between Cd2+-treated cells and 
vehicle-treated cells, standardized against total ZIP8 expression in each HUVEC 
sample. Each data point represents mean (± SEM) in duplicates from 3 experiments, 
n=6 for each plasmid  (D) Intracellular Cd2+ levels in HUVECs. Each column represents 
the difference of Cd2+ content between Cd2+-treated cells and vehicle-treated cells, 
standardized against total ZIP8 expression in each HUVEC sample. Each data point 
represents mean (± SEM) in duplicates from 3 experiments, n=4 for each genotype. 
p<0.05 by paired Student’s t-test. 
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SLC39A8-Ala391 variant is associated with higher levels of Zn2+ uptake in HepG2 cells 
 
In order to test whether the Ala391Thr substitution may affect the activity of ZIP8 on 
Zn2+ uptake, and to further elucidate the link between Zn2+ uptake, NF-  signalling, 
and cholesterol efflux, Zn2+ uptake assay was performed on HepG2 cells. A fluorescent 
dye (Zinquin) which binds to labile Zn2+ was used and detected by a flow cytometer. 
HepG2 cells were firstly been transfected with pCDNA3.1-SLC39A8-Ala391, Thr391 
plasmid or pCDNA3.1 vector, followed by incubation with zinc chloride and Zinquin. As 
shown in Fig. 3.11, the Ala391 variant exhibited a higher level of Zn2+ uptake under 
physiological concentration of Zn2+ treatment (18µM), compared to pCDNA3.1-
SLC39A8- Thr391 plasmid and pCDNA3.1 vector. 
A                                                                       B           
 
Figure 3.11. Zn2+ uptake result in HepG2 cells transfected with pCDNA3.1-
Ala/Thr391 plasmids. (A) A representative plot of flow cytometric analysis showing 
intracellular Zn2+ content (B) Quantification of intracellular Zn2+ content after 2h of 
ZnCl2 treatment (18µM), each value is the vector control and unstained sample 
V450/50 -subtracted reading value, and each bar represents median (± range) from 3 
samples. 
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3.2.4 SLC39A8-Thr391 variant is not associated with HDL3-mediated 
cholesterol efflux  
 
To examine whether quantitative cholesterol efflux measurements can be achieved 
using BODIPY-Ch, a time-course experiment was performed in HUVEC. Efflux of 
BODIPY-Ch increased over 24h, although significant cell death was also observed. A 
gradient range of HDL3 was used to determine the optimal concentration for cholesterol 
efflux. A positive correlation was observed between increasing amount of HDL3 and 
cholesterol efflux, with 25µg/ml of HDL3 resulting in an efflux rate of 4.27% over 4h 
efflux (Fig. 3.12). Minimal cell death was seen at this concentration and time period. 
Therefore 4h efflux period was used for further experiments. 
 
       A                                                                          B 
 
Figure 3.12. Optimization of HDL3-mediated cholesterol efflux in HUVECs. (A) 
HDL3 dose response curve of cholesterol efflux over 4h time period. (B) HDL3 dose 
response curve of cholesterol efflux over 24h time period. Efflux ratio was expressed 
as the percentage of the medium BODIPY-ch fluorescence from the total BOBIPY-ch 
fluorescence measured from the medium and cells. Each value was generated by 
subtraction of value from the vehicle-treated sample from the HDL3-treated sample 
which were transfected by the same plasmid or vector.  Data represent median (± 
range) of duplicates from two experiments. 
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Figure 3.13. HDL3-induced cholesterol efflux in HepG2 cells transfected with 
pCDNA3.1-SLC39A8-Ala/Thr391 plasmids. Cells were transfected with pCDNA3.1-
SLC39A8-Ala391, Thr391 and pCDNA3.1 vector, then treated with BODIPY-ch for 4h, 
followed by HDL3 (25µg/ml), or BODIPY-ch followed by vehicle. (A) Culture medium 
fluorescence intensity in samples with HDL3 treatment minus vehicle in cells 
transfected with the same plasmid. Experiments were conducted in duplicates from six 
independent experiments (n=12) (B) Each bar represents the transfection efficiency 
adjusted value for each plasmid shown in (A) subtract the value for vector control (n=6) 
(C) Levels of BODIPY-cholesterol in cell lyates (n=6) (D) Transfection efficiency of 
pcDNA3.1-SLC39A8 plasmids on HepG2 cells that were subjected to cholesterol efflux 
assay (n=12). Each bar represents median value ( ± range) of each sample. 
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In order to test whether the Ala391Thr substitution has any effect on cholesterol 
efflux capacity, HepG2 cells transfected with pCDNA3.1-SLC39A8-Ala/Thr391 
plasmids were used. Cells overexpressing the Thr variant showed a trend of higher 
cholesterol efflux levels, compared to Ala391 and vector control (Fig. 3.13 A). The 
intra-sample variability of intracellular cholesterol was large (Fig. 3.13 C), which could 
be due to interference of acidity with the fluorescence dye when acetic acid lysing was 
used. Therefore only medium cholesterol concentration was used for further analysis. 
Similar method can be found in the cholesterol efflux calculation published by S. 
Sankaranarayanan et al. 231 However, when the cholesterol efflux was adjusted against 
ZIP8 transfection efficiency, the mean value of adjusted cholesterol efflux appeared to 
be higher in Ala391 variant, as shown in Fig. 3.13 B. This could be caused by 
variations in each transfection, shown by the large SEM bars in Fig. 3.13 D. 
Overexpression of ZIP8 has enhanced the overall cholesterol efflux in HepG2 cells, 
however no conclusions can be drawn on any allelic influence as the difference 
between Ala391 and Thr391 variant was not significant.  
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3.2.5 Effect of Ala391Thr variation on cadmium-induced activation of cell 
signalling pathway  
 
Allele-dependent modulation of cadmium-induced ERK activation in HEK293 cells 
 
The potential involvement of Ala391Thr variation in MAPK pathway activation 
(ERK1/2 phosphorylation) following treatment with low dose Cd2+ was assessed in 
HEK293 cells. Cells were exposed to 1µM Cd2+ for different lengths of time and 
analysed for ERK1/2 phosphorylation over a period of 24h. An early ERK response to 
Cd2+ stimulation was detected as early as 1h, and remained elevated up to 24h. 
Phosphorylation of ERK2 was significantly higher in HEK293 overexpressing the 
SLC39A8-Ala391 variant, compared to cells expressing the SLC39A8-Thr391 variant 
and pCDNA3.1 vector at 24h (Fig. 3.14 C), whereas the lowest ERK activation was 
detected in cells transfected with vector control (Fig. 3.14 A). ERK1 phosphorylation 
was also elevated in cells transfected with SLC39A8 expression plasmids, however the 
difference between the Ala391 and Thr391 variant was not statistically significant at all 
time points (Fig. 3.14 D). ZIP8 expression levels in both Ala391 and Thr391-
transfected cells were similar at earlier treatment time points (up to 1h, shown in Fig. 
3.14 B), however gradually reduced after 1h up to 24h. This suggests degradation of 
overexpressed ZIP8 in transfected cells, 
possibly due to its interaction with Cd2+. The  Ala391 variant, which is associated with 
higher Cd2+ uptake levels shown in Fig. 3.10, corresponds to a significantly greater 
activation of ERK2 at a longer incubation time. Hereby it is plausible that the activation  
in ERK2 is caused by higher intracellular accumulation of Cd2+. 
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Figure 3.14. Phosphorylation of ERK1/2 in HEK293 cells transfected with 
pCDNA3.1-SLC39A8-Ala/Thr391 or pcDNA3.1 vector. (A) A representative 
immunoblotting image of expression of pERK1/2, total ERK1/2 and ZIP8 at different 
time points (B) Quantification of relative ZIP8 expression after different incubation 
periods of CdCl2 (C) and (D) quantification of immunoblots of phosphorylation of ERK2 
and ERK1 after 0h, 1h , 2h, 24h of CdCl2 treatment (1µM). Data shown are mean ( ± 
SEM) each genotype was done in duplicates from at least 3 separate experiments 
 
 
 Cadmium-induced ERK activation in HUVEC  
 
In order to investigate whether there is a genotypic effect of ERK1/2 activation in 
HUVEC induced by Cd2+, phospho-ERK1/2 expression was detected after 4 and 24 
hours of Cd2+ treatment (1µM). The expression change of pERK1/2 at 24h was 
bidirectional comparing to basal level, with a trend for upregulation observed at 4h of 
Cd2+ treatment (Fig. 3.15 B), although no significant difference was detected between 
the Ala/Ala and Ala/Thr genotypes (n=4) (Fig. 3.15 C&D). A larger number of sample 
for each genotype is a required to validate this finding, with a minimum sample size of 
13 being estimated by G*Power calculation. (critical t = 2.17881, power = 0.96). 
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Figure 3.15. Phosphorylation of ERK1/2 in HUVEC of Ala/Ala and Ala/Thr genotypes after 4h of cadmium treatment (1µM). (A) A 
representative immunoblot image of phospho-ERK1/2 and total ERK1/2 protein expression in cells of different genotypes (B) A representative 
immunoblot image of phospho-ERK1/2 and total ERK1/2 protein expression in cells been treated with CdCl2 for 0h, 4h and 24h (C) and (D) 
Quantification of pERK1 and pERK2 normalized to total ERK1 and ERK2 expression after 4h of Cd2+ incubation. Value represents mean 
(±SEM) of each genotype done in duplicates from 4 separate experiments.
Cd2+ incubation  
time (hr) 
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3.2.6 Different modulation of NF-κB activation of SLC39A8-Ala391 and 
Thr391 variant in response to cadmium  
Cadmium induced NF-κB activation in HEK293 cells  
 
To further examine the potential signalling pathway triggered by cellular uptake of Cd2+, 
activation of transcription factor NF-κB was detected by dual-luciferase reporter assay 
in HEK293 cells. We performed transient transfection using pCDNA3.1-SLC39A8-
Ala/Thr391 plasmids and κB-dependent firefly luciferase reporter plasmids to 
investigate whether the Ala391Thr variation mediates NF-κB activation through 
differences in the amount of Cd2+ uptake. As shown in Fig. 3.16 A, cadmium (1µM) 
induced a 10-fold increase in κB-dependent luciferase activity in HEK293 cells 
overexpressing ZIP8 compared with vector control after 2h of Cd2+ incubation. The 
SLC39A8-Ala391 variant associated with higher Cd2+ uptake showed stronger NF-κB 
activation compared to the Thr391 variant. However, longer Cd2+ treatment of 24h was 
shown to conversely inhibit NF-κB activation comparing to no Cd2+ control (Fig. 3.16 B). 
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Figure 3.16. Relative promoter activity of the NF-κB mediated by SLC39A8-
Ala/Thr391 plasmids following Cd2+ treatment. HEK293 cells were co-transfected with 
the mixture of luciferase plasmids, and pCDNA3.1-SLC39A8-Ala/Thr391 expression 
plasmids. CdCl2 were added 24h after transfection. (A) NF-κB luciferase activities after 2h 
incubation with 1µM Cd2+. Data are normalized ratios of firefly luciferase and renilla 
luciferase activity. Data are mean (±SEM) values from triplicates, repeated in 3 
experiments (B) Luciferase activity after 24h incubation with CdCl2. Data is generated from 
triplicates from one experiment, each bar represents median value with range of each 
sample.  
 
 
Inhibition of NF-κB in HUVEC of Ala/Ala and Ala/Thr under Cd2+ treatment  
 
In order to study whether there is any genotypic effect on NF-κB activation in HUVEC 
exposed to cadmium, cells of Ala/Ala and Ala/Thr genotype were used for detection of 
NF-κB effector elements such as IkBα, pIkkα/β. Cells were treated with CdCl2 (1µM) for 
2h, 4h or 24h before been harvested for immunoblotting assays. Served as an 
inhibitory protein, IkBexpression level is usually negatively correlated with NF-κB 
135#
#
activation. As shown in the immunoblot image after 2h of cadmium incubation (Fig. 
3.17 A), the expression level of IkBα was not clear enough to show any activation or 
inhibition of the NF-B pathway in repsonse to Cd2+. Despite the overall inhibition, 
Ala/Thr genotype exhibited a greater level of NF-κB inhibition comparing to Ala/Ala 
genotype at 2h and 4h time 
points (Fig. 3.17 C).  To further test our hypothesis, additional upstream regulator 
pIkkα/β was quantified. Depite the relatively high basal level of pIkkα/β in HUVECs (Fig. 
3.17 B, lane 3, 6, 9, 12), difference in the change of pIkkα/β relative expression 
between 4h and 24h time points was detected in HUVECs of Ala/Ala and Ala/Thr 
genotypes. As shown in the immunoblot quantification at 24h over 4h (Fig. 3.17 D), a 
sustained elevation of pIkkα/β level was found in HUVECs of the Ala/Ala genotype. 
This partially agrees with the previous findings on HEK293 cells, whereas significantly 
higher level of NF-κB activation was found in the Ala391 variant at a shorter Cd2+ 
exposure time (2h). These findings indicate that NF-κB pathway signalling may be 
differentially regulated in different cell lines under Cd2+ exposure. The variability of NF-
κB effector elements expression may have also been affected by occurrence of cell 
death under longer Cd2+ exposure.  
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Figure 3.17. Immunoblotting of NF-κB activation related elements in HUVECs of 
Ala/Ala and Ala/Thr genotypes. (A) A representative immunoblot image of IkBα 
expression after 2h of CdCl2 (1µM) incubation (B) A representative immunoblot image 
of pIkkα/β expression after 4h and 24h of CdCl2 (1µM) incubation (C) Quantification of 
relative IkBα expression at 2h, 4h and 24h time points. Each value in been normalized 
to t0 value of each sample. Data are mean (±SEM) values from duplicates from at least 3 
separate experiments (D) Quantification of the ratio of relative pIkkα/β expression between 
24h and 4h Cd2+ treatment in HUVECs. Data are mean (±SEM) values of 4 samples for 
2h 4h 24h
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each genotype, conducted in duplicates  
 
3.2.7 SLC39A8-Ala391 variant is associated with higher cytotoxicity under 
Cd2+ exposure 
 
It has been proven by many studies that cadmium exposure causes cell deaths.232 Cell 
toxicity assays were conducted in order to investigate whether there is any difference 
in cytotoxicity associated with different Cd2+ uptake levels caused by Ala391Thr 
variation. We used LDH and MTS assays on HEK293 and HUVEC to test this 
hypothesis.  
 
SLC39A8-Ala variant is associated with higher cytotoxicity in HEK293 and HUVEC 
 
Following the finding on the SLC39A8-Ala391 variant being associated with an 
elevation in Cd2+ uptake in HEK293 and HUVECs. We further studied the viability of 
these cells in the presence of low dose Cd2+ (1µM). After 24h of CdCl2 incubation, 
HEK293 overexpressing both Ala/Thr391 variants have undergone a morphological 
change by becoming smaller and changed from spindle-shaped to spherical-shaped, 
compared to the vector control (Fig. 3.18 A). This was accompanied by the presence of 
more floating cells in the culture medium. Cd2+ exposure resulted in higher levels of 
LDH in supernatant of the cells transfected with the pcDNA3.1-SLC39A8-Ala391 
plasmid compared with the pcDNA3.1-SLC39A8-Thr391 plasmid and vector control 
(Fig. 3.18 C), which indicates higher cell death. HUVECs of Ala/Ala genotype also 
exhibited higher cell death compared to Ala/Thr genotype (Fig. 3.18 C).  
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Figure 3.18. Effect of SLC39A8 genotype on cell death induced by cadmium. (A) 
Pictures illustrating phenotypic changes of HEK293 cells transfected with pCDNA3.1-
SLC39A8-Ala/Thr391 and vector control plasmids following 24h incubation with CdCl2 
(1µM) (B) Cd2+-induced LDH release in HEK293 cells transfected with pCDNA3.1-
SLC39A8-Ala/Thr391 plasmids, cells were loaded with CdCl2 48h after transfection. 
Each experiment was done in triplicates or more and repeated 3 times (C) Cd2+-
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induced LDH release in HUVECs of Ala/Ala and Ala/Thr genotypes. Both cell lines 
were subjected to 24h incubation of CdCl2. The level of toxicity, as measured by LHD 
levels in the cell medium. Value of each bar = LDH (Cd2+-treated samples-H2O-treated samples). Data 
are mean (±SEM) values from 3 experiments (n=4 for each genotype).  
 
SLC39A8-Ala391 variant is associated with lower cell proliferation in HEK293 and 
HUVECs 
 
In the CellTiter 96 AQueous One solution cell proliferation assay (MTS), a low 
dose of Cd2+ (1µM) showed varied cell proliferation patterns depending on the 
experimental condition. The number of proliferative (viable) cells  was lower in Ala391 
variant overexpressing cells, comparing to Thr391. However in HUVECs, cell 
proliferation seemed to be increased after 2h or 24h of CdCl2 incubation, with lower 
proliferation rate seen at 24h (Fig. 3.19 B). In HEK293 cells transfected with pCDNA-
SLC39A8-Ala/Thr391 plasmids, both 2h and 24h CdCl2 incubation  decreased the cell 
proliferation comparing to no Cd2+ controls (Fig. 3.19 C&D). Transfection efficiency was 
checked by immunoblot assay, as shown in Fig. 3.19 A. Cell proliferation rate indicates 
metabolically active cells, which usually reflects viable cells, but not necessarily. A 
second cytotoxicity assay is preferred to validate the toxic effect of Cd2+.   
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Fig.3.19. CellTiter 96 AQueous One Solution cell proliferation assay (MTS). (A) 
Immunoblot image showing transfection efficiency of pCDNA3.1-SLC39A8-Ala/Thr391 
plasmids in HEK293 cells (B) Viable cell percentage in HUVECs of Ala/Ala and Ala/Thr 
genotype after 2h or 24h of CdCl2 incubation Each value was standardized against 
vector control. Data are mean (±SEM) of duplicates from 2 experiment (n=4 for each 
genotype)  (C) Viable cell percentage in transfected HEK293 cells after 2h CdCl2 
incubation  (D) Viable cell percentage in transfected HEK293 cells after 24h CdCl2 
incubation. Data are mean (±SEM) of duplicates from 4 experiments. Data are calculated 
by Wilcoxon test. 
 
141#
#
3.2.8 Real-time qPCR quantification of downstream gene expression 
regulated by ZIP8-mediated cholesterol efflux  
 
We further investigated the expression levels of cholesterol transporter genes and 
transcription factors after conducting cholesterol efflux in HepG2 cells. Data were 
generated from the pooled results from samples treated with HDL3 and vehicles. There 
were no major differences between these two groups hence allowing combination of 
these data. The biggest difference in transcript levels of cholesterol transporters was 
observed in ABCA1. There seemed to be a trend of higher mRNA transcription levels 
of ABCA1 and PPAR-γ in Thr391 variant than in the Ala391 variant, however the 
difference between the two variants are not significant. Therefore there is not enough 
evidence showing preferential upregulation of any of these downstream genes (Fig. 
3.20). There was a 5000~15,000-fold change in SLC39A8 transcript level in the 
samples transfected with SLC39A8 expression plasmids. This could be due to a low 
power in small sample size or true findings. If this was a true finding, apart from the low 
expression of ABCG1 in HepG2 cells, the major cholesterol transporters ABCA1 and 
SR-BI have not shown any major transcriptional difference in the cells overexpressing 
SLC39A8 of genotypes. This finding can not be expanded to other cell lines, as 
macrophage and arterial wall efflux are also known to contribute to the overall 
cholesterol transported by HDL particles. If this was an issue of insufficient power, a 
more sensitive assay as well as optimitized assay conditions need to be developed. 
Knocking-down of SLC39A8 in HepG2 cells might be necessary prior to 
overexpression to reduce the background signal and to produce a cleaner cut-off point.  
The Thr391 variant is reported to be associated with lower levels of HDL-C in the 
GWAS. However recent studies have indicated cholesterol efflux capacity to be a 
better indicator of carotid intima-media thickness and angiographic coronary artery 
disease, comparing to HDL-C level.54 Therefore more robust experiments are required 
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to fully interpret the lipid GWAS result.  
 
Figure 3.20. Relative mRNA levels of ABCA1, ABCG1, SR-BI, PPAR-α, PPAR-γ, 
NF-κB1 in pCDNA-3.1-SLC39A8-Ala/Thr391 transfected HepG2 cells subjected to 
cholesterol efflux. Each value is relative to the vector control value and was 
normalized to 18s rRNA. Data are means (± SEM) of one experiment (n≥6 for each 
143#
#
genotype) 
 
3.3 Investigation of effect of rs13107325 on ZIP8 function and structure  
3.3.1 Bioinformatics prediction of Ala391Thr on ZIP8 function  
 
An intensive bioinformatics search was conducted to investigate the influence of the 
Ala391Thr substituiton on ZIP8 funtion. We applied a combination of in silico tools and 
molecular dynamics simulation to predict the structural and functional impact of the 
missense SNP on activity or stability of the ZIP8 protein. Different algorithms have 
been used for functional prediction, as listed below (Table 3.1). Out of the 10 
algorithmss used, 5 have predicted possible damaging effect, including PolyPhen 2.0, 
SIFT, SNAP, Panther and iMutant, 5 predicted either neutral or not damaging.  
 
SIFT indicated the amino acid change (Ala391Thr) in all three ZIP8 isoforms 
could cause a deleterious effect on the protein function. PolyPhe-2 suggested this SNP 
was benign in two of the isoforms and possibly damaging in the third isoform. Panther 
also predicted a possible deleterious effect from this SNP on the protein function. 
iMutant indicated a decrease in protein stability with reliability index of 7. However, 
SNP&Go and Mutpred both suggested neutral effect for this SNP. Overall, most of the 
tools predicted a possible change of protein function caused by the Ala391Thr 
substitution on ZIP8. The transcription factor binding site prediction tool Patch 
predicted the SNP either created or abolished binding sites of E2F, E2F-4, and E2F-1, 
whereas P-match predicted possible differences in binding of C-EBP, C/EBP-α, CREB 
and SP1. Experiments with the use of EMSA (electrophoretic mobility shift assay) and 
other techniques will be required to test these predictions.  
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Programs 
Prediction 
result 
(score) 
Notes Link Algorithms  
SIFT 
Deleteriou
s (0.01-
0.02) 
Damaging, 
however low 
confidence 
http://sift.jcvi.org based on evolutionary 
information 
PolyPhen
-2 
Possibly 
damaging 
Score=0.589 
(sensitivity: 
0.87; 
specificity 
0.91)  
http://genetics.bwh.
harvard.edu/pph2/ 
combine both protein 
structural/functional 
parameters and 
sequence analysis 
derived information  
SNAP Non-neutral  
Expected 
accuracy 78% 
https://www.rostlab.
org/services/SNAP/
submit 
uses in silico derived 
protein information 
based on the protein 
sequence 
Panther  Pdeleterious=0.75638 
subPSEC=-
4.13(<-3 
deleterious) 
http://pantherdb.org evolutionary analysis 
of coding SNPs 
iMutant 
Protein 
stability 
decrease 
Reliability 
index 7.0 
http://folding.biofold.
org/i-mutant/i-
mutant2.0.html 
change in structural 
stability 
SNPs&Go Neutral (6) 
  http://snps.biofold.o
rg/snps-and-
go/pages/method.ht
ml 
information based on 
protein sequence  
Mutpred 
No 
hypothesis 
Probability 
of 
deleteriou
s=0.147 
(>0.5)  
Gain of 
glycosylation 
at A391 (P = 
0.0443) 
http://mutpred.mutd
b.org 
based upon SIFT, and 
a gain/loss of 14 
different structural and 
functional properties 
Loss of helix 
(P = 0.1299) 
Loss of 
stability (P = 
0.1922) 
Gain of loop 
(P = 0.2045) 
Gain of sheet 
(P = 0.4423) 
dbSNP  not damaging    
http://www.snps3d.
org/ 
based on structure 
and sequence 
analysis  
Pmut 
analysis 
from 
mmb2 
neutral    http://mmb.irbbarcelona.org/PMut/ 
based on neutral 
networks and 
sequence/structural 
information, high 
success rate for 
predicting Mendelian's 
mutations 
PROVEA
N  neutral    
http://provean.jcvi.o
rg/seq_submit.php 
based on top 30 
clusters of closely 
related sequences 
(>75% global 
sequence identity) to 
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generate the 
prediction  
 
 
Table 3.1. Bioinformatics predicion of the effect of Ala391Thr variation on ZIP8 
function  
 
3.3.2 Bioinformatics prediction of Ala391Thr on ZIP8 structure    
 
Our functional data prompted further bioinformatics investigations into the 
impact of the Ala391Thr variation on ZIP8 structure. According to TMHMM prediction, 
in the protein containing the Ala residue at position 391, Ala is packed inside the α-
helical transmembrane domain, whereas the Thr residue locates just outside the α-
helix domain in the mutant protein sequence (Fig. 3.21 A).  
 
A homology-based 3D protein structure modelling was performed using the 
Robetta approach. Secondary structure analysis was performed to predict in silico the 
effect of Ala391Thr on the structure and dynamics of ZIP8. This was performed both 
on the Ala391 containing wild-type ZIP8 protein sequence and the mutant sequence 
containing Thr. The results revealed a total of 7 α-helical domains for both sequences. 
A noticeable change was observed at the α-helical structural transition (residues 390-
392) in the Thr391 mutant when overlapped with the Ala391 sequence. It is interesting 
to note that other transmembrane α-helical domain in close proximity with the mutation 
also shifted their position within the membrane as illustrated in Fig. 3.21 B. We 
speculate that the conformational transition also resulted in an increased solvent 
exposure of Thr391, in agreement with the higher hydrophilicity of this residue 
compared to Ala391. 
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Figure 3.21. Bioinformatics prediction of Ala391Thr variation in relation to ZIP8 
protein structure. (A) Graphical interpretation of the transmembrane helical domains 
predicted by TMHMM (B) Structural perturbation promoted by the Ala391Thr variation 
as shown by Robetta secondary protein structure prediction. The wild-type protein 
(Ala391) is displayed in yellow, and the mutatn protein (Thr391) is shown in blue. The 
image shows an overlapped simulation of the two protein structures. The Thr391 
residue (representated by the blue circle) shows a distance of 6Å from the 
Ala391 residue (represented by the yellow circle).
147#
#
4. Discussion 
 
Several different GWAS studies have reported association between a non-
synonymous SNP (rs13107325, Ala391Thr) in SLC39A8 and various CVD and non-
CVD traits.22; 57-59 The rare allele T has been associated with lower blood pressure and 
lower circulating HDL-C. SLC39A8 is one of the 14 members of the SLC39 gene family 
of metal ion transporters, which transport these ions from the cell exterior or lumen of 
intracellular organelles into the cytoplasm.69 This gene has not been previously linked 
with CVD pathogenesis, neither is it involved in any established pathways contributing 
to the disease. The physiological role of SLC39A8 remains to be elucidated.  
 
I sought to investigate the possible mechanisms of the association between 
SLC39A8 and blood pressure and HDL-C, including the impact of Ala391Thr variation 
on the expression and function of the gene product.  
 
This study demonstrated the impact of SNP rs13107325 in SLC39A8, and the 
corresponding Ala391Thr substitution on Cd2+ accumulation, activation of downstream 
signalling pathways and cell phenotype. In the latter part of study, the genetic impact of 
SLC39A8 on cholesterol efflux was assessed, as well as the downstream regulation of 
cholesterol transporter proteins. Based on the association of cadmium and 
cardiovascular disease, this study has provided some potential biological mechanisms 
for the reported BP GWAS association. The Ala391Thr variation reduced cellular 
uptake of Cd2+, which may further influence the developmenet of hypertension. It is 
hoped that these findings will facilitate more advanced studies on development of 
potential therapeutic target for prevention and treatment of hypertension.  
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4.1 Genetic investigation of Ala391Thr variation on SLC39A8 expression  
 
I first conducted gene expression studies to compare the mRNA and protein levels of 
SLC39A8 in HUASMC and HUVEC of the C/C (Ala/Ala) and C/T (Ala/Thr) genotypes.  
A trend of a higher mRNA transcript level for T allele comparing to C allele in HUASMC 
was observed (n=5) (Section 3.1.2, Fig. 3.2 B), suggesting that T allele is possibly 
preferentially transcribed over C allele. However at protein level, no significant 
difference was seen between cells of the Ala/Thr and Ala/Ala genotype in HUASMCs 
or HUVECs. The result is not statistically significant potentially due to the limited 
sample size for the heterozygous genotype, and the absence of rare homozygote 
genotype in both the HUASMC and HUVEC samples. A power calculation estimated a 
sample size of approximately 565 to obtain one rare homozygote (rare allele frequency: 
0.15, α error: 0.05, power: 0.95), which is more than double the size of our current 
dataset. The trend was not seen in HUVECs which had an even smaller sample size 
for each genotype, in which the direction of effect, if any, was unclear. Immunoblotting 
of four protein sub-fractions revealed a difference in cell localization and post-
translational modification of ZIP8 in different cell compartments, for instance the most 
modified form (possibly glycosylation) of ZIP8 was seen in the cytosolic fraction. The 
appearance of multiple bands detected in each fraction suggests co-existence of 
various multimers. All the bands can be reduced by a ZIP8 specific blocking peptide to 
different extent, which suggest the specificity of these bands.  
 
The potential mechanism of how exonic SNP might affect gene expression can 
be explained by two points: one is through the alternative splicing of the transcript. The 
polymorphic site is within a common region for all three transcripts of SLC39A8, 
therefore this SNP is unlikely to affect splicing; the second is  through the change of 
transcription factor (TF) binding sites which can sometimes occur at highly conserved 
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genomic regions. Protein-coding DNA have been reported to contain enhancer 
sequences functioning at the transcriptional level.225 Based on available ENCODE data, 
this SNP is not within any conserved transcription factor (TF) binding site, or TF ChIP-
seq region, neither is it involved in any epigenetic regulation. The mechanistic 
evidence supporting the regulation of this exonic SNP on gene regulation is weak.  
 
 
 4.2 In-vitro investigation of Ala391Thr variation on ZIP8 function 
 
Cadmium and zinc ions are both reported to be transported by ZIP8, which co-
transports 1 molecule of the metal divalent cation with 2 molecules of HCO3- in an 
electroneutral manner. Critical Cd2+ concentration in the kidney cortex is 1mM, above 
which kidney dysfunction appears, such as defective protein, amino acid, glucose, 
bicarbonate and phosphate reabsorption, a condition similar to features of Fanconi 
syndrome. The average circulating levels of Cd2+ in humans vary because the 
exposure can be environmental or dietary dependent. In order to determine the 
experimental dose, we used kinetics study as a reference which suggests a Km value 
of 0.62 µM for ZIP8-mediated Cd2+ transport in mouse fetal fibroblasts that fits the 
Michaelis-Menten model. The Km value is the concentration of Cd2+ at which uptake 
rate is half of Vmax (maximum uptake rate). A range of 1-10µM of Cd2+ has generally 
been used in the literature. In our assay, a concentration close to the Km value was 
used (1µM). The physiological concentration of Zn2+ is 18µM, which is the 
concentration we used in the Zn2+ uptake assay.  
 
The Cd2+ uptake assay conducted on transfected HEK293 cells and HUVECs 
showed a higher intracellular accumulation of Cd2+ in cells overexpressing the Ala391 
variant, and HUVECs of the Ala/Ala genotype after 2h of incubation with 1µM Cd2+. 
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The significant difference between Ala/Ala and Ala/Thr genotype in HUVECs (Fig. 3.10 
D) suggests a potentially cumulative model for the ZIP8-mediated Cd2+ transport. Our 
results suggest that Ala391Thr caused a reduced but not abolished ZIP8 function in 
Cd2+ uptake, as shown by the detectable intracellular Cd2+ in the Thr391 variant after 
adjustment with vector control (Fig. 3.10 C). This could also be due to the endogenous 
expression of Ala391-containing ZIP8 found in HEKs, which was not readily detectable 
by immunoblotting, or existence of other endogenous cadmium transporters.  
 
The Zn2+ uptake assay in transfected HepG2 cells also demonstrated a higher 
intracellular accumulation of Zn2+ in cells overexpressing the Ala391 variant compared 
to Thr391 after 2h of Zn2+ incubation (Fig. 3.11 B). Although more replications are 
needed to confirm this finding, this is consistent with the previous Cd2+ uptake result on 
that ZIP8 containing the Thr391 variant attenuates the protein’s function of metal ion 
transport. The association of rs13107325 T allele (Thr391) with lower SBP and DBP by 
the ICBP-GWAS30 may be linked with its reduced metal ion transport activity, 
particularly in Cd2+. 
 
A recent study has reported an association of rs13107325 with blood levels of 
Mn2+ (p=5.1 x 10-11, β= -0.77).233 ZIP8 was also shown to have a high affinity for Mn234 
and may be a preferred transporter in specific tissues or cell types.73; 235 In mouse 
kidney proximal tubule cells, Cd2+ uptake can be significantly inhibited by 10 times the 
concentration of Mn2+ or Zn2+, whereas Mn2+ uptake can only be inhibited by 30 times 
the concentration of Cd2+ or Zn2+. This suggests ZIP8-mediated Cd2+ uptake may be 
inhibited in the presence of Mn2+ in certain cell types.95 There is already some prior 
knowledge on the association between Mn2+ levels and various CVD outcomes, for 
example, low blood Mn2+ has been reported to be associated with renal dysfunction in 
the cross-sectional general population study in Korea;236 In the same study, higher 
Pb2+ and Cd2+ levels were found in the individuals with renal dysfunction (OR Pb 1.344, 
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95% CI=1.157-1.162; OR Cd 1.467, 95% CI=1.077-1.999);237 dietary Mn intake was 
negatively correlated with DBP, serum cholesterol and triglycerides;238 in a PM2.5 air 
pollution study from Beijing, Mn content in the air was associated with a reduction in 
SBP.239 Despite the unstandardized measurements in the existing reports, majority of 
the studies indicated a negative correlation between Mn and unfavourable CVD 
outcome. Assuming the Ala391Thr variation on SLC39A8 has a similar effect on Mn2+ 
transport (reduction of Mn2+ uptake), the resulting effect is likely to cause adverse CVD 
outcome (including SBP). Therefore Mn2+ is unlikely to be the confounder of the link 
between Cd2+ and blood pressure mediated by ZIP8, although this need to be further 
validated by the intracellular measurement of Mn2+ in ZIP8 expressing cell lines.  
 
In order to assess the inhibitory effect of other divalent metals which may be 
transported by ZIP8, we searched for relevant evidence in the literature. In RNA-
injected Xenopus oocytes, ZIP8 can significantly transport radiolabelled Cd2+, Co2+, 
Fe2+, Zn2+ > Mn2+, but not Cu (I or II).81 Zn2+ was shown to be the best inhibitor of Cd2+ 
influx, whereas Mn2+ didn’t block the Cd2+ influx. In mouse fetal fibroblast cultures 
stably overexpressing ZIP8 (rvZIP8 cells), Cd2+ influx can be competitively inhibited by 
other divalent metals in the following order: Mn2+ > Hg2+ >> Pb2+ = Cu2+ = Zn2+ = Cs2+.95 
However competition assays for Cd2+ and Zn2+ uptake cannot prove absolutely that 
ZIP8 can transport other metal ions; competitive inhibitors might have blocked the Cd2+ 
or Zn2+ uptake via interaction with thiol groups or by plugging up the transport 
channel.82 There are limitations to either of these systems in their relevance to the in 
vivo system. Oocytes are not the native cells where the ion channels are normally 
expressed, therefore it is often difficult to make a direct comparison because the native 
cells usually contain multiple types of channels. Mouse fetal fibroblasts are probably a 
better model, however cellular trafficking can be different between mice and humans. 
Overall, other than Mn2+, the inhibitory effects of other divalent metals on Cd2+ uptake 
seem to be moderate on these cell lines.  
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4.3 In-vitro investigation of Ala391Thr variation on Cd2+-induced signalling 
pathway activation  
 
Cadmium is a non-essential metal with no known biological functions. The entry of 
Cd2+ into cells have proven to be toxic to many cells, even at lower concentrations (e.g. 
0.1-10µM).232 Cadmium has been shown to activate the mitogen-activated protein 
kinases (MAPKs) which include ERK, c-Jun N-terminal kinases (JNK) and p38 kinase, 
albeit showing varied effects in different cell types.179; 240; 241 ERK is often activated 
following growth factor stimulation which stimulates cell proliferation, and protecting 
cells against apoptosis. We have shown in our study that Ala391Thr variation in 
SLC39A8 causes different levels of activation of the ERK1/2 pathway, particularly at 
24h after Cd2+ stimulation in HEK293 cells (Fig. 3.14). Recent studies showed 
sustained activation of ERK can be associated with or at least partly responsible for 
cell death signalling.193 A similar trend was seen in HUVECs of Ala/Ala and Ala/Thr 
genotypes, although the difference was not significant. It is intriguing to note that the 
strongest phosphorylation of ERK1//2 were found at the 4h time point in HUVECs, but 
remained elevated after 24h of Cd2+ treatment (Fig. 3.15). The reason for this 
observation may be attributed to the biphasic activation pattern of ERK, with a first 
peak at 2-6h after M phase, and a second peak at 14-20h, as reported in Chinese 
hamster ovary cells.242 The different regulation of ERK signalling may partially 
contribute to the observed phenotypic difference in different cell lines.  
 
ERK1 and 2 proteins are two kinases with similar identities and regulation 
mechanisms. Despite their similarities, recent studies have shown some apparent 
biological differences driven by these two kinases. Functional differences between 
ERK1 and ERK2 proteins are implicated in zebrafish development, as the two kinases 
target distinct genes during early embryogenesis and are involved in different 
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developmental processes.243 In mice, disruption of the ERK2 locus led to early 
embryonic lethality while those lacking in ERK1 didn’t cause death or affect living and 
reproductive ability; silencing of only ERK2 slowed down cell proliferation in mouse 
embryonic fibroblasts.244 Furthermore, ERK2 seems to have a positive role in 
controlling normal and Ras-dependent cell proliferation, whereas ERK1 may affect the 
overall signalling output by antagonizing ERK2 activity.245 From immunoprecipitation 
studies with MEK antibodies (shown in Fig. 4.1), in the absence of ERK1, binding of 
ERK2 to MEK appears slightly but significantly increased.245 Our data suggests that the 
effect of Cd-induced MAPK pathway activation is more profound via ERK2 signalling.  
 
 
Figure 4.1. ERK-specific gene silencing in NIH 3T3 cells differentially affects 
MEK-ERK interactions 
 
The other signalling pathway we investigated was NF-ĸB, which is a prominent 
factor in the cell death/survival balance. In response to inflammation stimuli, the 
canonical NF-ĸB pathway is activated to induce anti-apoptotic and/or survival genes; 
however other stimuli may result in repression of anti-apoptotic genes and induction of 
proapoptotic genes. The dominance of either of these processes is dependent on the 
cell type and nature of the inducing stimulus, which will determine the subsequent 
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biological events.208 The majority of in vitro and in vivo studies suggest Cd2+ induces a 
NF-ĸB dependent transactivation of oxidative stress genes, anti-apoptotic and 
protective target genes at concentration range of 10-50 µM for a period of 4-48 hrs.208  
 
In my dual luciferase reporter assay, NF-ĸB activation was detected in 
transfected HEK293 cells after 2h of exposure to 1µM Cd2+ (Fig. 3.16 A), however an 
inhibitory effect of NF-ĸB was seen after 24h of Cd2+ exposure (Fig. 3.16 B). Oscillation 
in the temporal response of NF-ĸB activity has been reported in IĸBβ and ε knockout 
mouse embryonic fibroblast cells, suggesting a dynamic mechanism by period and/or 
amplitude to regulate transcription of target genes.246; 247 IĸBα was reported to be 
responsible for the negative feedback mechanisms that allow the turn-off of the NF-ĸB 
response. In HEK293 cells transfected with pcDNA3.1-SLC39A8-Ala391/Thr391 
plasmids, we have detected a significantly higher activation of NF-ĸB in cells 
overexpressing Ala391. Therefore we conclude that Ala391 initiates a higher activation 
of NF-ĸB after 2h of Cd2+ treatment, with a treatment dose and duration consistent with 
the previous Cd2+ uptake assay and ERK signalling analysis.  
 
A different approach was employed in assessing the Cd-induced NF-ĸB 
response in HUVECs, which was immunoblotting of NF-ĸB effector elements (IĸBα, 
phospho-Ikkα/β, phospho-p65). After 2h incubation with Cd2+, a fluctuation of IĸBα 
signal was seen in HUVECs of either genotypes, the deprivation of serum in the culture 
did not seem to have any effect on the outcome. At longer time points of 4h and 24h, 
reduction in both phospho-Ikkα/β and phosphor-p65 were detected compared to basal 
level, which suggests the effect of Cd2+ on NF-ĸB signalling might be cell type 
dependent, or treatment dose/length dependent. More comprehensive assessments 
are needed to rule out the involvement of NF-ĸB signalling in HUVECs under 
stimulation of Cd2+.  
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In summary, in the cells with abundant ZIP8 expressions (HEK293), 
intracellular accumulation of Cd2+ may result in a sustained activation of ERK1/2 
kinases, with higher levels of ERK2 in cells expressing Ala391, suggesting the ERK 
and NF- ĸB are involved in the cellular response of Cd2+ entry which might trigger 
further regulatory elements that are responsible for the subsequent cell phenotype. 
However, we do not yet have enough evidence suggesting the cell phenotypic change 
induced by ZIP8-mediated Cd2+ uptake is ERK1/2 or NF-ĸB dependent in HUVECs.  
 
4.4 In-vitro investigation of Ala391Thr variation on HDL3-mediated 
cholesterol efflux and regulation of downstream gene expression  
 
The ICBP-GWAS study also reported an association between Ala391Thr and HDL-C.57 
HDL particles are critical acceptors of cholesterol from lipid-laden macrophages, and 
HDL-C levels have been found to be inversely related to CHD risk.248 Some of the 
attributes of HDL in mitigating CHD risk include mediating cholesterol efflux, promoting 
nitric oxide production, and having anti-inflammatory properties.249 We aimed to 
investigate the possible involvement of ZIP8 in cholesterol efflux pathways, possibly 
through its ability of transporting Zn2+.  
 
HDL is highly heterogeneous in size and composition. Approximately 65% of 
the HDL protein mass is apoA-I with 12-15% apoA-II.250 HDL3 is the small-medium sub-
fraction of HDL with a density of 1120-1180 g/ml. HDL3 has been shown to be an 
efficient cholesterol acceptor with high portion of apolipoprotein A (apoA) I-II.47 ATP-
binding cassette (ABC) transporters are the main mediators of cholesterol efflux from 
cells to apoA-I and HDL.251 ABCA1 deficiency causes both Tangier disease and 
familial HDL deficiency, two pathologies characterized by very low levels of plasma 
HDL.252 The expression of ABCA1 has been reported to be induced by peroxisome 
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proliferator-activated receptor γ (PPAR-γ) activators through a possible upregulation of 
liver-x-receptor α.253 The potential role of ZIP8 in these observations warranted further 
study with an improved cell model. Recent studies pointed out that circulating HDL-C 
levels being an inadequate measurement for CVD risk,54 supported by failures in the 
clinical trials of HDL increasing drugs (i.e. nicotinic acid and fibric acid derivatives). 
HDL-C fractions or cholesterol efflux capacity may appear to be a more precise metric 
associated with the CVD outcome considering the heterogeneous functions of HDL in 
vivo. Overexpression of ZIP8 on HepG2 cells has significantly promoted cholesterol 
efflux over a period of 4h, however the difference between Ala391 and Thr391 can be 
differentially interpreted with or without adjustment for transfection efficiency (Fig. 3.13). 
The high level of transfection efficiency together with endogenous ZIP8 expression 
may have confounded the results and masked any potential net difference between the 
two alleles. Studies in HUVECs have been aborted due to the lack of samples with the 
rare allele genotype. Therefore it is not clear at this stage whether the Ala391Thr 
variation on SLC39A8 have any influence on HDL3-mediated cholesterol efflux.  
 
The enhanced cholesterol efflux by overexpressing ZIP8 prompted further 
investigation into the study of downstream gene expression by real-time qPCR, 
including key cholesterol transporters, i.e. ABCA1, ABCG1, SR-BI, and transcription 
factors i.e. PPAR-α, PPAR-γ and NF-ĸB. There was a trend towards increased 
transcription levels of ABCA1 and PPAR-γ in cells overexpressing the Thr391 variant 
(Fig. 3.20), however no major difference between the Ala391 and Thr391 variants was 
seen in the expression levels in all the genes tested. These observations may be true, 
or may be not due to the lack of sensitivity in our experimental design which was not 
optimal for capturing the differential expression regulation pattern of these genes. We 
have not developed a method that allows simultaneous measurements of cholesterol 
efflux, gene expression and intracellular content of Zn2+. Therefore the relationship 
between Zn2+ and cholesterol efflux has not been validated in this study.  
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4.5 Cadmium-induced cell death mediated by ZIP8 
 
In 1950, the focus of cadmium toxicity was initially on its damage to lungs and kidneys, 
and subsequently testicles were also identified to be another target organ under low 
dose cadmium exposure.254 The WHO identified renal dysfunction as the critical effect 
of cadmium in the International Program on Chemical Safety.255 The Cadmibel study 
including 2327 subjects have reported a 10% probability of tubular dysfunction when 
UCd reaches 2 µg/day.256 However the effect of low environmental exposure of Cd on 
kidney is low as men with UCd and BCd of 7.5 nM and 6.1 nM showed no progressive 
renal damage. The critical concentration in the organ is defined as the concentration 
when adverse functional changes, reversible or irreversible, occur in the most sensitive 
cells of the organ.257 The critical Cd2+ concentration in the kidney cortex is 1mM, above 
which kidney dysfunction appears.258 Morphological changes were observed in 
transfected HEK293 cells under Cd2+ treatment (1µM for 24h), compared to a vehicle 
control. This phenotypic change was accompanied with LDH and MTS cytotoxicity 
assays showing a higher cytotoxicity in cells transfected with SLC39A8-Ala391 plasmid, 
compared to SLC39A8-Thr391 (Fig. 3.18). With the same allele being associated with 
higher blood pressure and higher Cd2+ uptake, this phenotypic change may be directly 
associated with entry of Cd2+. This direct link between Cd2+ uptake and cell toxicity has 
already been established in other cell lines such as hepatocytes and renal tubular 
MDCK cells.259; 260 The expression levels of ZIP8 have been shown to be the highest in 
kidney, lung and testis in mice,89; 235 which appear to be the main target organs for Cd 
toxicity. It is postulated that ZIP8 may play a critical role in Cd-induced cell death and 
dysfunction in these organs, which remains to be proven in future experiments.  
 
The vascular endothelium system has also emerged to be a main target of Cd2+ 
toxicity for both acute injury and disease progression.261 Cadmium can exert its toxicity 
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to the vascular endothelium through direct vasoconstriction and inhibition of nitric 
oxide,262 peroxidation of membrane lipids,263 inhibition of tube formation,264 increase of 
endothelial permeability and other endothelial dysfunction.261 These actions can lead to 
the initiation and promotion of atherosclerosis. This is supported by the epidemiological 
observation of higher frequencies of atherosclerosis in a Cd-contaminated area in the 
Netherlands.141 Additionally, Cd2+ level has been observed to be independently 
associated with early atherosclerotic vessel wall thickening in healthy female 
individuals.265 With experimental studies, Cd-fed apoE-/- mice showed a marked 
increase in plaque area with upregulation of VCAM-1 and Hsp60, and endothelial 
leakage.125 In line with the allele encoding Thr391 being associated with lower blood 
pressure, our findings in HUVECs identified cell of the Ala/Thr genotype having a lower 
Cd2+ uptake and Cd2+-induced cell death when compared to cells of the Ala/Ala 
genotype. These morphology and viability changes may alleviate the toxicity of Cd2+ 
and restore normal endothelial function.  
 
We have not been able to distinguish the type of cell death in this study, 
whether being apoptosis or necrosis. Expression of apoptotic marker (cleaved form of 
caspase-3) and anti-apoptotic marker Bcl-2 expression were assessed in cells treated 
with Cd2+ of various concentrations and durations by immunoblotting. The cleaved 
caspase-3 signal was not detected after various designated Cd2+ treatment, and similar 
levels of Bcl-2 expression were in the two groups of different genotypes. A time course 
study is required in the future as caspase-3 activity may peak at different time-points 
depending on cell type. It is too early to conclude the type of cell death yielded by Cd is 
non-apoptotic.  
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4.6 Bioinformatics investigation of Ala391Thr variation on ZIP8 secondary 
structure  
 
In a study on nonsynonymous SNPs in the proteins for which structures were known, 
45% of the missense variants were mapped to structurally and functionally important 
regions, suggesting that a large fraction of nonsynonymous SNPs can affect the 
encoded proteins.266 Conservation analysis revealed a high degree of conservation of 
the Ala391 amino acid among known homologues (Fig. 1.3 D). The degree to which 
amino acid position is evolutionarily conserved, is strongly dependent on its structural 
and functional importance. This missense substitution has a high possibility of causing 
a deleterious effect on the protein function.  
 
Various algorithms such as Robetta, Uniprot and TMHMM Server V.2.0 have all 
predicted 7 transmembrane domains (α-helices) within the ZIP8 protein. According to 
Robetta’s predicted configuration, α-helix 6 undergoes a conformational change that 
corresponds to the substitution of the amino acid (AA) 391 (Fig. 3.21 B). The 
substitution from a hydrophobic amino acid (Ala) to a hydrophilic polar amino acid (Thr) 
may change the position of the amino acid across the phospholipid bilayers of the cell 
membrane. The non-polar AAs cause proteins to be embedded in the membrane while 
polar AAs cause portions of the proteins to protrude from the membrane. Some polar 
AAs are also found inside membranes and create a channel through which hydrophilic 
molecules can pass through. Most transporters have a single substrate binding site 
with activity following the Michaelis-Menten kinetics.267 My in vitro results on Cd2+ 
transport warrants further study on the ZIP8 structure-function relationships by the 
study of specific sequence for substrate recognition, to investigate whether the 
Ala391Thr is directly involved in specific interaction with the substrate transport.  
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.  The prediction of the secondary structure was based on protein homologues 
with a known structure. The fundamental pitfall in homology modelling is that the 
differences between the target and template will reduce the accuracy of the model. 
Therefore the quality of the resulting model primarily depends on the sequence 
similarity between the template and target.268 The sequence similarity between the 
template and the known homologue is around 28%.  
 
4.7 Alternative approach and future work   
 
           Looking back on this project, there are a few areas which can be improved. 
Along with the study of Zn2+ and Cd2+ uptake mediated by ZIP8, the uptake of other 
metal ions (i.e. Mn2+, Fe2+) could also have been investigated. A universal approach 
such as inductively coupled plasma mass spectrometry (ICP-MS) may be ideal for the 
detection of the majority of the trace metals in the cells. With regards to the lack of 
primary cells with the rare genotype (Thr/Thr), the recent launch of CRISPR-CAS9 
technology will be able to overcome this limitation by editing the genome to introduce 
single nucleotide mutation in the desired cell lines. The results generated from primary 
cells with endogenous Thr/Thr genotype would complement our functional experiments 
on the overexpression system.   
 
    There are certain limitations to this study as cell lines do not always mimic the 
behaviour of primary cells, therefore it is crucial to validate our findings in vivo. To our 
knowledge, the global SLC39A8(-/-) knockout mice was prone to be early embryonic-
lethal, and died between 48 hours postnatal and gestational day 18.5.83 It is therefore 
impossible to test whether mice lacking SLC39A8 will develop a hypertension 
phenotype over time. Other models with either knockdown or knock-in of SLC39A8 can 
be used in the future to study the relationship between long term Cd exposure and the 
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development of hypertension. 33; 269  
 
5. Summary  
#
############# #This study characterised the functional impact of SNP rs13107325 in SLC39A8 
leading to the subsequent Ala391Thr substitution in the gene product, in particular the 
effect of ZIP8-mediated Cd2+ accumulation, downstream activation of the signalling 
pathways and cell behaviour. A genetic difference was observed in both the 
overexpression system as well as the primary cells, although the majority of the 
pathway activities was more apparent in the transfected HEK293 cells. The phenotype 
difference was more likely to be caused by change in protein function rather than gene 
expression, given that the evidence gained on the effect of the Ala391Thr variation on 
gene expression was inconclusive.  
 
 Bioinformatics analysis further supported the hypothesis that Ala391Thr 
substitution induced structural changes on the protein, specifically through a shift of the 
transmembrane α-helical domain, changing the biochemical properties of the exposed 
residues. High conservation degree of Ala391 on ZIP8 suggests its importance for the 
correct protein function. Further advances in structural biology for membrane proteins 
will be necessary before further details on these changes can be reliably assessed. 
 
 Epidemiologically, high levels of cadmium were found to be associated with 
numerous adverse cardiovascular effects such as hypertension, atherosclerosis, 
abnormal cardiac function, myocardial infarction, and peripheral arterial disease.116; 141; 
143; 270 Chronic Cd2+ exposure is associated with HTN in animal models,148 although this 
relationship is somewhat inconclusive in humans.116; 127; 133 Conflicting findings call for 
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future studies for the genetic mechanisms underlying these observations/ interactions. 
Most of these studies have focused on the relationship between extracellular levels 
(blood and urine) of Cd2+ and blood pressure, however the impact of intracellular Cd2+ 
content has not been investigated on the population level. The findings in this study 
may prompt more investigations to assess the tissue specific accumulation of Cd2+ in 
the general population in relationship to BP.  
 
   This study advances our understanding of the genetic impact on the protein 
function of ZIP8 in metal ion transport, and provides preliminary mechanistic 
investigations into the GWAS association. Although the precise mechanism for Cd2+ as 
a risk factor for CVD remains unresolved, it does provide functional characterization of 
a BP associated non-synonymous SNP within SLC39A8. Pharmacological inhibition of 
SLC39A8 may be of benefit to the risk allele-bearing individuals, particularly if heavy 
metal exposure was present in the surrounding environment. However, given the small 
effect size of common hypertension-associated variants, the therapeutic benefit gained 
from one biological target may be moderate. In that context it is important to note that 
even a 2 mmHg lowering of SBP result in 10% lower stroke mortality and about 7% 
lower mortality from IHD or other vascular causes in middle aged people (40-69 years 
old).6 Therefore producing persistent reduction in BP of even just a few mmHg will 
have a large impact on the general population in preventing hypertension related 
events like stroke or IHD. The knowledge gained from our study may encourage and 
facilitate the development of novel therapeutic interventions with stratified healthcare 
potential. 
 
 
 
#
#
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Appendices 
A1. Primer sequences 
 
 Primer name  5’!3’ 
1 KASP rs13107325_ALT-fam  GAAGGTGACCAAGTTCATGCTGGCATTTT
GGTGGGCAACAATTTCA 
2 KASP rs13107325_ALC-vic GAAGGTCGGAGTCAACGGATTGCATTTTG
GTGGGCAACAATTTCG 
3 KASP rs13107325_C2 CATGCCTCCAGCAAGTGCAAATATAATAT 
4 genomic DNA forward primer F1 TCC TGC ACC TTG TCT CTC CT 
5 Genomic DNA forward primer F2 GAGACTTTGTGATCCTACTCAAT 
6 genomic DNA reverse primer R AGC AGA AGG CCA CCC TTA GT 
7 SLC39A8 cDNA forward primer F1 GAG GAG TTT CCC CAC GAG TT 
8 SLC39A8 cDNA forward primer F2 TCC TGC ACC TTG TCT CTC CT 
9 SLC39A8 cDNA reverse primer R2 GGT GAA ATC GGT TTT TCT TCC 
10 SLC39A8 cDNA reverse primer R3 AAC ATG CCT CCA GCA AGT G 
11 Cloning Hind III forward  ATGCAAAGCTTCTCGCCATGGCCCCGGG
TCGCG 
12 Cloning EcoR I reverse  ATGCAGAATTCTTACTCCAATTCGATTTCT
CCTGCA 
13 Mutagenic forward primer GCAACAATTTCACTCCAAATATT 
14 Mutagenic reverse primer AATATTTGGAGTGAAATTGTTGC 
15  SLC39A8 plasmid insert primer 1 CCCAAATAACCAGCTCCAAA 
16 SLC39A8 plasmid insert primer 2 AGCTGCACTTCAACCAGTGT 
17 SLC39A8 plasmid insert primer 2 GGCTGGCTATTGGGACTCTT 
18 SLC39A8 plasmid insert primer 2 TGGTGTGACATGCTATGCAA 
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19 SLC39A8 plasmid insert reverse 
primer  
GGCTGGCTATTGGGACTCTT 
20 SLC39A8 qRT-PCR primers Forward: ATGTTGAGAAGGCAGTTGC 
Reverse: ATGACCATTCTGACCATATGTC 
21 SR-BI qRT-PCR primers Forward: GAACTTCTGGGCAAATGTGG 
Reverse: TAGCTTCATGGATCGGCAG 
22 PPAR-α qRT-PCR primers Forward: CATTTGCTGTGGAGATCGT 
Reverse: CTGAGCACATGTACAATACCC 
23 PPAR-Υ qRT-PCR primers Forward: GGCGAGGGCGATCTTGACAGG 
Reverse: TGCGGATGGCCACCTCTTTGC 
24 NF-κB qRT-PCR primers Forward: TACAGGTCCAGGGTATAGC 
Reverse: AGATTTAGTAGTTCCAGGATGG 
25 ABCA1 qRT-PCR primers Forward: AAAGACACCAGCATGAAGGA 
Reverse: AAGCTTCAAGTTTGAGCTGG 
 
A 2. Solution recipes (all components listed as final concentration in mM) 
A 2.1 Subjects and samples  
 
PSS solution - NaCl 110 mM, CaCl2 0.15 mM, KCl 5 mM, MgCl2 2 mM, HEPES 10 mM, 
NaHCO3 10 mM, KH2PO4 0.5 mM, glucose 10 mM, EDTA 0.49 mM 
 
A 2.2 DNA study 
 
The reagent mix for post PCR restriction enzyme digestion reaction - 10µl DNA (from 
PCR reaction), 2µl 10 x buffer, 4u BcgI enzyme (2u/µl), 6µl nuclease-free H2O in a total 
reaction volume of 20µl. 
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DNA lysis buffer - 10Mm Tris pH 8.0, 10Mm EDTA, 100MmNaCl, 0.5% SDS. 
PCR recipe for genomic DNA and cDNA amplification - 1xPCR buffer, 2.5mM MgCl2, 
0.2mM dNTP, 10µM primer mix, 1u Taq polymerase (Sigma, D4545), 12.5ng/50ng 
genomic DNA or 50ng cDNA in a total volume of 25µl.  
 
A 2.3 RNA study  
Reverse transcription (RT) reaction recipe - 1xbuffer, 3mM MgCl2, 1mM dNTP, 20u of 
RNase inhibitor (Promega, N251A), 0.5/1µg of total RNA, and 200u of M-MLV reverse 
transcriptase (Promega, M1708) in a total volume of 25µl. 
 
A 2.4 Protein study 
5 x loading buffer – 0.313 M Tris-HCl (pH 6.8 at 25°C), 10% SD, 0.05% bromophenol 
blue, 50% glycerol  
RIPA Lysis buffer for protein extraction- 50mM Tris, HCl pH7.4, 150mM NaCl, 0.5% 
sodium deoxycholate, 1% NP-40, 0.1%SDS 
Protease inhibitor (PI) - 1mM PMSF, 1µg/ml leupeptin, 1µg/ml Aprotinin, 1µg/ml 
pepstatin. 
Homogenization buffer- 10mM Tris HCl pH7.2, 1mM EDTA, 250mM sucrose, 1 x P.I.) 
Chemiluminescence ECL - luminol, p-coumaric acid, Tris 8.5 and 30% H2O2  
 
A 2.5 Cell culture 
HUASMC supplements (final concentration) - 
15% fetal bovine serum (FBS, Appleton Woods, FB021), 1.67mM L-glutamine (Sigma, 
G7513, 200mM) and 0.83% penicillin-streptomycin (Sigma, P0781) (10,000 units 
penicillin and 10 mg streptomycin per mL), epidermal growth factor human (Sigma, 
E9644) 0.5ng/ml, human fibroblast growth factor (SLS, F5542-25µg) 2ng/ml, insulin 
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from bovine pancreas (SLS, I6634-100mg) 5ng/ml.   
HUVEC supplements (500 x concentration) - 
15% fetal bovine serum (FBS, Appleton Woods), 1.67mM L-glutamine (Sigma, G7513, 
200mM) and 0.83% penicillin-streptomycin (Sigma, P0781) (10,000 units penicillin and 
10 mg streptomycin per mL), human beta-endothelial cell growth factor (Sigma, E1388-
25) 1.25mg/ml, endothelial cell growth supplement from bovine neural tissue (Sigma, 
E2759) 2.25mg/ml, thymidine (Sigma, 89270-1g) 1.25mg/ml, heparin from porcine 
intestinal mucosa (H3393) 5,000 units/ml. 1ml of the 500 x supplements was used a 
500ml bottle of M199 medium.   
 
Freezing medium components - 
70% FBS, 10% DMSO and 20% respective culture medium 
 
A 2.6 Cloning  
The PCR reaction for site-directed mutagenesis and generation of pcDNA3.1(+)-ZIP8- 
threonine plasmid - 1x reaction buffer, 50ng plasmid DNA, 125ng primer mix, 1µl dNTP 
mix, 2.5u QuickChange Lightning enzyme, and nuclease-free H2O to a final volume of 
50µl. 
 
A3 Sequence of pcDNA3.1-SLC39A8 expression plasmid inserts  
pcDNA3.1(+)-SLC39A8-Ala391 (C allele) plasmid sequence  
ATGGCCCCGGGTCGCGCGGTGGCCGGGCTCCTGTTGCTGGCGGCCGCCGGCCT
CGGAGGAGTGGCGGAGGGGCCAGGGCTAGCCTTCAGCGAGGATGTGCTGAGCG
TGTTCGGCGCGAATCTGAGCCTGTCGGCGGCGCAGCTCCAGCACTTGCTGGAGC
AGATGGGAGCCGCCTCCCGCGTGGGCGTCCCGGAGCCTGGCCAGCTGCACTTC
AACCAGTGTTTAACTGCTGAAGAGATCTTTTCCCTTCATGGCTTTTCAAATGCTAC
180#
#
CCAAATAACCAGCTCCAAATTCTCTGTCATCTGTCCAGCAGTCTTACAGCAATTGA
ACTTTCACCCATGTGAGGATCGGCCCAAGCACAAAACAAGACCAAGTCATTCAGA
AGTTTGGGGATATGGATTCCTGTCAGTGACGATTATTAATCTGGCATCTCTCCTCG
GATTGATTTTGACTCCACTGATAAAGAAATCTTATTTCCCAAAGATTTTGACCTTTT
TTGTGGGGCTGGCTATTGGGACTCTTTTTTCAAATGCAATTTTCCAACTTATTCCA
GAGGCATTTGGATTTGATCCCAAAGTCGACAGTTATGTTGAGAAGGCAGTTGCTG
TGTTTGGTGGATTTTACCTACTTTTCTTTTTTGAAAGAATGCTAAAGATGTTATTAA
AGACATATGGTCAGAATGGTCATACCCACTTTGGAAATGATAACTTTGGTCCTCAA
GAAAAAACTCATCAACCTAAAGCATTACCTGCCATCAATGGTGTGACATGCTATGC
AAATCCTGCTGTCACAGAAGCTAATGGACATATCCATTTTGATAATGTCAGTGTGG
TATCTCTACAGGATGGAAAAAAAGAGCCAAGTTCATGTACCTGTTTGAAGGGGCC
CAAACTGTCAGAAATAGGGACGATTGCCTGGATGATAACGCTCTGCGATGCCCTC
CACAATTTCATCGATGGCCTGGCGATTGGGGCTTCCTGCACCTTGTCTCTCCTTC
AGGGACTCAGTACTTCCATAGCAATCCTATGTGAGGAGTTTCCCCACGAGTTAGG
AGACTTTGTGATCCTACTCAATGCAGGGATGAGCACTCGACAAGCCTTGCTATTC
AACTTCCTTTCTGCATGTTCCTGCTATGTTGGGCTAGCTTTTGGCATTTTGGTGGG
CAACAATTTCGCTCCAAATATTATATTTGCACTTGCTGGAGGCATGTTCCTCTATAT
TTCTCTGGCAGATATGTTTCCAGAGATGAATGATATGCTGAGAGAAAAGGTAACT
GGAAGAAAAACCGATTTCACCTTCTTCATGATTCAGAATGCTGGAATGTTAACTGG
ATTCACAGCCATTCTACTCATTACCTTGTATGCAGGAGAAATCGAATTGGAGTAA 
pcDNA3.1(+)-SLC39A8-Thr391 (T allele) plasmid sequence 
ATGGCCCCGGGTCGCGCGGTGGCCGGGCTCCTGTTGCTGGCGGCCGCCGGCCT
CGGAGGAGTGGCGGAGGGGCCAGGGCTAGCCTTCAGCGAGGATGTGCTGAGCG
TGTTCGGCGCGAATCTGAGCCTGTCGGCGGCGCAGCTCCAGCACTTGCTGGAGC
AGATGGGAGCCGCCTCCCGCGTGGGCGTCCCGGAGCCTGGCCAGCTGCACTTC
AACCAGTGTTTAACTGCTGAAGAGATCTTTTCCCTTCATGGCTTTTCAAATGCTAC
CCAAATAACCAGCTCCAAATTCTCTGTCATCTGTCCAGCAGTCTTACAGCAATTGA
ACTTTCACCCATGTGAGGATCGGCCCAAGCACAAAACAAGACCAAGTCATTCAGA
181#
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AGTTTGGGGATATGGATTCCTGTCAGTGACGATTATTAATCTGGCATCTCTCCTCG
GATTGATTTTGACTCCACTGATAAAGAAATCTTATTTCCCAAAGATTTTGACCTTTT
TTGTGGGGCTGGCTATTGGGACTCTTTTTTCAAATGCAATTTTCCAACTTATTCCA
GAGGCATTTGGATTTGATCCCAAAGTCGACAGTTATGTTGAGAAGGCAGTTGCTG
TGTTTGGTGGATTTTACCTACTTTTCTTTTTTGAAAGAATGCTAAAGATGTTATTAA
AGACATATGGTCAGAATGGTCATACCCACTTTGGAAATGATAACTTTGGTCCTCAA
GAAAAAACTCATCAACCTAAAGCATTACCTGCCATCAATGGTGTGACATGCTATGC
AAATCCTGCTGTCACAGAAGCTAATGGACATATCCATTTTGATAATGTCAGTGTGG
TATCTCTACAGGATGGAAAAAAAGAGCCAAGTTCATGTACCTGTTTGAAGGGGCC
CAAACTGTCAGAAATAGGGACGATTGCCTGGATGATAACGCTCTGCGATGCCCTC
CACAATTTCATCGATGGCCTGGCGATTGGGGCTTCCTGCACCTTGTCTCTCCTTC
AGGGACTCAGTACTTCCATAGCAATCCTATGTGAGGAGTTTCCCCACGAGTTAGG
AGACTTTGTGATCCTACTCAATGCAGGGATGAGCACTCGACAAGCCTTGCTATTC
AACTTCCTTTCTGCATGTTCCTGCTATGTTGGGCTAGCTTTTGGCATTTTGGTGGG
CAACAATTTCACTCCAAATATTATATTTGCACTTGCTGGAGGCATGTTCCTCTATAT
TTCTCTGGCAGATATGTTTCCAGAGATGAATGATATGCTGAGAGAAAAGGTAACTG
GAAGAAAAACCGATTTCACCTTCTTCATGATTCAGAATGCTGGAATGTTAACTGGA
TTCACAGCCATTCTACTCATTACCTTGTATGCAGGAGAAATCGAATTGGAGTAA 
 
